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Optimal tuberculosis (TB) treatment remains the backbone of effective TB control 
programmes. However, TB drugs are often associated with adverse drug reactions 
(ADR) that affect treatment adherence and cure. Cutaneous adverse drug reactions 
(CADR) are more commonly associated with Human Immunodeficiency Virus 
(HIV)/TB co-infection, occurring in up to 7% of patients. If severe, CADR require 
treatment interruption and hospitalisation.  There are no standardised guidelines for 
managing CADR to TB therapy. Current practice in South Africa involves drug 
rechallenge, a process, which aims to identify the offending drug and modify the 
treatment regimen. This practice can carry significant risks that need to be weighed 
against the benefits.   
 
Despite significant resources required to manage CADR, there is no available data 
regarding their economic impact. Alternate strategies to manage TB therapy-associated 
CADRs and their cost have never been evaluated. The purpose of this study is to 
evaluate the economic impact of TB therapy-associated CADRs in South Africa and 
compare the cost of drug rechallenge with alternative strategies. 
 
Methods 
Data was obtained from 97 patients, admitted to the Groote Schuur Hospital 
dermatology ward with TB therapy-associated CADR. Clinical data pertaining to 
hospitalisation, diagnostic/monitoring tests and drug prescriptions was extracted from 
patient medical records. Healthcare and patient-related costs were obtained from 
financial department records, interviews and hospital admission records. Alternative 
drug regimens for CADR management were derived from literature and expert clinical 
advice. Costs were estimated using an ingredient’s approach in 2016 US dollars. A cost-
comparative analysis was performed comparing the cost of the current practice with 
alternative options. Univariate sensitivity analysis was used to investigate the 





The cost of managing a TB therapy-associated CADR was $6,525 per patient. Within 
this population the average cost of managing a CADR in a patient with DS-TB was 
$5,831 (95% CI: 8438; 10727). The main contributor of CADR costs was hospitalisation 
amounting to  $3,638/patient (62% of total cost). Alternative CADR management 
strategies using outpatient-initiated second-line regimens containing rifabutin, 
bedaquiline and delamanid cost 44-55% less than drug rechallenge depending on the 
drug regimen used ($2,651/patient to $3,276/patient). Sensitivity analyses indicated that 
drug rechallenge was most sensitive to hospitalisation costs, whereas second-line 
treatment strategies were sensitive to TB drug costs. The average total loss experienced 
by patients as a result of the CADR was $530 (25% of their annual income), as 
compared to an estimated loss in the alternate regimens of $154 (10% of their annual 
income). Societal costs with alternate regimens were also lower at 46-66% that of 
current cost of $6,134. 
 
Conclusion  
CADR to TB treatment represent a significant economic burden to the healthcare system 
and affected patient. The alternate strategy of outpatient-initiated second-line therapy 
provides an economically feasible option by implementing an ambulatory practice of 
care despite using more expensive drugs. Shorter hospitalisation reduces patient and 
healthcare costs. This data should inform policy makers on optimal resource use within 
the healthcare system. Once the effectiveness and risk of drug-resistance of these 









Tuberculosis (TB) remains a major disease burden, particularly in the developing world 
where human immunodeficiency virus (HIV) co-infection is a major driver of the TB 
epidemic. While the World Health Organization (WHO) millennium development goals 
have promoted better case detection and access to treatment with great success, the 
number of individuals still affected is substantial [1]. These affected individuals account 
for significant healthcare expenditure and suffer considerable personal loss. South 
Africa, where the research was conducted, has one of the highest per year incidence rates 
of TB at 834 cases per 100 000 population, with HIV co-infection rates being as high as 
50% in parts of the country [2]. 
 
First-line TB drugs; rifampicin, isoniazid, pyrazinamide and ethambutol, are both highly 
effective and affordable for the treatment of TB [3-5]. However, these drugs carry a risk 
of serious adverse drug reactions (ADR) such as hepatotoxicity and cutaneous adverse 
drug reactions (CADR) that often require treatment interruption and hospitalisation with 
significant mortality. To ensure optimal treatment and cure, patients often have to be 
rechallenged with the same drugs to identify and eliminate the offending drug [6-9]. 
Early withdrawal of the offending drug is necessary and associated with favourable 
patient outcomes in CADR [10]. Yet, TB treatment interruption is associated with 
significant mortality, especially if occurring during the intensive phase (initial 2 months) 
of therapy [3, 11]. With longer interruptions resulting in poorer outcomes. Thus, re-
initiation and optimisation of TB treatment as soon as possible, balancing the risk of 
death from ADR and that from progressively worsening TB, is critical. Oral rechallenge, 
defined as a controlled administration of a drug in order to diagnose the offending drug 
in a hypersensitivity reaction, is the gold standard.  In vitro methods like the lymphocyte 
transformation tests have low specificity and after being used for many years are still 
considered experimental and not widely used [6].  Oral rechallenge carries a significant 
risk of recurrence of a life-threatening ADR. It is for this reason historically that many 
authors were against rechallenging with any drug in severe CADR like Stevens Johnson 
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syndrome (SJS), toxic epidermal necrolysis (TEN) and drug rash with eosinophilia and 
systemic symptoms (DRESS).  
In support of rechallenge there have been scattered reports in the literature of patients 
with severe CADR successfully rechallenged with first-line TB drugs to eliminate the 
offending drug from the regimen [12-15]. Rechallenge protocols differ between 
countries and centres without any general consensus on a method of rechallenge [6, 16, 
17]. At Groote Schuur Hospital (GSH), hundreds of patients with TB-associated CADR 
have been successfully rechallenged using the framework outlined below.  
 
Once hospitalised, all potential offending drugs are stopped and patients are allowed to 
reach biochemical and clinical baseline. Following this the potential offending first-line 
TB drugs are introduced sequentially and additively while clinical and biochemical 
parameters are monitored for rechallenge reactions. This allows identification of the 
causative drug [18, 19]. Typically, the most effective TB drugs, isoniazid and rifampicin 
are rechallenged first [6, 16, 17, 20, 21]. Based on patient sensitivities, co-morbidities 
and drug availability, the most effective and appropriate individualised TB drug regimen 
is derived. This process typically requires a protracted hospital stay placing substantial 
financial burdens on the patient and the healthcare service. Following drug rechallenge, 
patients are often subjected to prolonged treatment courses, specifically in cases where 
regimens exclude the first-line drugs, resulting in further personal burden.  
 
The development of newer TB therapies has not kept up with the rate at which the TB 
epidemic has escalated. Alternate first-line drugs such as rifabutin in South Africa, are 
being shown to be as, if not more, effective as their primary first-line counterparts [22, 
23]. The newer second-line drugs bedaquiline and delamanid, have passed phase 2b 
trials and have shown promising results in terms of rate of and time to sputum 
conversion [24, 25].  Phase 3 trials for bedaquiline are currently underway with phase 3 
trial results of delamanid expected to be available in 2018. In South Africa access to 
these drugs is limited requiring approval from the TB advisory boards. These highly 
effective second-line drugs offer the option of an all-oral alternative for those who 
cannot use standard first-line drugs for any reason. Thus, avoiding the use of second-line 
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injectables, which are not only painful, but require daily clinic visits for the drugs to be 
administered if used in an outpatient setting. 
 
With these newer effective treatment options in mind, we proposed an alternative 
therapy using mainly second-line drugs, avoiding drug rechallenge to optimise therapy 
while reducing costs associated with the rechallenge process. Patients would be admitted 
after the onset of CADR to allow for stabilisation, after which a regimen to which they 
have never been exposed would be started and they would be discharged for follow up in 
the community as per the National TB Programme (NTP) guidelines [26, 27]. Although 
second-line TB drugs are more costly than the first-line drugs [28, 29], the cost of 
hospitalisation associated with second-line therapy and ADR has been shown in many 
studies to be the greatest driver of treatment cost [26-28, 30].  
 
TB and poverty have been shown to be on a perpetual cycle. TB more commonly affects 
poor people. TB disease and patient costs then result in a further loss of income and 
economy, perpetuating poverty. Patient level costs in the form of lost income (30-40% of 
annual income while on TB treatment) and disease related bills are higher during 
hospitalisation compared to treatment as an outpatient [31, 32]. Decentralised models of 
continuing optimum TB therapy may therefore also reduce patient level costs.  
 
In resource-poor settings where budget constraints dictate practice, an evaluation of 
available treatment options is necessary to optimise expenditure while maintaining 
adequate patient access to health care. Cost-analyses often focus on the cost to the 
healthcare system with few studies considering the cost to the patient. Diseases are 
dynamic and this is highlighted by the TB/HIV pandemic and emergence of drug-
resistant TB. Management strategies therefore too need to be adaptive and newer TB 
drugs need to be trialed. Once proven effective, they should be incorporated into 
treatment regimens. This will result in increased demand, reduction in cost of 
distribution and ultimately cost to the consumer. Patients should be offered the most 
effective and tolerable regimens to afford them the best outcomes while maintaining 
optimal quality of life.  
 
 4
1.1 Rationale and justification for research 
In South Africa, despite widely implemented TB control programmes, an overburdened 
healthcare system has failed to adequately curb the TB epidemic resulting in a 
persistently high incidence of TB.  Resources, both financial and otherwise need to be 
allocated to areas where they will yield maximum benefits for the patients and the 
healthcare system. Economic analyses, as part of a broader strategy, are needed to 
provide data on optimisation of resource management and patient treatment.   
 
The occurrence of CADR to first-line TB drugs that requires interruption of treatment 
can be as high as 20% in HIV-infected populations [6]. This is particularly concerning in 
countries such as South Africa with high HIV and TB burdens. The cost of managing 
CADR to first-line TB drugs in South Africa is likely to be high due to the prolonged 
hospital stay, monitoring tests and drug substitutions that are required. However, these 
costs have never been fully determined. With newer second-line drugs that have better 
side effect profiles, becoming more available, alternative treatment regimens are not 
only feasible, but also more appealing. Furthermore, it is unknown whether first-line 
drug rechallenge or immediate second-line therapy is a more economically feasible 
approach to managing TB patients who develop CADR to first-line TB drugs. These 
data will be important to policy makers for rational planning, allocation of resources, 
determination of optimal prevention and management strategies, prioritization of 
funding for competing healthcare issues as well as inform future cost effectiveness 
analyses. 
 
1.2 Objectives of the study 
 To determine the individual cost per patient of TB therapy-associated 
cutaneous adverse drug reactions (CADR) using the current practice of drug 
rechallenge with first-line TB drugs.  
 To compare the overall cost of drug rechallenge with first-line TB drugs to a 
hypothetical strategy of the immediate use of second-line drugs for the 
management of DS-TB patients who develop CADRs to first-line therapy. 
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 To determine the effect of varying specific component parameters on the cost 
of drug rechallenge and the alternative treatment regimens in a sensitivity 
analysis. 
 To determine the costs incurred directly by patients who suffer from  a TB 
therapy associated CADR and subsequent rechallenge in terms of lost income 
and medical expenses. 
 
1.3 The research questions 
 What is the current cost to the healthcare system and to the patient of 
managing TB-therapy associated CADR in South Africa? 
 Is it more affordable to manage a CADR to first-line TB therapy in DS-TB 
patients by in-hospital drug rechallenge with first-line TB drugs, or 
immediate second-line outpatient therapy? 
1.4 Thesis outline 
This study presents the costs related to managing a CADR to TB therapy in a 
predominantly HIV-infected population in South Africa. Costs are calculated based on 
the current practice of drug rechallenge to optimise an individual patient’s TB therapy. 
Chapter 1 provides an introduction to the thesis topic and outlines briefly the rationale 
for undertaking the cost analysis. The literature review is found in Chapter 2. Chapter 3 
offers an explanation of the study design and methodology. Findings of the study are 
presented in Chapter 4 as costs of current rechallenge practice as well as alternative 
treatment options. Within this chapter a comparison of costs of available options is 
presented along with a sensitivity analysis of the main contributors to overall cost. A 
discussion of the study findings in the context of South Africa and in relation to the 
available literature is found in Chapter 5. Chapter 6 concludes the main study finding 
and provides recommendations for future analyses.   
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2. LITERATURE REVIEW 
 
2.1 Epidemiology of Tuberculosis 
TB is one of the most prevalent infectious diseases globally. In some countries, 
predominantly in the developing world, TB has reached epidemic status making it a 
public health emergency. According to the WHO, TB is one of the top 10 causes of 
death worldwide by a single infectious agent. South Africa, where this work was 
conducted, together with India, Indonesia, China, Nigeria and Pakistan account for 60% 
of the world’s TB infections [2]. South Africa has one of the highest number of annual 
incident cases at 834 per 100 000 population (Figure 2.1), with 50% of these cases co-
infected with HIV in parts of South Africa [1].  
 
Figure 2.1: Global estimated TB incidence for 2015 [1]. 
 
In 2015, 10.4 million people were infected worldwide and there were 1.8 million deaths 
due to the disease; 0.4 million of these deaths occurred in individuals with HIV [2]. TB 
was the cause of death in 35% of people infected with HIV in 2015. The vast majority 
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(95%) of TB related deaths occurred in low- and middle-income countries and 60-80% 
of these individuals are co-infected with HIV [2, 19] (Figure 2.2). In South Africa, the 
TB epidemic is further fueled by poor socio-economic circumstances associated with 
overcrowding, hostel living among migrant workers, use of congested public transport 
systems and a high rate of HIV co-infection, all promoting the spread of TB by smear-
positive patients. The typical clinical course of TB, characterised by prolonged latency 
and asymptomatic period, often delays treatment-seeking efforts by infected individuals 
resulting in disease transmission. It is estimated that a single infected person could infect 
up to 15 people per year [2].  
 
Figure 2.2: Estimated HIV prevalence in new and relapse TB cases in 2015 [1]. 
 
Multi-drug resistant TB (MDR-TB) is defined as resistance to at least rifampicin and 
isoniazid. MDR-TB can either be acquired, typically through treatment interruption or 
non-adherence (acquired resistance), or via transmission of MDR strains, known as 
primary MDR-TB [33]. The incidence of MDR-TB was estimated by the WHO to be 
480,000 in 2015, with a further 100,000 people being diagnosed with rifampicin-





Figure 2.3: Global percentage of new cases with MDR/RR-TB in 2015 [1]. 
 
2.2 Pathogenesis of Tuberculosis 
Mycobacterium tuberculosis (M. tuberculosis) is the causative agent of TB. The main 
site of infection is the lung (pulmonary TB), but M. tuberculosis can also affect other 
organs (extra- pulmonary TB) or spread to multiple organs via the peripheral blood 
(disseminated TB). Transmission of the bacilli is typically airborne, spread via cough 
aerosols from infected individuals, but can also occur through direct inoculation. Inhaled 
bacilli travel through the respiratory tract and eventually end up in the terminal alveoli 
where resident cells such as alveolar macrophages and neutrophils engulf the bacilli 
[34]. These cells function as the first-line of defense against M. tuberculosis. Once the 
bacilli are engulfed, additional cell types of the adaptive immune system, such as 
activated T lymphocytes, are recruited and interact to form a granuloma. A granuloma is 
a concentration of immune cells that effectively contains the M. tuberculosis [35].  
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In the majority of infected individuals, M. tuberculosis bacilli are contained within the 
granuloma in a non-replicating state known as latent TB infection (LTBI). The WHO 
estimates that about one third of the world’s population, which could be up to 80% of the 
population in developing countries, has LTBI [2]. However, in a small proportion of 
individuals, when the balance between host immunity and the bacterial response is 
altered, the bacilli undergo replication. If the immune system is no longer able to contain 
the infection, this results in primary active disease [36]. A small number of latently 
infected individuals may develop active TB, known as reactivation TB, particularly if 
their immune system becomes compromised. Immunocompetent people have a 10% 
lifetime risk of developing active TB [37]. However, those with compromised immune 
status from malnutrition, diabetes, malignancy and, most notably, HIV, have a 20-30 
times increased risk of developing TB at a rate of 8-10% per year [37]. 
 
2.3 Relationship between HIV and Tuberculosis 
TB is the most common opportunistic infection affecting HIV-infected individuals, with 
50-80% of patients with TB being HIV co-infected in Southern Africa [1, 38]. It has 
been well documented that HIV is one of the major drivers of the TB epidemic. 
Defective alveolar macrophages as well as a lack of CD4 T cells are thought in part to 
contribute to the increased susceptibility to TB in HIV-infected individuals [38]. HIV 
increases the risk of progression from latent to active TB, as impaired host immunity 
results in inadequate containment of the disease [37]. Lawn et al. clearly showed that the 
TB notification rate increased concurrently with the rate of HIV prevalence within the 
peri-urban population in the Western Cape province of South Africa [39]. Over the study 
period of 1996-2004, the TB notification rate increased 2.5-fold from 32 to 188, with the 
HIV prevalence increasing from 6% to 22%. The TB notification rate for HIV-infected 
participants was calculated to be 4,381 cases per 100,000 persons (95% CI, 3570-5313 
cases per 100,000 persons) and 656 cases per 100,000 persons in the HIV-uninfected 





Table 2.1: Tuberculosis (TB) notification rates and the prevalence of HIV infection in a peri-
urban community in the Western Cape, South Africa, 1996–2004 [39]. 
 
The risk of TB is greatest within the first year of HIV infection [40, 41]. TB is often one 
of the first opportunistic infections heralding the individual being infected with HIV, but 
can occur at any stage with the risk increasing as CD4 count decreases [41]. 
Furthermore, the stage of HIV infection often has an effect on clinical presentation of 
TB, which can affect the ease of TB diagnosis. At greater degrees of immunosuppression 
with correspondingly lower CD4 counts, the radiological manifestations become less 
typical and disseminated TB becomes more common [42].  
TB is also known to advance HIV progression, possibly due to increased immune 
activation, accelerating eventual death, especially in case of untreated HIV infection [43, 
44].  
 
2.4 Diagnosing Tuberculosis  
Diagnosis of TB, though at times challenging, is an important aspect TB control 
programmes. Conventional methods of direct sputum smear microscopy examination by 
auramine fluorescent microscopy, sputum culture, chest radiograph (CXR) and 
tuberculin skin test have their own various limitations [45]. Typically, patients are 
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screened for symptoms including: cough, fever, weight loss and night sweats lasting 
more than 3 weeks. Symptom screening for TB has a sensitivity of 93%, but specificity 
is very low (36%) [46]. An absence of these symptoms has a negative predictive value of 
97.7% to exclude TB [47].  Smear microscopy is still used in many developing country 
laboratories but suffers from low sensitivity and in a high HIV prevalence setting, 
patients with active TB, are often smear-negative. In a Kenyan study of 1,389 
participants with an overall HIV prevalence of 45%, 66% of the participants with TB 
were smear-negative [48]. Sputum culture is considered the gold standard of TB 
diagnosis but availability of results can take up to 6 weeks. CXR as a diagnostic tool for 
TB, also has limitations, as it is subject to both inter- as well as intra-provider variability. 
In HIV co-infection radiological findings often differ from typical features of cavitation 
and upper lobe infiltrates, to more atypical features of non-cavitatory infiltration and 
consolidation in the mid and lower lung zones dependent on the patient’s immune status 
[49]. More typical CXR features often correspond to smear-positive TB, with sensitivity 
of the CXR being up to 68% [48].  However, specificity is low (67%) resulting in 
patients being frequently started on TB treatment despite having negative smears (45%) 
[48]. 
Although not available at the onset of this study, the Xpert® MTB/RIF assay has greatly 
improved diagnosis accuracy and efficiency leading to its large scale roll out as the 
primary tool for TB diagnosis in South Africa [50]. In a sample population of 1,730 
patients in 4 countries the test accurately diagnosed TB in 98.2% of smear-positive TB 
cases and 72.5% of smear-negative TB cases [50]. Specificity was reported to be 99.2% 
in these participants. The Xpert® MTB/RIF assay can diagnose TB as well as 
rifampicin-resistance as a surrogate marker for MDR-TB to aid in distinguishing patients 
from those with DS-TB. The assay is a polymerase chain reaction (PCR) based platform 
that probes regions of the gene responsible for the development of rifampicin resistance 
as a surrogate marker for drug resistance [45]. Within Boehme et al.’s population, 
MTB/RIF testing accurately identified 97.6% of rifampicin-resistance by phenotypic 
drug-susceptibility testing and 98.1% of rifampicin-susceptible bacilli [50].  
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As a result of the significant personal and public health consequences of untreated TB, a 
high index of suspicion and clinical judgment are often used as the basis upon which to 
initiate empiric TB therapy while investigations are still pending [3]. Empiric TB 
therapy is often itself a key factor in the delay of accurately diagnosing TB. This is 
particularly important in cases of disseminated or extra-pulmonary TB where CXR and 
sputum investigation aimed at detecting pulmonary TB are likely to be negative, yet 
patients still have the TB symptomatology.  
Diagnosis of disseminated and extra-pulmonary TB provides a significant challenge. 
Investigations are often more costly and require the patient to be seen at a hospital as 
compared to diagnostic tools for pulmonary TB (PTB) that can be implemented at the 
primary health care level. Diagnostic methods range from less invasive radiology such as 
sonography of the abdomen and computerised tomography (CT) scans; to more invasive 
tissue histopathology of lymph nodes or any available affected tissues, bronchoscopy, 
and/or lumbar puncture to detect TB of the central nervous system. As with CXR, 
radiological investigations often have suggestive features such as intra-abdominal lymph 
nodes, splenic micro-abscesses and free fluid. Once again, tissue diagnosis and culture is 
the only definitive way of confirming TB infection [51]. In advanced HIV abdominal 
TB, which is relatively common, has characteristic features making abdominal 
sonography a reliable diagnostic tool as shown by Heller et al. [52]. 
 
2.5 Treatment of drug-sensitive Tuberculosis 
Prompt and appropriate initiation of TB treatment limits not only transmission, but also 
potential life-threatening complications of the disease. There are 3 main objectives of TB 
treatment: (1) to rapidly reduce the number of actively growing bacilli; (2) to reduce 
disease transmission and disease severity by targeting populations of persistent bacilli 
allowing for durable cure after treatment completion; and (3) to prevent the development 
of drug resistance [3]. To meet these objectives, the TB treatment regimen of a 
prolonged course with combination chemotherapy was developed. DS-TB treatment is 
divided into two phases; the intensive and continuation phase. The intensive phase, 
which spans the initial 2 months of therapy, comprises a 4-drug regimen of rifampicin, 
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isoniazid, pyrazinamide and ethambutol. The continuation phase includes the final 4 
months of therapy and, comprises only rifampicin and isoniazid. This combination 
therapy has been shown to decrease the risk of drug resistance while allowing for a 
shorter duration of therapy [4].  Rifampicin and pyrazinamide, through their sterilizing 
activity, are the key drugs that allow for the shortening of the duration to 6 months [22, 
53]. Regimens containing a rifamycin (in this case rifampicin) throughout the treatment 
course are superior [5]. 
Current TB therapies and treatment strategies have proven to be highly effective with the 
WHO stating that 49 million lives were saved through accurate diagnosis and treatment 
of TB over the last 15 years and the global incidence of TB has fallen by 1.5% since 
2000 [2]. 
Despite the efficacy of TB treatment, many barriers to completion and cure still exist. 
With the protracted course of treatment, significant patient responsibility is required. 
There has been a shift to a more patient-centered approach to the management of TB 
with emphasis being placed on educating the patient and the community as well as 
tailoring treatment to suit the individual. Despite this improved ‘‘treatment literacy” 
where patients are educated about treatment, side effects and potential complications, 
adverse effects are most commonly the reason patients default from any medication [3]. 
 
2.6 Treating Tuberculosis in the context of HIV 
Due to the increased risk of mortality with concomitant HIV and TB infection (estimated 
between 10-50%), South African guidelines currently recommend that TB treatment is 
initiated first followed by antiretroviral therapy (ART) 2-8 weeks later [54].  Delay in 
ART initiation allows for a decline in the TB bacterial load. With initiation of ART, the 
immune system is boosted with risk of immune reconstitution system (IRIS), an 
exaggerated immune response to the TB bacilli [6, 38, 54]. The severity of IRIS is 
associated with the bacilli load. This approach in the majority of patients is associated 
with improved survival, but also reduces the risk of drug interactions and overlapping 
toxicities. All patients who are HIV/TB co-infected irrespective of CD4 cell count 
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became eligible for ART with the update of South African TB guidelines in 2013, 
although this was not the case when this study was initiated [55]. Individuals co-infected 
with HIV and TB between 2009 and 2013 were only eligible for ART based on the 





























Table 2.2: Eligibility guidelines for ART and ideal first-line regimens with their associated 








2010  CD4 count <200 
cells/mm3  
OR  
CD4 count <350 
cells/mm3  
-In patients with 
TB/HIV  
-Pregnant women  
OR  
WHO stage IV 








TDF + 3TC/FTC 
+ EFV/NVP  
Stable on d4T 
regimen: 
d4T + 3TC + 
EFV  
EFV preferred 























2013 CD4 count <350 
cells/mm3  
              OR 
All types of TB  
              OR 




TDF + FTC (or 
3TC) +EFV  




TDF + FTC/3TC 
+ EFV  
FDC preferred  
 
Contraindication 







TDF, AZT and 














2015 CD4 <500 
cells/mm3 
              OR 
Clinically stage 3 
or 4 disease 




Hepatitis B virus 
co-infection 
Newly diagnosed 
 TDF + FTC 
(3TC) + EFV 
 FDC preferred 
 
If on d4T 
 Change to TDF if 
virologically 








to EFV and 
NVP use LPV/r 
 
Contraindication 














Key: 3TC=lamivudine, ABC=abacavir, Cr= creatinine, CADR=cutaneous adverse drug reaction, 




2.7 Drug related toxicities  
The concomitant initiation and use of ART and TB treatment has significant drawbacks. 
Not only do clinicians managing these individuals have to deal with the significant risk 
of IRIS, there is also a high risk of drug-drug interactions and overlapping adverse drug 
reactions (ADR); the most notable being hepatotoxicity and CADR.  Adverse drug 
reactions have been defined by the WHO as ‘‘A response to a drug which is noxious and 
unintended, and which occurs at doses normally used in man for the prophylaxis, 
diagnosis, or therapy of disease, or for the modification of physiological function’’ [57]. 
2.7.1 ADR related to TB therapy 
The incidence of ADR to first-line TB therapy varies widely from 8-85% largely due to 
variation in definitions, study design and population based factors [58]. Major adverse 
events, defined as those requiring hospitalisation or interruption of therapy, overall seem 
to be less common than the milder reactions at 12.8% compared to 41.1%, which was 
noted at a teaching hospital in Brazil [58, 59].  
Literature reports an incidence of 53% of individuals on TB therapy experiencing 
adverse events. In a study by Michael et al. in a Nigerian population, 30% of whom were 
HIV co-infected, the majority of adverse events to TB drugs was mild and resolved 
within 2 weeks of starting therapy [60].  
Hepatotoxicity and CADR are two of the more serious ADR related to TB treatment. 
They are often the primary reason of treatment interruption; hospitalisation; prolonged 
illness; inadequate treatment and potential life-threatening events further increasing 
morbidity and mortality [6-8]. Studies have shown that the majority of cases of 
hepatotoxicity and CADR occur during the intensive phase of therapy [19, 37, 61].  
2.7.1.1 Hepatotoxicity 
Studies have reported up to 28% of patients on TB treatment experiencing hepatotoxicity 
with Hassen et al. reporting that 11.5% of patients developed hepatotoxicity while 
receiving TB treatment [37]. Of the four first-line TB drugs, rifampicin, isoniazid and 
pyrazinamide are known hepatotoxins.  
 
 17
The definition of hepatotoxicity varies in the literature, but comprises both clinical as 
well as serological manifestations that occur as a result of exposure to a hepatotoxin. The 
definition favoured in the South African context is: (1) an alanine transaminase (ALT) 
level>120IU/l with nausea, vomiting, abdominal pain or jaundice, or (2) ALT>200 IU/l 
and asymptomatic or (3) total serum bilirubin concentration >40µmol/l [37, 62]. 
Despite slightly varied cut offs of raised levels of liver enzymes, aspartate transaminase 
(AST) and ALT for the diagnosis of hepatotoxicity, the literature reports an incidence of 
hepatotoxicity of between 6.9% and 11.5% [9, 37, 63]. TB drug induced hepatotoxicity 
was found to occur in the first 6 weeks of initiation of therapy in 93% of cases, but 
occurring sooner, within 14 days (range 4-60) of treatment initiation in HIV/TB co-
infected patients [37]. Various risk factors have been identified for the development of 
hepatotoxicity. Hassen et al. found disseminated TB (p=0.001) and malnutrition (body 
mass index <18.5kg/m2) (p=0.010) were independent risk factors for the development of 
hepatotoxicity [37].  
 
Hepatotoxicity can occur both independently, as an ADR, or in conjunction with CADR. 
Liver function abnormalities are not commonly associated with TEN, but occur in up to 
50% of cases of DRESS. Involvement can range from a mild hepatitis to fulminant 
necrosis with an associated increase in mortality and is frequently related to prolonged 
periods of hospitalisation [64]. Hepatotoxicity also influences rechallenge practice with 
pyrazinamide not being rechallenged due to its direct association as a hepatotoxin [65].  
2.7.1.2 Cutaneous adverse drug reactions 
CADR is defined as an undesirable change to structure or function of the skin, the 
appendages or the mucous membranes due to administration of a drug [64]. Studies 
report variable incidences (5.7% to as high as 23% in some populations) of CADRs to 
TB therapy, largely due to differences in study design, populations as well as a lack of 
consistent case definitions and disease severity grading [6, 11, 61, 66, 67].  
All first-line TB drugs (rifampicin, isoniazid, pyrazinamide and ethambutol) can 
potentially cause CADR [65].  However, the extent to which each of the first-line drugs 
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is implicated remains unclear. Some authors suggest that pyrazinamide is the most 
common offending drug [11, 68]. Conversely, Yee et al. found that rifampicin was most 
commonly implicated in CADR occurring in HIV-infected patients (hazard ratio: 2.4–
2.9, isoniazid; hazard ratio: 8.0, rifampicin; and hazard ratio: 2.1, for pyrazinamide) [68]. 
In a study conducted at Groote Schuur hospital, rifampicin was found to be the most 
common offender [65]. 
These cutaneous manifestations can vary from; mild, requiring no intervention, to those 
requiring topical or mild systemic therapy, to severe and life-threatening. Although the 
majority of patients will have milder forms of CADR such as morbilliform rashes and 
urticaria, up to 17% can develop more severe forms associated with an epidermal 
necrolysis and systemic involvement [11]. A third of patients require hospitalisation and 
up to 75% of patients will need to have their drug regimen modified either as an 
inpatient or outpatient following development of CADR.  
2.7.1.2.1 Clinical phenotypes of TB-associated CADR 
There is a wide range of CADR associated with TB drugs (Table 2.3). These vary from 
the milder forms such as drug exanthems, which are usually self-limiting requiring only 
supportive management, to the more severe forms of SJS (Figure 2.4), SJS/TEN overlap 
and TEN (Figure 2.5)[11]. These are associated with epidermal and mucosal necrosis 
(10% epidermal detachment in SJS, 10-30% in SJS/TEN overlap and >30% in TEN), 
occasionally systemic involvement and may progress to skin failure if not managed 
correctly [6]. Mortality in these cases can be up to 40% specifically in the more severe 
forms of TEN, even with optimal care in tertiary specialist departments and intensive 
care units [69]. In patients with active TB, the development of SJS and TEN is 
associated with increased mortality [70]. Notably, the more severe reactions often 
initially resemble the milder forms of drug exanthems, so the reaction does need to be 
monitored for potential progression [6]. Drug rash with eosinophilia and systemic 
symptoms (DRESS) (Figure 2.6) has a latency period of up to 3 weeks. Systemic 
























Figure 2.6: DRESS Syndrome with visible urticarial papules [16].
 
 20







Erythematous macules and/or 
papules, start centrally becoming 
generalized +/- confluent. 









SJS/TEN Painful dusky macular erythema, 
blisters, Nikolsky sign, erosive 
mucositis in ≥2 surfaces, 






4-21 days Prodrome of flu-
like symptoms, 
high fever, malaise, 
rarely pneumonitis. 




and avoidance of 
offending drug. 
DRESS Itchy exanthem or urticarial 
papules/plaques, erythroderma, 
non-erosive mucositis.  








and avoidance of 
offending drug. 
LDR Itchy symmetrical flat-topped 
purplish papules or macules 
becoming confluent, scale, may be 
photodistributed [72], longstanding 
lesions may hyperpigment or 
depigment, may have oral lesions. 
N/A Months to 
more than a 
year. 
None Mild No interruption of 
offending agent as no 
acute markers on 
rechallenge [73, 74]. 
Table 2.3: Clinical phenotypes and associated features of cutaneous adverse drug reactions occurring as a result of TB therapy. 
* The “Latent period” could be shorter in already sensitized patients  
Key: BSA=body surface area, CADR=cutaneous adverse drug reactions, DRESS=drug reaction with eosinophilia and systemic symptoms, LDR= lichenoid drug reaction, SJS=Steven’s Johnson 
syndrome, TEN= toxic epidermal necrolysis 
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2.7.2 ADR related to ART 
ADR due to ART is also a common occurrence. In a Swiss cohort of 1000 patients receiving 
combination ART, 47% of patients were reported to have clinical adverse events [75]. 
Furthermore, the risk of drug hypersensitivity in HIV-infected individuals is thought to be much 
greater as compared with HIV-uninfected individuals [70, 76, 77].  
CADR have been described in varying frequency and with varying clinical manifestations with 
all classes of ART. Cutaneous manifestations range from hyperpigmentation and hair loss to SJS 
and TEN [78]. As is the case with CADR due to TB therapy, exact incidence is often difficult to 
estimate due to differing study designs and disease definitions. However, in a study conducted in 
a tertiary hospital in India, 16,5% of mucocutaneous manifestation in HIV-infected individuals 
using ART were CADR, the severity of which was not defined [76].  
The non-nucleoside reverse transcriptions inhibitors (NNRTI) class, of which nevirapine (NVP) 
and efavirenz are commonly used in South African Treatment guidelines, are the most 
commonly associated with CADR occurring in up to 26% of patients [78]. In a study of 27 
consecutive pregnant women with SJS/TEN, NVP was found to be the offending agent in 95% of 
the women [79]. CADR associated with nucleoside reverse transcription inhibitors (NRTI), such 





2.7.3 Drug-drug interactions between TB therapy and ART 
Even in cases where treatment is well tolerated, the high pill burden associated with the 
two concomitant diseases, impacts on patients’ adherence to therapy. Added to this is the 
impact of increased risk of ADR. Adverse events occur more commonly in HIV-infected 
individuals (26.7%) as compared to HIV-uninfected individuals on TB therapy (13.3%) 
[80]. Furthermore, there is a 1.7 fold increase of serious ADR related to TB therapy in 
individuals with HIV co-infection [60].  
 
Hoffmann et al. found that TB therapy, when used concurrently with ART, resulted in an 
8.5 fold increase in the risk of developing hepatotoxicity [81]. This is likely due to IRIS, 
causing hepatic inflammation and elevated transaminase levels in the liver whether ART 
was started prior to or following TB therapy initiation [81]. 
 
CADR are also more commonly associated with HIV infection, with HIV being one of 
the clinical characteristics related to the development of CADR (p=0.001), along with 
polypharmacy (p=0.003) and autoimmune disorders (p=<0.001) [11]. The role of HIV in 
CADR development is further supported by a UK study where the CADR was severe 
enough to warrant treatment interruption in 13% of HIV-infected patients as compared 
to 8% in the HIV-uninfected population [7]. Thioacetazone is an example of a drug used 
historically to treat TB, which was found to have such a strong association with 
SJS/TEN and mortality thereof in HIV/TB co-infected patient that WHO recommended 
that its continued use be abandoned [6, 7, 82, 83].   
 
With HIV co-infection predisposing individuals to the risk of CADR to TB therapy as 
well as ART being an independent cause of CADR, it is often difficult to determine 
which drug is the causative agent. In addition, IRIS in itself could present a picture 
suggestive of an ADR adding to the diagnostic conundrum [62]. In many cases 
identifying the causative agent may be easier based on treatment durations; i.e. the last 
introduced being the most likely to have caused the reaction. The Naranjo ADR 
probability scale (see appendix 1), a widely accepted questionnaire used to establish a 
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temporal relationship between exposure to a drug and the subsequent ADR, further 
supports this notion [84]. Rechallenge reactions enable clinician to prove causality and 
subsequently add to this score resulting in a higher Naranjo probability.  
2.7.4 IRIS as a confounder in the diagnosis of ADR 
There is no diagnostic test to confirm the presence of IRIS, with diagnosis being based 
on the clinical presentation and exclusion of other causes for the patient’s symptoms [62, 
85]. Typical IRIS is associated with mycobacterial, fungal and viral infections. 
Unrecognised infections may be unmasked or in cases where patients have already been 
diagnosed with an opportunistic infection, there may be recurrence or worsening of the 
symptoms despite effective treatment [85]. Diagnosis of IRIS relies on; 1) an 
improvement of symptoms on treatment for the opportunistic infection before ART; 2) 
worsening clinical condition suggestive of an opportunistic infection soon after starting 
ART; and demonstration of a response to ART (improving CD4 count and suppressed 
viral load) as well as 3) exclusion of alternative causes for deterioration (bacterial or 
additional opportunistic infection, ADR, poor adherence, or resistance to treatment) 
[85]. TB-IRIS typically presents with fever, lymphadenitis, pulmonary infiltrates and 
effusions [86]. These symptoms could therefore be associated with the systemic features 
prior to CADR or with hepatitis.  
2.8 Management of TB drug associated toxicities 
In cases of severe reactions, patients are usually hospitalised and all potential offending 
drugs (TB drugs and ART) are withdrawn. The clinical symptoms and biochemistry are 
closely monitored, as these are early indicators of worsening condition of the patient. 
The same parameters typically improve on withdrawal of the offending drug.  Less 
severe reactions, defined as those, with rash and pruritis, without systemic or mucosal 
involvement, requiring supportive therapy are managed at a clinic level according to the 
South African National TB guidelines [87].  
Withdrawal of the offending drug has been shown to be associated with a more 
favourable outcome in the cases of CADR, which is used to justify treatment 
interruption [10]. This practice is supported by both the American Thoracic Society as 
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well as British Thoracic Society guidelines which recommend stopping therapy in cases 
of severe hepatitis until there is a resolution of the biochemical disturbance and 
improvement in symptoms [88]. Drug withdrawal could be associated with increased 
mortality for affected patients in the intensive phase and, particularly, in the first two 
weeks of therapy. Furthermore, interruptions can lead to drug resistance, especially if 
patients remain on mono- or dual-drug therapy. Such sub-optimal regimens can result in 
impaired action against rapidly dividing bacilli leading to disease progression and 
transmission to other susceptible or exposed individuals [6, 62]. In a multivariate 
analysis of 820 individuals, interruption of treatment was associated with increased risk 
of death in the intensive phase (hazard ratio: 3.20; p=0.001) [11]. Similarly, the San 
Francisco Tuberculosis Control Programme found that treatment interruption in the 
intensive phase was associated with increased mortality (hazard ratio: 3.15; 95% CI: 1. 
52–6 .52; p = 0.002). Mortality was even higher when reviewed in the HIV-infected 
population (hazard ratio: 3.47; 95% CI: 1. 27– 9.50; p = 0.02) [3]. 
Based on the literature, it is clear that treatment needs to be interrupted, or at least the 
offending drug withdrawn, to allow for recovery and a more favourable patient outcome 
in terms of the adverse reaction. However, treatment needs to be reinitiated promptly to 
prevent excessive patient morbidity and mortality. One of the more widely used methods 
of ensuring this is drug rechallenge, which is discussed below. 
 
2.9 Principles of rechallenge of first-line TB Therapy  
The gold standard to diagnose drug hypersensitivity is a drug provocation test (DPT), in 
which there is controlled administration of the drug to prove causality [18].  The 
European Network for Drug Allergy and the European Academy of Allergology and 
Clinical Immunology interest group on hypersensitivity has developed guidelines for 





Figure 2.7: Guidelines for DPT [18]. 
 
Various methods of rechallenge have been debated in the literature. Current practice at 
Groote Schuur hospital involves using a full dose of the TB drugs sequentially and 
additively in keeping with guidelines of ‘administering the drugs via the same route and 
in the same form that it was originally taken’ [18]. Sharma et al. showed that full dose 
rechallenge compared to dose escalation is not associated with increased risk of 
reintroduction reactions [17]. Full regimen reintroduction allows for treatment to be 
optimised more rapidly, but has the disadvantage in that individual causative drugs can’t 
be identified should a rechallenge reaction occur. This method is also associated with an 
increased risk of hepatotoxicity [89]. The order in which the drugs should be 
rechallenged is still contentious. Some strategies suggest rechallenge with the least likely 
offending drug first [6]. Whereas others favour reintroduction of rifampicin and 
isoniazid, the most effective drugs, first to optimise the treatment regimen [6]. 
Consensus as to which of the currently used drugs is the most likely implicated in the 
CADR has not been reached. Rifampicin has been identified as the most common 
offending drug in a predominantly HIV-infected population by both Yee et al. and 
Lehloenya et al. who found that reintroduction reactions were caused by rifampicin in 
35% of their study population [6, 68]. At Groote Schuur hospital, the rechallenge 
sequence follows the hypothesis that isoniazid has the highest early bactericidal activity, 
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followed sequentially by rifampicin, pyrazinamide and ethambutol [20, 21]. This 
theoretically minimises the risk of developing resistance during the early phases of 
rechallenge by eliminating highest number of viable bacilli.  
Upon presentation with CADR, all patients with severe reactions are typically admitted 
for inpatient stabilisation and monitoring. All potential offending drugs are withdrawn 
and patients receive supportive therapy while clinical and biochemical parameters are 
monitored. Once the patient is clinically and biochemically normalized, 3 second-line 
anti-TB drugs to which the patient has not previously been exposed are initiated as 
‘bridge’ therapy (Figure 2.8). Literature largely reports that duration on bridge therapy 
can vary widely based on the extent of systemic involvement and hepatic injury [90]. In 
a population of 175 patients undergoing TB drug rechallenge the average time to 
stabilisation before rechallenge could be initiated was between 17-21days [17]. The use 
of bridge therapy aims to minimize the risk of developing mycobacterial resistance 
during the prolonged rechallenge period with the individual first-line drugs, by avoiding 
periods of mono- or dual-drug therapy. Lehloenya et al. in Cape Town, South Africa 
have reported using a combination of aminoglycosides (streptomycin, amikacin or 
kanamycin), quinolones (ofloxacin or moxifloxacin), terizidone, ethionamide, linezolid, 
clofazimine or para-amino-salicylic acid dependent on the hospital’s treatment 
guidelines, drug availability and toxicity profile in relation to the patient’s co-
morbidities [6]. Sharma et al. in an Indian study used a similar bridge therapy in their 
population combining ethambutol, streptomycin and one of the fluoroquinolones [17]. 
Though stabilisation periods in CADR are typically managed as inpatients, consensus 
statements on management of drug-induced liver injury (DILI) to TB therapy provide 
guidelines for outpatient management, which provide the possibility that the same could 
be applied to CADR [62]. According to these guidelines moderate DILI (ALT>200), in a 
clinically well patient, can be managed as an outpatient with TB therapy being stopped, 
a bridging regimen of streptomycin, moxifloxacin and ethionamide started and ALT 




Following withdrawal of the offending drug but prior to reinitiating therapy, patients are 
either desensitized (in the case of IgE mediated reactions) to the offending drug or a 
suitable alternative drug(s) is added in their existing regimen [65]. It is well documented 
that there is a limit to effective TB therapy and many alternatives to the first-line 
combined chemotherapy are inferior, have different and potentially more adverse effects 
resulting in a need for a longer treatment course of up to 24 months [6]. To further 
support the preferred use of first-line drugs, there is compelling evidence that rifampicin-
based regimens are superior to those which exclude rifampicin in terms of a favourable 
outcome of TB and disease relapse [17, 91, 92]. The concept of drug rechallenge has 
been developed to identify and exclude the offending drug and subsequently modify the 
treatment regimen rather than removing all first-line TB drugs. This strategy aims to 
create the most effective and safe patient specific regimen.  Thus, once on bridge therapy 
first-line TB drugs are then sequentially and additively rechallenged. This typically takes 
about 30 days as reported by Lehloenya et al. who rechallenged TB treatment in TB/HIV 
co-infected patients at a tertiary centre in Cape Town, South Africa [65]. A drug is 
considered an offender if a rechallenge reaction occurs on repeat exposure then reversed 
upon its withdrawal [6, 84].  
The interval between introducing drugs during rechallenge is also contentious and in 
some studies has been found to be too short to exclude overlapping toxicities of drugs 
[19]. These studies have found that with too short an interval between rechallenge, it is 
difficult to establish causality based on the rechallenge reactions occurring upon re-
exposure to the offending drugs [19]. However, in a predominantly HIV-infected 
population in Cape Town, 22 of the 23 reactions occurred within 72 hours of 






With first-line TB therapy being more effective, rechallenge to build regimens based on 
first-line therapies seems prudent. However, rechallenge can carry a significant risk to 
the affected patient. Lehloenya et al. reported that 50% of their predominantly HIV-
infected (91%) population developed rechallenge reactions. Although the majority of the 
reactions were mild and resolved spontaneously, there were 6/23 (26%) moderate and 
4/23 (17%) severe reactions upon re-introduction of the offending drug [65]. The authors 
concluded that although rechallenge is feasible and frequently successful, the process is 
not entirely benign and requires close inpatient monitoring. In this study, the mean 
hospital stay was 30 days (range 24-47) for inpatient stabilisation, with a further 18 days 
(range 14-33) needed to complete the rechallenge process [65].  
 
2.10 Alternatives to drug rechallenge 
In instances of severe drug reactions, some authors recommend ensuring the patient is 
never re-exposed to the offending drugs and an alternative regimen is devised [14, 15]. 
A potential alternative to rechallenge involves initiating patients directly onto second-
line therapy. This is typically the case in drug-resistant TB (DR-TB), or in cases where 
there are significant contra-indications to rechallenge such as severe comorbidities, 
pregnancy and in those where there is an unacceptable risk of life threatening 
rechallenge reactions [6, 88].   
Second-line regimens are less effective (48-60% success rate), have a greater risk of 


















at 4 day 
intervals. 
Figure 2.8: Overview of drug rechallenge process in CADR. 
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significantly more expensive than first-line alternatives [26, 27, 30]. These regimens are 
generally reserved for cases of MDR-TB.  
2.10.1 Second-line TB therapy regimens 
In patients with rifampicin-resistant TB (RR-TB), or MDR-TB, the WHO guidelines 
recommend a regimen that comprises at least 5 anti-TB drugs known to be effective 
[93]. This regimen should include pyrazinamide (PZA) along with 4 other drugs 
comprising:  
 1 drug from group A  
 1 from group B  
 and at least 2 from group C (see Table 2.4). 
 
Table 2.4: Medicines recommended for the treatment of rifampicin-resistant and multidrug-




If the minimum number of drugs cannot be comprised using the above formula, it is 
recommended that a drug from group D2 and other drugs from D3 may be added to 
make the 5 drugs in the regimen.  
In confirmed DR-TB cases, the regimen should be further strengthened with high dose 
isoniazid (INH) and, or ethambutol (EMB) [93]. In cases of INH-resistance, resistance is 
either to the katG or inhA promoter gene [94]. Mutations result in TB bacilli being 
resistant to low dose INH, with higher doses 0,4ug/ml as compared to 0,1ug/ml being 
effective. The efficacy is thought to be as a result of not all the population of bacilli 
being resistant to INH, thus resulting in death of those that are not, and those with low 
dose resistance being susceptible to higher doses [95]. A South African study has shown 
that more than 10% of MDR-TB may benefit from high-dose INH [94]. 
The shorter MDR-/RR-TB regimen should be 4-6 months of kanamycin, moxifloxacin, 
prothionamide, clofazimine, pyrazinamide and high dose ethambutol followed by 5 
months of moxifloxacin, clofazimine, pyrazinamide and ethambutol [96]. Therefore, 
there is now an intensive phase of 4-6 months consisting of 4 second-line drugs 
compared with 8 months of ≥4 second-line drugs in the conventional regimen. This is 
followed by a 5-month continuation phase of 2 second-line drugs compared to ≥12 
months of ≥3 second-line drugs. Until early 2016, treatment for RR-TB and MDR-TB 
could be up to 20 months, costing $2,000-$5,000 per patient. This shortened regimen 
results in an overall cost saving with an estimated cost of $1,000 per patient [1].  Despite 
the reduction in per patient cost, there is risk for worsening drug resistance if used 
inappropriately, thus highlighting the importance of appropriate patient selection [96]. 
This regimen has been suggested for cases of pulmonary MDR-TB/RR-TB that is not 
resistant to second-line drugs, but excludes pregnant women. An understanding of the 
construction of such second-line regimens is necessary in contemplating and developing 
alternatives to the rechallenge process.  
Options of shortening second-line drug regimens, in the context of DR-TB, have been 
evaluated in the literature. The Bangladesh regimen has been heralded as a successful 9-
month regimen for patients with MDR-TB achieving an 84% cure rate [97]. This 
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regimen comprises a minimum 4-month intensive phase with gatifloxacin, ethambutol, 
pyrazinamide, clofazimine, kanamycin, prothionamide and isoniazid, which is extended 
if sputum smears were positive after the initial 4 months. The continuation phase was 
started once sputum smears were negative and was only 5 months long. The continuation 
phase comprised gatifloxacin, ethambutol, pyrazinamide and clofazimine [97]. However, 
this study excluded HIV-infected individuals and patients had optimal personal and 
family support through trial centres. The STREAM study (Standardised Treatment 
Regimen of Anti-Tuberculosis Drugs for Patients with MDR-TB) is an ongoing trial to 
evaluate the use of shorter regimes and compare efficacies of WHO regimens with the 
Bangladesh regimen. Additionally, some of the regimens being evaluated will attempt to 
exclude injectables [98].   
Development of new and alternate drugs has expanded the treatment options with some 
second-line drugs, as well as some alternative first-line drugs, having benefits over the 
conventional 4-drug first-line regimen. For example, rifabutin a first-line line drug is 
favoured over rifampicin when patients are on protease inhibitors as part of ART as 
there is less induction of cytochrome P3A [22]. Furthermore, rifabutin may be associated 
with a lower incidence of severe adverse effects than its rifamycin counterpart while 
retaining the effectiveness of rifampicin [22, 23, 99]. In 80% of cases where rifampicin 
is not tolerated, the literature has shown that rifabutin can be tolerated [22]. Caution 
must be exercised in CADR related to rifampicin, as rifabutin use carries a 9-fold 
increased risk of adverse reaction (CI 1.6–55) [22]. CADR occurred in 23.2% (p<0.01) 
of Chien et al.’s population, but were mild requiring only symptomatic 
support [100].  However, Lehloenya et al. in a study of rifabutin use following DRESS 
to rifampicin, now totaling 14 consecutive patients, found that rifabutin is well tolerated 
and there was no cross reactivity between the two drugs in this specific population 
(personal communication) [99].  
Due to its unique mechanism of action by binding subunit C of the enzyme necessary for 
energy generation in M. tuberculosis, bedaquiline interferes with energy metabolism 
[101-103]. Thus bedaquiline has proven to be promising in cases of MDR-TB where 
regimens can’t easily be constructed [24]. Bedaquiline based regimens including 
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kanamycin, ofloxacin, ethambutol, pyrazinamide, and cycloserine or terizidone were 
found to have a 48% rate of sputum-culture conversion when compared to placebo as 
well as a faster time to conversion of 83 days compared with 125 days (p<0.001) [24]. 
Yet, in a phase II randomized control trial by Diacon et al. there was increased mortality 
in the bedaquiline group. No mechanism of causality was identified and deaths occurred 
a median of 329 days after the last dose [104]. Bedaquiline is known to cause QT 
prolongation and may be associated with a risk of hepatotoxicity. Despite these risks, the 
WHO still recommends the use of bedaquiline for treating DR-TB and it is likely to be 
useful as part of an alternative regimen for managing CADRs to first-line TB drugs 
[105]. 
Delamanid, another new second-line TB drug, has been granted approval by the 
European Medicines Agency (EMA) based on a phase II study that involved 481 
individuals with DR-TB over a 2 month period [25]. Delamanid was found to increase 
the proportion of patients who achieved sputum culture conversion when given for 2 
months (45.4% vs. 29.6%, p=0.008)[106]. Skripconoka et al. showed that delamanid 
improved survival rates with only a 1% mortality in the delamanid group compared to 
8% mortality in the population not receiving delamanid (P<0.001) [107]. Delamanid in 
these trials was used alongside pyrazinamide and 4 other second-line drugs known to be 
effective. As with bedaquiline, there is also an increased risk of QT prolongation, but no 
studies to date have reported prolongation as an adverse event due to delamanid [25]. 
Furthermore, in the 2-month trial by Gler et al. there were no more adverse events in the 
group receiving delamanid than those receiving placebo [106].  
2.10.2 ADR to second-line TB therapy 
ADR to second-line TB drugs are common ranging from mild to severe, with up to 25% 
of patients experiencing ADR requiring the offending agent to be permanently 
discontinued [108]. Within the commonly used second-line regimens the most common 
adverse reaction has been shown to be ototoxicity at 41%, with CADR accounting for 
5% in a study of 263 Turkish patients [109]. Tinnitus (40%) and hearing loss (23%) 
were 2 of the 4 commonest side effects reported in a Namibian study with a high HIV 
prevalence of 53% [110]. In South Africa through the DOTS-Plus cohort of 2079 
 
 33
patients, 7% of patients experience ADR to second-line TB therapy, 39% of which is 
ototoxicity [111].  
2.10.3 The use of second-line TB therapy for DS-TB 
There is a paucity of robust data as to the effectiveness of second-line TB therapy in the 
treatment of DS-TB. It is not clear whether the efficacy of second-line agents in the 
treatment of DR-TB can be extrapolated to cases of DS-TB.  
 
Many studies have evaluated the use of second-line drugs in addition, or as substitutes to 
one or more of the first-line drugs in the standard regimen as a means of shortening 
treatment duration [112]. Merle et al. substituted ethambutol for gatifloxacin in the 
intensive phase and continued the drug along with rifampicin and isoniazid for a 2-
month continuation phase for total treatment duration of 4 months. While the shortened 
regimen resulted in increased compliance and a lower treatment failure rate, there was a 
higher rate of relapse as compared to the standard regimen [113]. The REMoxTB study 
evaluated the substitution of ethambutol with moxifloxacin in the standard regimen as 
well as moxifloxacin with isoniazid in the comparator arm with regard to the possibility 
of a shortened treatment regimen for DS-TB. Although both moxifloxacin-containing 
regimens produced a more rapid decline in bacterial load than the standard treatment 
regimen, noninferiority for these regimens was not shown, thus not allowing for a 
shortened duration of TB therapy [114]. Conde et al. found the use of rifapentine; 
moxifloxacin, isoniazid and pyrazinamide used in the intensive phase of TB therapy 
were at least as bactericidal as the standard intensive phase regimen with equivalent 
adverse events [115].  
 
The TB Alliance’s STAND trial is a novel 3-drug regimen comprising both first- and 
second-line TB therapy in the form of pretomanid, moxifloxacin and pyrazinamide 
(PaMZ) for the treatment of both DS-TB as well as MDR-TB. The purpose of this study 
was to assess the efficacy, safety and tolerability of the drugs in patients with DS-TB 
and selected patients with MDR-TB. In phase 2b of the clinical trial (known as NC-002) 
which enrolled more than 200 patients in South Africa and Tanzania the new 
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combination therapy was shown to be safe, well tolerated as well as having an overall 
superior bactericidal activity when compared to first-line therapy during the trial period 
(0·155, 95% Bayesian credibility interval 0·133–0·178 compared to 0·112, 0·093–
0·131) [116]. Upon 2 month follow up 71% of patient on PaMZ had negative sputum 
cultures for TB as compared to 38% of patients on original first-line TB regimens. Of 
importance is that PaMZ was found to be effective independent of HIV status [117]. 
Phase 3 of this trial was discontinued in light of the even more promising results seen in 
phase 2b clinical trials (NC-005) with bedaquiline, pretomanid and pyrazinamide (BPaZ) 
as well as bedaquiline, pretomanid, moxifloxacin and pyrazinamide (BPaMZ). BPaz was 
found to kill 99% of TB bacteria over 14 days and has the potential to decrease TB 
treatment to 3 months in clinical trial completed in 2014 [117]. The NC-005 trial is still 
being carried out and results are as yet not available. 
 
Despite promising trial results, with potential future treatment options, the lack of robust 
data results in a delay of these options being included in standard management guideline 
of ADR. However, the above trials demonstrate the possibility of second-line drugs 
being used as alternative to successfully treat of DS-TB as well as improve DR-TB 
therapy.  
2.10.4 ART and second-line TB therapy 
As in patients on first-line TB therapy and ART, drug-drug interactions may be 
problematic with second-line drugs and ART. There is no debate as to the benefit of 
treating both TB and HIV with this benefit outweighing the risk of drug-drug 
interactions. Medécins Sans Frontières (MSF) conducted a study on 67 HIV/MDR-TB 
co-infected patients in Mumbai India between 2007 and 2011 [118]. Eleven patients 
required hospitalisation for their ADR, but none were severe enough to warrant stopping 
the entire MDR or ART regimen. Within this population ADR included gastrointestinal 
upset (45%), peripheral neuropathy (38%), hypothyroidism (32%), psychiatric 
symptoms (29%) and hypokalaemia (23%). Commonly implicated drugs included 
traditional second-line therapy of streptomycin, kanamycin and the fluoroquinolones as 
well as efavirenz, zidovudine, nevirapine and lopinavir [118]. Shean et al. looked at 
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ADR in 115 patients with XDR-TB [119]. Within this population, although ADR were 
common (68% of the population), the type frequency and severity of the ADR was not 
influenced by the HIV status [119]. Furthermore, in a systematic review of 10 
observational studies with a total of 217 patients with DR-TB on ART, overlapping side 
effects of ART and TB therapy were found, but there was insufficient data to determine 
whether ART increased adverse drug reactions when used with TB therapy [120].  
Rifabutin is preferred to rifampicin in higher-income settings as rifampicin is a potent 
inducer of drug metabolism resulting in lower concentrations of protease inhibitors 
[121]. However, concomitant use of rifabutin and nevirapine or lopinavir/ritonavir can 
result in increased levels of rifabutin due to the inhibition of cytochrome P450 
metabolism, with risk of rifabutin toxicity [122]. The same increase in exposure has been 
identified with bedaquiline, yet the clinical significance is still to be determined [123]. 
Ethionamide with ART therapy may result in increased incidence of gastro-intestinal 
intolerance and neuropsychiatric side effects [121].  Although no published evidence 
exists for the use of delamanid and ART in HIV-infected individuals with DR-TB, 
studies in healthy individuals suggest than there are no additional dose adjustments 
required [124]. Table 2.5 below outlines the overlapping toxicities due to ART and TB 




















2.10.5 Obstacles in second-line TB therapy 
Although these factors are associated mainly with MDR-TB treatment, they also need to 
be considered when developing an alternative regimen containing second-line drugs for 
CADR management. 
In cases of MDR-TB, delayed diagnosis of drug-resistance often results in inadequate 
treatment with first-line drugs. In more resource poor settings, such as found in the 
Lesotho cohort, the absence of initial drug sensitivity testing (DST) meant that 97% of 
patients with MDR-TB had previously been treated for presumed DS-TB. Furthermore, 
65% of these had been treated twice or more for DS-TB [125]. During this suboptimal 
therapy, higher bacillary loads can cause parenchymal destruction, cavitation and walled 
off areas limiting drug penetration and leading to increased transmission and chronic 
disease [29]. 
Another factor resulting in delayed initiation of second-line therapy is the reliance on 
inpatient initiation of treatment. In many countries, and many parts of South Africa, this 
is standard practice. Inpatient initiation of second-line TB therapy is thought to improve 
mostly clinical outcomes for patients and limit disease transmission to the greater 
community [125]. With the ever-increasing incidence of MDR-TB this practice has 
many of its own drawbacks. The shortage of hospital beds translates to patients being 
diagnosed, but having to wait months for admission to a MDR-TB hospital to be 
initiated on treatment [125]. This then results in an increased risk to the community as 
patients aren’t admitted at diagnosis and are often maintained within the community on 
suboptimal therapy. Furthermore the practice of inpatient management increases the risk 
of nosocomial transmission due to poor infection control measures, especially in 
resource-poor settings [125]. The need for inpatient treatment places significant 
economic pressure on not only the healthcare system, but also patients themselves. 
One of the influential factors hindering efficacy of treatment are patients who default 
(0%-44%) from treatment due to long duration of expected treatment, adverse effects or 
poor provider-patient relationships [29, 126]. Shean et al. found that default rates were 
up to 29% in MDR-TB patients treated in the West Coast/Winelands of South Africa 
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[126]. Adverse events associated with drugs are known to be obstacles to adherence. 
Nathanson et al. reviewed adverse events from the DOTS-plus initiative (programme 
specific to MDR-TB) in 818 patients from 5 study sites [127]. The most common 
adverse effects were nausea/vomiting (32.8%), diarrhoea (21.1%), arthralgia (16.4%), 
dizziness/vertigo (14.3%) and hearing disturbances (12%). Despite these adverse events, 
only 2.1% of patients stopped treatment. However, 30% of patients required removal of 
the suspected agent. This highlights the importance of patient follow-up to proper 
management of adverse events that would otherwise result in treatment interruption or 
cessation. 
 
2.11 Cost of adverse drug reactions 
With the evident number of cases of ADR, a substantial cost is associated with the 
management and treatment of these reactions. Marques et al. carried out a systematic 
review of 31 observational studies that evaluated to the costs of ADR [128]. Cutaneous 
events as an adverse event of a single type constituted 13% of reactions reported in 4 of 
the 13 studies [128]. Only a single study, by Noize et al. reported on CADR that was not 
related to treatment used in therapy for malignancies, which was ketoprofen, a non-
steroidal anti-inflammatory drug [129]. Within this study ADR amounted to €316 per 
case with serious ADR costing 9 times that [129]. Eleven percent of the population 
required hospitalisation for their ADR [129]. Within the remaining studies in the review, 
the cost of adverse reactions occurring in hospital ranged from €943.40 to €5,972.74 
[130-135].  
 
All studies reported costs relating to the management of the ADR.  Costs including the 
hotel cost, medications and personnel cost. Within the populations reported to exhibit 
CADR, the costs were between $1,920 and $6,325 [136, 137]. Costs in the Gyllensten et 
al. population, that comprised 4970 adults included from a population-based 
observational retrospective cohort study, encompassed the societal cost of illness, which 
included both direct and indirect costs (average of $6,325). Direct costs referred to cost 
of healthcare services as well as dispensed medications, whereas the indirect costs 
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included the individuals’ loss to productivity [136]. The Borovicka et al. cost of CADR, 
related only to the direct costs of treating the ADR [137]. This population was made up 
of 132 adults managed at the department of Dermatology, Northwestern University. 
Noize et al. found that the cost of severe CADR, was nine times higher than the less 
severe forms at €3,383.56 compared to €373.33 [129]. Most studies are reported from 
America and Europe. Of note is that above studies range from 1999-2016, costs would 
therefore need to be adjusted to USD and inflated to reflect current costs, resulting in 
potentially higher than reported estimates. A recent study published in the journal of 
rheumatology assessed the cost of severe CADR (SJS, TEN and DRESS) to allopurinol 
as a means of establishing cost effectiveness for genotyping prior to allopurinol use. 
CADR cost in this population spanned 10 years and included costs related to 
hospitalisation. The mean cost for managing CADR was $8,452 in the total population 
and $2,947 per patient if those who demised are excluded [138]. Within the reviewed 
literature a study by Mehta et al. was the only South African study describing the 
contribution of ADR to patient morbidity, hospitalisation and mortality in 665 patients 
admitted to hospital. TB drugs were reported as causing renal complications, but not 
CADR and costs of ADR were not estimated [139]. None of the studies report on costs 
of CADR attributed to first-line TB therapy, which is one of the aims of our study.  
 
2.12 Cost of second-line TB therapy 
A costing analysis by Pooran et al. comparing the costs of DS-TB, MDR-TB and 
extensively drug-resistant TB (XDR-TB), found that DR-TB cases placed a 
disproportionate burden on the national TB budget. Drug-resistant cases accounted for 
2.2% of the TB cases, yet cost 32% of the estimated 2011, national TB budget [28]. A 
smear-positive DS-TB case in 2011 cost $191.66, with smear-negative ($252.54) and 
retreatment cases ($455.50) being more expensive, with an overall estimated cost per 
case of $256.61 [28].  Within this study MDR-TB treatment was found to be twenty-six 
times greater at $6,771.92 (inpatient = $5,930.02, outpatient =$14,348.94), of which 





Figure 2.9: Parameters contributing to the total cost per patient for DS-TB, MDR-TB and XDR-
TB [28]. 
 
It was previously thought that MDR-TB was too expensive to treat, but drugs have 
become more affordable through the general decrease in drug costs and various funding 
opportunities in low-income countries [29]. In Pooran et al.’s study drug costs accounted 
for 45% of the spending in DR-TB [28]. Suárez et al. carried out a feasibility and cost-
effectiveness analysis in Peru of MDR-therapy, which comprised 18 months of 
kanamycin, ciprofloxacin, ethionamide, pyrazinamide and ethambutol [140]. Within 
their analysis they found that their programme cost US$0.6million per year equating to 
8% of the National Tuberculosis Programme Budget. The cost per disability adjusted life 
year (DALY) saved was US$21, with the average treatment cost per patient being 
US$2,381. The cost per DALY saved was lower than the per-person gross domestic 
product of many countries proving the intervention cost-effective [140]. 
Despite treatment with more costly drugs being deemed cost-effective, treatment of 
MDR-TB can cost thousands of dollars per patient for their treatment course. Alternative 
strategies need to be devised to ensure sustainability of treatment programmes.  Generic 
treatments options of antiretroviral medications, as was seen in HIV/AIDS, allowed for a 
rapid price decrease and an up-scale of treatment [141]. Gotham et al. in their estimate of 
generic pricing of new TB drugs found that costs of regimens could be reduced in some 
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case by up to 97% (41-97%). Novel regimens comprising these generic drugs could 
allow for 5-10 times more patients to be treated within the current budgets [141]. 
Cost of MDR-TB treatment has many contributing factors with many centres favouring 
inpatient therapy.  Schnippel et al. found that the cost of inpatient treatment for DR-TB 
was 40 times more than that of treating DS-TB in South Africa with 95% of this cost 
attributed to prolonged inpatient therapy [30]. These authors noted that the South 
African National TB Programme has adopted a greater move to more outpatient therapy. 
However, only 30-40% of drug-resistant patients would qualify for outpatient therapy 
based on current guidelines, which require specifically that patients are smear-negative 
and in good clinical condition. Cox et al. explored this approach to treatment and also 
found that hospitalisation, along with treatment failure, were the greatest drivers of cost 
[26]. They also noted that facility costs for decentralised services might be greater due to 
economics of scale. This model benefits the patients in seemingly less out-of-pocket 
expenditure for themselves and their families. Sinanovic et al. found that a fully 
decentralised model of care was 42% less costly than a treatment plan involving full 
hospitalisation, with the reduced number of days in hospital being the key-contributing 
factor [27]. Pooran et al. with their sensitivity analysis, found that inpatient day costs had 
the most significant influence on XDR-TB costs. Similarly the MDR-TB group analysis 
was most sensitive to changes in proportion hospitalised and duration of treatment [28]. 
While decentralised treatment may improve the patient experience in this regard, it still 
remains unclear how it would affect patient wellbeing.  
Seung et al. found a community-based model of MDR-TB care to be feasible and 
effective by creating a working relationship between hospital-based and community-
based care in order to maximise resources and ensure close follow up of patients [125]. 
Within their population only patients requiring high level of care or those unable to 
ambulate were hospitalised for initiation of treatment. During the course of treatment, if 
patients became ill or suffered adverse effects they too were hospitalised, but discharged 
back to community-based care as soon as possible [125]. 
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By reducing duration of therapy to the WHO approved shortened regimen for MDR-TB, 
there is a potential to further reduce cost attributed to second-line therapies being more 
expensive than their first-line counterparts [93]. 
2.13 Indirect costs of TB therapy 
In calculating expenditure, one often focuses on the cost to the healthcare system, and 
the associated economic impact, while overlooking the affected individual. The 
relationship between poverty and TB has been mentioned previously, with poor socio-
economic circumstances being a risk factor for contracting TB and hindering treatment 
completion. Numerous studies and strategies to enhance adherence and treatment 
completion are often centered on social support of patients. 
This relationship is two-fold and it is also well documented that TB exacerbates poverty. 
The loss of income due to illness, which is approximately 3-4 months and 20-30% of 
annual household incomes for patients, results in an overwhelming economic burden 
[32].  
TB patient costs typically include out-of-pocket medical costs (tests, administration fees 
and costs associated with hospitalisation), cost of travel to hospital or healthcare sites, as 
well as other treatment related costs such as meals while at clinic visit or supplementary 
foods recommended by healthcare providers and can be substantial. Gospodarevskaya et 
al. found that patient costs related to continuation phase (US$74 in Tanzania and US$56 
in Bangladesh) were lower than the intensive phase (US$150 in Tanzania and US$111 in 
Bangladesh). However, even the lower continuation phase costs represented a significant 
proportion of the annual national income (89% and 77%) [31].  
Ramma et al. reported in their cohort of MDR-TB patients, a drop in proportion of 
income earners from 37%-3% while on treatment [32]. Productivity loss due to 
hospitalisation was the main contributor to patient cost.  Furthermore, 81% of the 
population reported MDR-TB social grants being their primary source of income. 
Decentralisation and outpatient TB treatment therefore seems to reduce health sector 
costs and may potentially reduce patient costs. Yet Ramma et al. also noted that patient 
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costs in terms of transport, nutritional supplements and healthcare visits are greater in 
the outpatient model. Within this population 81% reported being dependent on social 
grants to cover the additional burden the disease places on households [32]. This 
dependence on social grants places a further strain on a country’s general economy. 
It is clear that TB treatment is associated with significant direct and indirect costs. Even 
in uncomplicated treatment cases, patients often experience significant income loss. 
Although, in cases of CADR, the facility and treatment costs become even more 
substantial, raised by the protracted hospital stay required in carrying out the rechallenge 
process. Second-line treatment alternatives can also incur significant costs. As an 
alternative to current in hospital practice of CADR management, a new outpatient 
approach with second-line therapy could potentially be cost saving.  
 
2.14 The value of our study 
In South Africa, TB control programmes and an overburdened healthcare system have 
failed to curb the TB epidemic.  Despite effective TB therapy, the incidence of TB and 
new infections remains high. Furthermore, the prevalence of HIV within South Africa 
not only fuels the TB epidemic, but also places its own burden on the healthcare system 
and health expenditure. With the increasing demand on healthcare services, resources 
and funds need to be allocated to where they are most needed. Healthcare needs to be 
both effective in treating the patient and preventing spread to the community, but should 
also be sustainable. Thus, economic analyses are needed to provide data on optimal 
strategies of patient management and treatment.  
ADR can have significant effects on morbidity and mortality. Nevertheless, it is 
important that patients remain on optimum treatment. Rechallenge, to reinitiate first-line 
TB therapy, or changing a patient to second-line alternatives, need to be comparatively 
studied to determine efficacy. Comparisons need to be drawn as to which practice has 
the best overall impact on the patient’s wellbeing by limiting treatment interruption, 
improving cure rates, reducing disease relapse and curbing the TB epidemic.  
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Rechallenge is not a benign process and the risks and benefits of rechallenge need to be 
evaluated on an individual patient basis. In cases of severe adverse drug reactions due to 
first-line TB drugs, where there is no drug resistance and treatment failure is less likely 
to occur, it is unclear what the most economical treatment option is. It remains unknown, 
if lengthy hospitalisation and patient monitoring during the rechallenge period in an 
attempt to resume treatment with first-line TB therapy is an economically optimal 
strategy. Furthermore, the cost and cost-effectiveness of an alternative treatment strategy 
using second-line therapy has yet to be adequately evaluated. Although prolonging 
treatment with more expensive second-line drugs does at first sight seem to naturally be 
the more expensive approach, outpatient approaches with ambulatory MDR-TB care 
seem promising and an excellent potential for cost saving. This saving is not only to the 
healthcare system but to the patient in terms of an improved quality of life with a shorter 
hospital stay and a more community or patient-centered approach to care.  
The lower efficacy, toxicity and cost of second-line therapies seem to be a deterrent to 
their favoured use over first-line treatments. However, in a population with 
uncomplicated TB who could potentially have a shorter course of therapy on an 
outpatient basis, the feasibility of such a strategy needs to be determined. This study will 
attempt to evaluate the cost of current practices comparing them to a potential alternative 
strategy of outpatient second-line therapy for patients with DS-TB who are intolerant to 
first-line TB drugs.  
In our analysis, we hope to provide answers as to what is the most economically feasible 
way to limit treatment interruption and achieve treatment completion. The strategy, 
when faced with this unique subset of the population, should be one that allows for 
optimisation of patient health and wellbeing while reducing the strain on already 





3.1 Study design: 
A comparative cost analysis was performed to 1) estimate the overall cost of CADR to 
TB therapy, following which 2) the traditional practice of sequential and additive drug 
rechallenge using first-line TB drugs was compared with an alternative strategy of 
immediately initiating second-line TB therapy in patients with DS-TB who develop a 
CADR to first-line TB treatment. 
 
Costing of the current rechallenge strategy for patients with CADR to TB therapy and 
the second-line treatment strategy was performed from the perspective of the healthcare 
system as well as patient loss in the primary analysis. Data was collected from a study 
cohort comprising of patients with probable or confirmed TB that were admitted to the 
Dermatology ward of Groote Schuur Hospital (GSH), a tertiary hospital in Cape Town 
South Africa, during the period from May 2010-July 2015 with a CADR and at least one 
first-line TB drug in their current treatment regimen. Medical records were 
retrospectively reviewed and relevant clinical information was extracted. Cost data 
relating to the management of each individual patient suffering from a CADR was 
collected from appropriate sources and used to calculate the total and per patient cost of 
managing the CADRs. This data provided the source for our first objective of 
determining the cost of CADR to first-line TB therapy using the current rechallenge 
process.  
 
Based on extensive literature review regarding principles of second-line therapies used 
for MDR-TB treatment and in conjunction with clinical advice from Professor Gary 
Maartens (Head of the Division of Clinical Pharmacology, University of Cape Town, 
UCT and previous head of Infectious Diseases and HIV Medicine, University of Cape 
Town, UCT) and Associate Professor Helen Cox (Division of Medical Microbiology, 
UCT), whom are both experts regarding development of TB drug regimens for DS-TB 
and DR-TB, we constructed alternative TB drug regimens as a substitute to drug 
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rechallenge. This was done, as there is a lack of data regarding alternatives to the 
commonly used primary TB drugs for DS-TB. Second-line TB drug costs and dosage 
recommendations were obtained from the relevant literature and clinical sources.  
 
Costs directly incurred by CADR patients were determined for the study cohort and 
hypothetical population. Patients’ annual salaries were collected and used to determine 
out-of-pocket expenses due to lost income from hospitalisation. In cases where patients 
were unemployed, standard minimum wage values were used as a proxy for income as 
was performed in previous studies [32, 142]. These out-of-pocket expenses were 
expressed as a percentage of annual income. Direct costs included fees for medical 
expenses but excluded transportation, food and guardian costs.  Based on annual income 
patients were further classified according to the Western Cape government payment 
schedule, which classifies patients according to their ability to pay for healthcare 
services. Using this classification, the cost to patient for the treatment course was 
determined (Appendix 4) [143].  
 
Although the cohort recruitment time frame ranged from May 2010-July 2015, costs 
were expressed in 2016 US Dollars ($), so as to ensure relevancy in the current 
economic landscape. In all cases, costs were inflated to 2016 costs in South African 
Rand (ZAR) using the South African consumer price index [144]. Costs were then 
converted to USD at an exchange rate of US$1=R14,69 (average exchange rate for 2016; 
Currency Converter/Foreign Exchange Rates/OANDA) [145].  In cases where drug costs 
were not available in South Africa, costs were taken from the literature and converted to 
USD using the above mentioned method [146, 147]. 
 
3.2 Study population 
Medical records of CADR patients who presented at the dermatology ward in GSH from 
the period of May 2010 to July 2015 were evaluated. All patients who were suspected of 
having a CADR related to TB treatment in this cohort were included as the study 
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population. Due to the retrospective nature of the study a convenience method of 
sampling was employed.  
 
Patients included those with TB on at least one first-line drug in their treatment regimen. 
Patients within the population could also have been on ART and/or prophylaxis or 
treatment for opportunistic infections commonly associated with HIV e.g. co-
trimoxazole. In cases of patients only being on TB therapy, first-line TB drugs were 
rechallenged, and second-line drugs were rechallenged or replaced based on the Naranjo 
probability score for the individual drugs. An example is terizidone, which has hardly if 
ever been documented to cause CADR, with notoriety of a drug being a key component 
to the Naranjo score [84]. In cases where patients were on ART or other potential 
offending drugs and TB therapy at the time of presentation the Naranjo score was used 
to assess probability of the drug having caused the CADR. Based on the Naranjo score, 
as to whether an ART drug was a possible, probable or definite offender, the regimen 
was changed to exclude that drug and alternative ART and treatment/prophylaxis for 
opportunistic infections were initiated and no rechallenge was performed for these drugs. 
Thus, patients were only rechallenged with first-line drugs to exclude TB drugs as the 
offending drug and potentially establish alternate therapy as the more likely offending 
drug.  
 
In cases of an unconfirmed diagnosis of TB, further investigations were carried out in an 
attempt to confirm TB. Those who were diagnosed with definite or probable TB after 
consultation with infectious disease specialists were then rechallenged. Those with 
improbable or unlikely TB did not undergo rechallenge [148].  
 
The TB population was further divided into 4 subgroups (Figure 3.1). Those with 
confirmed DS-TB in the intensive phase (first two months) of TB therapy on all 4 first-
line TB drugs. Those in the continuation phase (last four months) of TB therapy on 
rifampicin and isoniazid, as well as those unnecessarily treated for TB who were found 
to not have TB [148]. The last group was those with DR-TB on second-line TB therapy 
that included at least one first-line TB drug. Within the DR-TB population there is a 
 
 48
wide variety of sensitivities, which could also include first-line drugs. Although these 
drugs are not necessary for the successful treatment of DR-TB, isoniazid, pyrazinamide 
and ethambutol are valuable add on components in second-line regimens and thus first-




Figure 3.1: Breakdown of the subgroups of the study population.  
 
 
All costs incurred by these subgroups of the TB population were calculated. Totals and 
averages were calculated for each period of the rechallenge process for the DS-TB 
population as a whole, for the 3 subgroups of patients within the DS-TB group and those 
with DR-TB. Breaking down the costs to reflect the proportion each group contributed to 
the total allowed for a more accurate cost comparison with the hypothetical cohort who 
would only have DS-TB. In the cost comparison the DR-TB cost would be excluded as it 
is near to impossible to derive a regimen based on the same principle of excluding all 
agents to which the patient had been exposed while creating an effective regimen as was 
applied to those with DS-TB.  
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3.3 CADR management strategies 
Various methods of rechallenge have been debated in the literature [65]. However, the 
method of drug rechallenge used in our study cohort was standardised and reflects the 
current   practice employed at GSH.  
3.3.1 Rechallenge to first-line TB drugs 
In our study cohort, once a CADR was diagnosed, all suspected offending drugs were 
withdrawn from the patient’s’ treatment. Various investigations are then carried out and 
the patient is supportively managed and monitored until all clinical and laboratory 
parameters have returned to the patient’s expected baseline. This period is defined as the 
period of stabilisation (Figure 3.2). 
 
Once baseline is reached, an alternative regimen consisting of second-line TB 
medications, to which the patient has never been exposed, are used as a ‘bridge’ therapy 
for at least 2 weeks. This reduces the risk of developing drug resistance, as a result of 
monotherapy, while drugs are reintroduced. First-line drugs from the initial regimen are 
reintroduced sequentially and additively. This is done to identify the causative drug and 
subsequently tailor a treatment regimen for each patient that is the most effective and 
least toxic. The Naranjo ADR probability scale was used to guide need for rechallenge 
with first-line TB therapy (Appendix 1) [84]. The rechallenge period is defined as the 
period from which ‘bridge’ therapy was initiated until the patient was either discharged 
from hospital on optimal therapy with normal clinical and biochemical parameters or 
had a less favourable outcome.  
 
Following discharge from hospital, patients continued on their individualised drug 
regimen as an outpatient until treatment was completed (optimised treatment period).  
The treatment period varied for each patient and was dependent on the particular drug 
regimen that was implemented. For a small percentage of patients, data on their post 
discharge management was available and in these cases real patient data was used in the 
costing for the post discharge (optimised treatment) period. In cases where this 
information was not available, the frequency of clinic visits and laboratory investigations 
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during the outpatient treatment period was guided by the National TB Programme (NTP) 
management guidelines as well as clinical expertise. It was assumed that patients were 
compliant on their treatment and completed the total duration of the prescribed course 
and attended all clinic follow-ups. Follow-up after discharge consisted of specialist 
dermatologist visit at 6 weeks, which is the current practice at GSH. We included more 
regular, weekly visits for the first month following discharge then monthly follow up at 
the TB clinic with a medical officer as we assumed these patients were at a higher risk of 
developing adverse drug reactions or defaulting from treatment. Sputum culture was 
performed every 6 months and following treatment completion. Additionally, screening 
liver function serological tests and differential cell counts were done initially weekly 
then at monthly intervals. For alternative regimens using bedaquiline, delamanid and 
fluoroquinolones (moxifloxacin, levofloxacin), we included appropriate screening tests 
to account for risk of cardiac abnormalities and other side effects commonly associated 
with these drugs (discussed under the specific regimens, Section 3.2.2).  
In some instances, CADR patients were admitted to other referral centres before being 
admitted to GSH where they may have even been started on the rechallenge process or 
the rechallenge process attempted. In these cases where patients were already on 
appropriate bridging therapy, the rechallenge period was determined from the point of 
admission to GSH. In other instances where patients were either inappropriately 
rechallenged or not tolerating the rechallenge drugs, they were managed as a new patient 
upon admission to GSH where all medication was stopped. 
3.3.2 Alternative treatment regimens 
As there is no literature addressing the proposed alternative management, optimal 
therapies were derived based on data from current drug trials and clinical advice from 
experts in the field. Alternative treatment strategies were devised for DS-TB patients 
only. In those with DR-TB there is no possibility of an effective alternative regimen that 
would exclude all TB drugs to which the patients were exposed.  In the alternative 
treatment strategy, patients were assumed to skip the rechallenge process and 
immediately initiate treatment using a combination of second-line TB drugs.  The 
alternative regimen was devised in order to develop an optimal therapeutic regimen 
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while limiting the time spent in hospital and avoiding rechallenge. This was achieved by 
using drugs to which the patient had never been exposed, thereby avoiding rechallenge 
with potential of reactions and the associated inpatient monitoring. As our alternate 
regimens were only devised for patients known to have DS-TB, they avoided full MDR-
TB based treatment regimens that include drugs likely to be unnecessary in DS-TB that 
are associated with more frequent and severe ADR and higher costs [26, 27, 30].   
 
A number of alternative drug regimens were proposed including an option for patients 
who developed CADR during the intensive phase of TB therapy and those who 
developed their CADR in the continuation phase of therapy (Figure 3.2).   
 
If a patient developed a CADR after the intensive treatment phase, they were initiated on 
rifabutin and ethionamide for an additional 4 months from the time of CADR 
stabilisation. 
 
Traditional continuation phase therapy comprises rifampicin and isoniazid for 4 months. 
Rifabutin has sterilizing activity, which has been shown to be comparable if not better 
than rifampicin, with earlier sputum smear and culture conversion [23, 149]. Rifabutin 
has potentially better tolerability with increased treatment adherence and completion 
making it an appropriate substitute for rifampicin in cases of rifampicin intolerance [22, 
23, 100]. In 80% of cases where rifampicin is not tolerated, the literature has shown that 
rifabutin can be tolerated [22]. Furthermore, Lehloenya et al. have reported on 6 
consecutive HIV-infected patients who developed DRESS to rifampicin and tolerated 
rifabutin, with a further 10 cases having been added to their cohort since publication of 
the initial data [99]. Side effects of rifabutin are usually mild; gastro-intestinal upset, 
headaches and arthralgia occur commonly. Monitoring is required for more severe 
adverse events such as hepatitis, neutropenia and thrombocytopenia. For these a regular 
AST, ALT and bilirubin with a white cell and platelet count are recommended [150]. 
Acquired rifampin resistance amongst HIV-infected patients has also been shown to be 
equivalent between the two rifamycins, dependent rather on the rifampin-dosing 
schedule [151].  
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Ethionamide is a structural analog of isoniazid and the two drugs are thought to share a 
common mode of action being potent inhibitors of mycolic acid synthesis [152, 153]. 
For this reason, there has always been a concern that the two drugs might have 
overlapping hypersensitivity reactions as well as the risk of cross-resistance, in that 
patients with INH-resistant TB may also be resistant to ethionamide resulting in poorer 
outcomes for patients with DR-TB [154]. Fortunately Lehloenya et al. have recently 
shown that hypersensitivity does not overlap in cases of CADR [155]. Potential 
activators of ethionamide have been identified which may enhance its efficacy but these 
have not been studied in as much detail as isoniazid [152, 156]. The use of ethionamide 
is based on specialist advice supported by research showing that the use of ethionamide 
in MDR-TB regimens is associated with treatment success as a surrogate for its efficacy 
[157]. Common side effects include gastro-intestinal upset and headaches with 
drowsiness and low mood, but do not require specific monitoring. Gastro-intestinal upset 
occasionally makes the drug intolerable and may require a regimen change to terizidone 
[150].  
 
If a CADR developed during the intensive phase then a number of different treatment 
regimens were assessed. These include:  
1) Regimen 1: moxifloxacin, rifabutin and ethionamide for 9 months. 
2) Regimen 2: rifabutin, levofloxacin and bedaquiline for 6 months followed by 
rifabutin and levofloxacin for a further 3 months. 
3) Regimen 3: delamanid, levofloxacin and rifabutin for 6 months followed by 
rifabutin and levofloxacin for a further 3 months. 
As previously mentioned, both rifabutin and ethionamide can be considered feasible 
alternatives for DS-TB treatment. However, in constructing our regimen for those 
developing a reaction in the intensive phase using second-line drugs, we were faced with 
the potential of having to develop longer regimens. The potency of rifabutin in this 
instance has enabled us to argue for a 9-month treatment course. In further support, a 
shorter 9 month course of TB therapy has also been validated by the WHO as well as the 
Bangladesh regimen, which is an alternative to the WHO shortened TB therapy for 
patients with MDR-TB [96, 97].  
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Moxifloxacin and levofloxacin are drugs from the group known as fluoroquinolones. 
Fluoroquinolones are thought to have effective activity against intracellular 
mycobacteria due to their wide distribution throughout the body [158, 159]. 
Moxifloxacin is one of the fluoroquinolones that has the potential to shorten TB therapy 
as it has the greatest bactericidal activity with the shortest minimum inhibitory 
concentration (the lowest concentration of a chemical that prevents detectable bacterial 
growth) [159, 160]. Moxifloxacin activity has been shown to be comparable to that of 
isoniazid with the time to kill 50% of viable bacteria being lower in isoniazid than 
rifampicin and moxifloxacin [161, 162]. It was therefore used in our regimen as a 
valuable substitute for isoniazid. Moxifloxacin is generally well tolerated, but does have 
propensity to cause gastro-intestinal upset as well as mild drug hypersensitivity. 
Standard monitoring as is employed for rifabutin was thought to detect possible adverse 
events related to moxifloxacin [159]. Levofloxacin provides an alternative to 
moxifloxacin with similar effect when bedaquiline is used due to the lower rate of QT 
prolongation (discussed later) with this combination [163, 164]. Levofloxacin is well 
tolerated with a study showing equivalent, and in some cases, lower rates of adverse 
events as compared to first-line treatment regimens [165].  
 
Bedaquiline is a relatively new TB drug associated with enhanced and rapid sputum 
conversion rates [104]. It has been approved by the WHO and is now used in patients 
with pre-XDR and XDR-TB. Use of bedaquiline in other instances is protected through 
advisory committee permission. Patients are granted use in situations where no other 
substitutes are available to protect against the development of drug resistance. 
Bedaquiline is associated with an increased risk of QT interval prolongation. The QT 
interval is the measure of the time between the start of the Q wave and the end of the T 
wave in the heart’s electrical cycle (seen on electrocardiograph-ECG), representing 
electrical depolarization and repolarization of the ventricles [166, 167]. Prolongation 
represents delayed ventricular repolarisation predisposing to re-entrant tachycardia such 
as torsades de Pointes [166]. This risk is further exacerbated when used in conjunction 
with moxifloxacin. The long half-life of bedaquiline (5 months) typically results in it 
being prescribed for the first 6 months of therapy, yet monitoring is required after the 
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drug is discontinued to cover the presence of any circulating residual drug that may 
result in adverse events [167]. The Centres for Disease Control recommends baseline 
ECG, potassium, calcium and magnesium monitoring with ECG being repeated at 2, 12 
and 24 weeks. AST, ALT, bilirubin and alkaline phosphatase should be monitored at 
baseline and monthly to screen for potential hepatotoxicity [168]. 
 
Although trials show delamanid to have excellent treatment potential it is currently only 
available in South Africa through MSF and use requires both MSF and government 
regulatory approval [25]. WHO guidelines on delamanid use report the only drug 
specific side effects to be QT prolongation (p=0.048 for the dose of 100mg compared 
with placebo and p=0.005 in use of 200mg compared with placebo) [124]. This risk is 
only notable when used in conjunction with regimens containing a fluoroquinolone such 
as ours (levofloxacin). To this end monitoring of ECG as well as electrolytes that can 
contribute to cardiac abnormalities such as potassium is recommended [25, 124]. 
 
In instances where rifabutin is not tolerated, a regimen would have to be devised 
excluding the rifabutin but then lasting 18 months. However, use of the NIX regimen, 
which comprises bedaquiline, pretomanid and linezolid for 9 months could be an 
alternative [169]. The NIX regimen is an all oral regimen which is currently in phase 3 
of clinical trials providing an all oral alternative regimen for patients with XDR-TB 
predicted to be able to cure TB in 6-9 months [169]. However, due to pretomanid not 
being readily available with costs largely unknown an evaluation for the cost of this 
regimen as an alternative was not undertaken. 
 
We assumed that patients in the alternative treatment arm would undergo standard 
monitoring tests most commonly associated with the drugs used in each of the proposed 
regimens. The frequency of monitoring tests was based on NTP guidelines related to 
monitoring for development of specific drug-induced adverse reactions in patients on 
MDR-therapy and included the parameters discussed above [168]. Assuming that the 
stabilisation period prior to rechallenge would be equivalent using both strategies, we 
compared the cost of using these alternative treatment strategies with the rechallenge 
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strategy up to treatment completion. It was assumed that treatment in the alternative 
strategy was outpatient initiated as the literature provides substantial evidence for 




Figure 3.2: Flow chart illustrating the arms of the study model.  
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3.4 Data sources 
Actual clinical information and, in most cases, costs directly incurred by the healthcare-
system were used in this analysis thus representing ‘real-world’ data. Cost data was 
obtained from relevant sources including review of financial records and interviews with 
financial administrative staff. When actual cost data was unavailable, in cases of second-
line drug costs, estimates from the literature were used. The costs of each resource item 
were used to calculate per patient and overall cost of managing TB patients who develop 
a CADR to TB drugs at GSH. The main analysis was performed from the perspective of 
the healthcare provider as well as the patient. Details of the clinical data and cost 
components used in the analysis are given below. 
3.4.1 Clinical data 
Hospital records of the patients’ admission to the GSH Dermatology ward as well as 
clinic and referral records were reviewed. Relevant clinical data pertaining to the period 
from diagnosis of CADR to treatment completion was extracted. Data included; patient 
HIV status, CD4 count, ART information, TB diagnosis and treatment details, date of 
admission and discharge to determine duration of hospitalisation, additional inpatient 
dressings, investigations, specialist consults that patients may have required and data 
pertaining to rechallenge and ultimately their discharge treatment prescription.  
Completion of TB treatment was defined as a completion of the determined treatment 
period, which was decided upon discharge. The majority of patients are discharged to the 
community with their care transferred to primary level clinics. Unfortunately, clinic 
records of patients completing treatment were not readily available and many patients 
were lost to follow up. As such we did not have outcome data after treatment completion 
for all patients in the study cohort. In cases where post discharge management was 
known, this was extracted and patient specific costs were calculated. Where not 
available, we assumed monitoring and investigations were carried out according to 
standard South African NTP treatment guidelines. 
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3.4.2 Study periods 
For the current practice of rechallenge, the costs were divided into 3 different periods 
shown below:  
3.4.2.1 Stabilisation Period:  
This period was defined from the time of onset of CADR, through the period of in 
hospital stabilisation until the point at which clinical and biochemical markers had 
normalised. This period was assumed to be the same for the alternative treatment 
strategy.  
3.4.2.2 Rechallenge Period: 
The rechallenge period was defined as the time from initiation of bridge therapy, after 
the patient’s baseline had been reached, up to the point of the patient being discharged. 
During this period, first-line therapies were re-introduced sequentially to identify the 
potential offending drug. 
3.4.2.3 Optimised Treatment Period: 
After the rechallenge period, an individualised treatment regimen was defined for each 
patient based on suspected offending drug/s, duration of treatment prior to CADR and 
expert opinion. This period referred to the time from discharge up to completion of the 
individualised treatment.  
3.4.3 Hospitalisation costs 
Hospitalisation cost refers to the daily cost of a patient admitted to hospital. This 
included bed, food, and basic nursing. The hospital cost accounts for the existing 
hospital infrastructure as well as overhead costs such as electricity, water and 
maintenance. Both tertiary and secondary hospitalisation costs were obtained. GSH and 
Victoria Hospital finance departments provided per day costs for tertiary and secondary 
level hospitals, respectively. These costs represented the actual cost incurred by the 
hospital. Primary care clinic visit costs were obtained from two TB clinics located in the 
Cape Town Metro region, Langa Clinic and Chapel Street Clinic.  
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3.4.4 Medical and allied health professionals staff costs 
Medical consultations by specialist physicians and registrars (specialists in training), as 
well as allied health professionals, were included in the costing analysis. Allied health 
professionals referred to individuals integral to the management of this cohort of patients 
such as; physiotherapists, occupational therapists, speech therapists, dieticians, social 
workers and ART counselors.  Health professional costs were calculated using the 
Provincial Government of the Western Cape (PGWC) 2016 circular of annual salaries 
and included basic salaries and benefits. The average (mid-range) salary in each 
personnel category was applied in the analysis to account for the varying levels of 
experience of the staff treating the patient. The hourly salary was then calculated (annual 
salary/days worked per year/8-hour day). The time spent for each consultation was 
variable and not recorded in the patients’ medical records. We assumed this time to be 
15 minutes per consult based on interviews with consultants from the different 
departments. The admitted patients were seen by dermatology registrars daily 
($7.00/15min consult) and the consultant dermatologist ($8.00/15min consult) three 
times a week in the ward. Consults with other specialists were calculated at the same 
rate, allied health professionals were $3.00/consult, with social worker or ART 
counselor consults being $2.00/consult.  These consults were on a referral basis and cost 
was calculated according to the number and length of the consults noted in the medical 
records of each patient.  
3.4.5 Diagnostic tests, pathology and laboratory investigations 
Laboratory and radiological investigation costs were calculated for each patient per 
investigation multiplied by the number of times each investigation was carried out 
according to hospital and National Health Laboratory Services (NHLS) records. Costs of 
radiological investigations including X-rays, CT scans and ultrasound were obtained 
directly from the GSH finance department. Laboratory and pathology test costs were 
obtained from the NHLS 2016 state price list. The NHLS is the laboratory service 
servicing government healthcare facilities, from clinic level to tertiary hospitals in South 
Africa. As such these prices directly reflect the cost incurred by the healthcare system. 
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Other studies have also directly used NHLS test costs in their cost analyses [28, 170, 
171]. 
3.4.6 TB drug costs 
Currently used first- and second-line TB drug costs were obtained from the GSH 
pharmacy drug order lists and represent state tender prices (PGWC: Metropole Region, 
Western Cape). These costs represent costs to the NTP in South Africa. Costs were 
calculated per patient from inpatient treatment charts while in hospital, with only 
administered doses being included in costing as well as doses according to the discharge 
prescription. As delamanid is currently not freely available, drug costs were obtained 
from published literature [25, 146, 147]. Outpatient costs for discharge medications were 
calculated according to the issued discharge prescription. It was assumed that all doses 
were taken and the treatment course completed.  
3.4.7 Dressings and ancillary medications   
Ancillary medications in the case of TB therapy typically refer to therapy used to 
prevent side effects of the drugs; for example, pyridoxine to prevent peripheral 
neuropathy and vitamin D and calcium to counteract the side effects of steroid use. 
However, use of these drugs is standard practice when prescribing the drugs with known 
adverse effects. This cost was therefore not included in the cost of our management. 
Within our study population ancillary medications and dressings referred rather to 
medications other than TB therapy required by the patients admitted as a result of the 
CADR for the management of the CADR and associated symptoms. These medications 
included largely analgesics and antibiotics used to manage symptoms and complications 
of the CADR. Chronic medications that the patients may have been taking as well as 
ART for associated co-morbidities was not included in the definition or costing of the 
ancillary medication. Only medications and dressing directly related to the CADR, or 
hospitalisation as a result of the CADR were included in the costing. Ancillary 
medication costs were also obtained from the GSH pharmacy drug order lists (PGWC: 
Metropole Region, Western Cape). Inpatient medication and dressing cost was 
calculated per dosage or administration as recorded in the in-patient treatment and 
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dressing charts. Costs were therefore only applied to medication and dressings signed off 
as having been given in order to account for missed, or doses not given. Dressings used 
commonly included paraffin gauze (Jelonet™) dressings for excoriated mucous 
membranes such as the lips, steroid dressings of varying strengths for the body, as well 
as non-adherent dressings like Mepitel™, Natural tears and fluocinolone gel to prevent 
adhesions in affected mucous membranes. Included under dressing costs were the 
entities of Sitz and betadine baths, which were used in various cases for washing of the 
affected areas. All dressing and their associated costs are included in the table of costs 
(Appendix 3).  
3.4.8 Patient level costs 
Patient level costs were determined in a secondary analysis. Costs incurred directly by 
patients were calculated according to the expected loss of income due to hospitalisation 
as well as their expected medical bill for the treatment period. This cost was based on 
their employment status and annual income. In cases where patients were unemployed or 
earning close to minimum wage, they were assigned a proxy of income equivalent to the 
lowest minimum wage earner in South Africa. This was an entry-level worker at the city 
council earning $97/month (working 8 hours per day and 22 days/month) [142]. Patients 
making use of government subsidised healthcare facilities are assigned to a level of 
payment subsidy according to their ability to contribute to the cost of their healthcare 
(Appendix 4) [143, 172]. According to their payment bracket, personal treatment related 
expenses were allocated and calculated. These out-of-pocket expenses were then 
expressed as a percentage of their annual income. As data was collected retrospectively, 
there was no information available on other expenses (transport, food etc.) or guardian 
costs they might have incurred related to the course of their illness and accessing of 
treatment. Patient loss in our population refers only to the loss of income from days of 
work missed due to hospitalisation as well as the expected medical expenses that the 





Patient level costs were also estimated for the alternative regimens. This estimate was 
based on the percentage of the costs that the hypothetical patient would be liable for as 
per the proportions of patients in the original study population and their classification in 
the payment subsidy structure.   
 
3.5 Data cost collection 
A bottom-up ingredient’s approach was used to calculate the total cost (for the study 
period) and the cost per patient based on the unit costs for each defined period of the 
rechallenge process. Within the analysis CADR patients with TB were considered as the 
total population, following which patients with DS-TB and DR-TB were separated with 
the DS-TB group being further divided into those in the continuation phase of treatment, 
those in the intensive phase of treatment and those unnecessarily treated for TB and 
calculations were made accordingly. Costs were only assigned to data relating to each 
patient’s care that was administered or experienced as noted on the various data sources 
(clinical folders, NHLS systems) for each period of the rechallenge process. 
Assumptions of costs were made for the periods of stabilisation during which the patient 
may have been given a pass-out in that it was assumed they would use all the prescribed 
medication. Similarly, in the optimised treatment phase in cases of missing data, costs 
were applied according to the discharge treatment prescription as well as the standard 
NTP guidelines on monitoring and patient follow up. It was assumed that all treatment 
was completed and all appointments attended with all monitoring tests carried out. 
Totals and averages were calculated for DS-TB population and DR-TB population as a 
whole as well as for the 3 separate subgroups of the DS-TB population.  
 
3.6 Analysis 
A decision-analytic model was used to determine the cost estimates of drug rechallenge 
compared to immediate initiation onto second-line therapy in DS-TB patients. The cost 
data collected for the study population was used to determine the cost of first-line drug 
rechallenge in cases of CADR. The cost of second-line therapy was determined 
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separately using an ingredients approach for a theoretical cohort based on literature and 
clinical advice. Patient level costs that applied to the actual study population and 
estimated costs for the hypothetical cohort were determined in a separate analysis.  
 
The primary outcomes included (i) the total and per patient cost of managing CADR 
cases to first-line TB treatment (ii) the comparative and/or incremental per patient cost 
of first-line drug rechallenge versus immediate second-line treatment initiation in DS-TB 
patients. The timeframe of the analysis was from onset of the CADR to TB treatment 
completion. Secondary analyses included (i) a univariate sensitivity analysis and a 
multivariate scenario analysis to determine the key cost drivers in managing CADRs in 
all strategies and (ii) a patient-perspective cost analysis to determine out-of-pocket 
expenses incurred by patients suffering from a CADR to TB therapy. 
3.6.1 Analysis packages 
Analysis and calculations, as well as figures where necessary, were done using 
Microsoft Office (2015) Excel and column statistics were performed using GraphPad 
Prism version 6.0 (GraphPad Software, La Jolla California USA). The decision tree was 
constructed using TreeAge Pro 2015, R1.0. (TreeAge Software, Williamstown, MA).  
3.7 Sensitivity analyses 
A univariate sensitivity analyses were carried out to explore the implications of 
uncertainty around the cost variables used in the analysis. Additionally, specific 
parameters were varied to determine how pragmatic changes in the model affected the 
cost of each strategy.   
 
These included: 
 Hospital costs: Costs of hospital stay were doubled and halved. Duration of 
hospitalisation was also increased (doubled in the rechallenge period of the study 
population) and an extra month of inpatient therapy included in the alternate arms of 
therapy.  The effect of outpatient stabilisation was also included. 
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Severe drug reactions are typically referred to tertiary level hospitals where patients 
are seen by treating dermatologists as well as other specialist units. Hospital costs are 
likely to vary between provinces and countries. To account for this variation, we 
analysed changes in total daily cost by halving as well as doubling the per day 
hospital cost. Practically in our data set current cost refers to tertiary hospitalisation 
cost, whereas hospitalisation at a secondary level hospital would be equivalent to 
half this cost. Furthermore initiation of each drug can be done at 4-8 day intervals in 
the literature [6, 16]. Within our population this is typically done at 4-day intervals 
but an alternative cost was analysed using introduction at 8-day intervals. For the 
alternate regimens, we analysed the impact of a month-long period of hospitalisation 
after starting the second-line drugs to monitor for the potential development of an 
ADR. The impact of outpatient stabilisation on total cost was also evaluated.  Based 
on literature approach to outpatient stabilisation with DILI, we extrapolated that 
patients with DRESS and an ALT<100 at presentation would be a lower risk 
population, eligible for outpatient stabilisation [62].  
 
 Laboratory and radiological investigations: Costs of laboratory investigations and 
radiology were increased by 50% and halved within the population.  
When patients are unwell and when clinically indicated, laboratory investigations 
need to be carried out. However, daily-screening investigations can be of little 
benefit. More specific tests may have a greater sensitivity and a substantial impact 
on overall cost. The sensitivity analysis was carried out to see how the unit cost per 
patient was affected through the use of less frequent and more specific screening 
protocols. 
 
 Category of personnel: The time spent by personnel attending to study patients was 
doubled and halved. Increased and reduced frequency of consultations by specialist 
dermatologists at current cost was also evaluated.  
The cost analysis was performed incorporating double the estimated time for the 
consultation with current staff (30 minutes) and half (7 minutes) instead of current 
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15-minute consultations. Furthermore, the baseline frequency of consultant review 
was 3 times a week, but this was varied from daily consults to weekly consults to 
determine the impact on overall cost. 
 
 Drug pricing: Costs of TB and ancillary medication used was doubled as well as 
halved.  
Sensitivity analysis of drug costs was done to determine the effect of a reduction of 
the cost of drug therapies has on the overall cost of rechallenge as well as the 
alternative arm of therapy. Drug costs were halved and doubled to account for the 
range of costs as described in the literature [28, 173, 174]. 
 
 Fluctuation of the ZAR/USD exchange rate: Lowest and highest rates recorded for 
2016. 
 
The exchange rate of South African rand to US dollar fluctuated substantially during 
2016. In order to explore the implication of using the average exchange rate for this 
period we also calculated overall costs based on the lowest (1USD=R13.26) as well 
as highest (1USD= R16.86) exchange rate recorded for this period [145]. This is 
important as in cases where drugs are internationally sourced fluctuations in 
exchange rate may have significant implications in the various costs of the 
regimens. 
 
 Patient costs in terms of societal costs: Patients annual incomes doubled and halved.  
As many of the study population were classified as being unemployed an income 
proxy of a general worker earning the minimum wage was assigned in order to 
estimate the patient loss in terms of loss of annual income. Higher patient costs 
ultimately result in higher societal costs. To account for the potential under-
estimation of patient incomes, in cases were the data may have been captured 
incorrectly or they may be informally employed, annual incomes were doubled. To 
contrast this in instances where patient may in fact be casually employed and 
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earning less than the minimum wage due to fewer days of employment or 
completely unemployed with no subsidised income, annual incomes were halved.  
 
In addition, a scenario analysis was undertaken in which multiple variables were altered 
simultaneously in order to determine their effect on overall cost. This was done for both 
“best” and “worst” case scenarios. In the “best” case scenario hospital costs were halved 
to model those of secondary level hospitals ($32.06 per day). Patients were assumed to 
be healthier or more tolerant of the rechallenge and alternative therapies requiring fewer 
monitoring tests. Furthermore, daily management was by training dermatologists with 
weekly specialist dermatologist review. TB drug costs were halved to model a situation 
where they are affordable and readily available, especially in the case of the newer 
second-line drugs of bedaquiline and delamanid.  
 
To contrast the “best” case, the cost of a “worst” case scenario was determined to model 
a situation where patients were very sick and costs were higher. Specifically, the length 
of hospitalization was increased in the rechallenge period, amounting to 8 days between 
each drug being reintroduced as opposed to 4 days. In the alternate arms an additional 
30-day in-patient monitoring period was included before patients were discharged on the 
hypothetical alternative treatment regimens to allow for monitoring of potential 
development of ADRs. As the patients were seemingly less tolerant, they were seen 
daily by specialist dermatologists and lab investigation costs were increased by 50% to 
account for the potential increase in tests these patients would warrant. Within this 
scenario TB drug costs were also doubled making for a situation in which drugs are 
costly and hard to come by.  
The total per patient cost of each strategy in these two scenarios were estimated and 
compared to determine the most influential factor that affected these costs.  
3.8 Ethical considerations: 
Ethics approval was granted by the University of Cape Town, Faculty of Health 
Sciences, Human Research and Ethics Committee on the 22 April 2016 (HREC REF: 
240/2016) (see Appendix 2). The study posed no risk to any of the participants. All 
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identifying particulars of patients were removed from the database. Furthermore, the 
database was stored, password protected with access limited only to authors and 
supervisors. All participants had given consent during their hospital stay for their records 





The main study findings will be presented in this chapter. Firstly, the baseline 
characteristics of the study population will be reported. In section 4.2 the resources 
required for the process of rechallenge will be identified and valued for a total cost of the 
CADR with standard procedure in currently practiced at Groote Schuur Hospital. 
Section 4.3 presents the estimated costs of the alternative drug regimens that would be 
used in place of the rechallenge process. Section 4.4 comprises a comparison and cost 
consequence of the alternate arms of the study and section 4.5 presents the results of the 
sensitivity analyses. Lastly section 4.6 will look at patient related costs attributed to by 
the CADR. 
 
4.1 Baseline characteristics 
Data was obtained from a cohort of 97 patients admitted to the dermatology ward at 
GSH with a CADR to TB drugs, at least one of which was a first-line drug, during the 
period from May of 2010 to July of 2015. Based on microbiological and drug sensitivity 
testing as well as clinical and radiological evidence, the majority of patients, 89 (92%) 
were suspected of having DS-TB, 4 (4%) MDR-TB, 2 (2%) had rifampicin mono-
resistant TB and the other 2 (2%) had isoniazid mono-resistant TB (Table 4.1). Within 













Table 4.1: Baseline characteristics of the study population that developed a CADR to TB 
therapy admitted to the Dermatology ward at Groote Schuur Hospital.  



























































Key: ART=anti-retroviral therapy, CADR=cutaneous adverse drug reaction, DRESS=drug reaction with 
eosinophilia with systemic symptoms, DS-TB=drug-sensitive TB, HIV=Human immunodeficiency virus, 
INH=isoniazid, IQR= interquartile range, LDR=lichenoid drug reaction, MDR-TB=multi-drug resistant 





Within the HIV-infected population, 29/85 (34%) were on ART, 19 of the 85 patients 
(22%) were within 2 weeks of starting TB therapy and 37/85 (44%) had been on TB 
treatment for longer than 2 weeks and should have been on ART.  
Sixty-eight of the patients had PTB, with the remainder (27) having extra-pulmonary TB 
and in 2 instances the patient was only on INH prophylaxis used for the prevention of 
TB in HIV-infected patients as well as those who may be immuno-compromised as a 
result of another systemic illness or as a result of immuno-suppressive therapy, such as 
corticosteroids used in the treatment of many systemic illnesses.  
 
DRESS was diagnosed in the majority (60/97, 62%) of cases while SJS was the second 
most commonly occurring CADR (22/97, 23%) (Table 4.1). All CADR occurred a 
median of 26 days (IQR 17; 43) after the initiation of TB therapy in the study 
population.  
4.1.1 Rechallenge population outcomes 
Of the 97 patients admitted with CADR to TB drugs, 85 (88%) were rechallenged with 
first-line TB drugs. Twelve patients were not rechallenged. One patient was admitted 
with a lichenoid drug reaction (LDR) and treatment was continued under supervision, a 
further 2 patients had been on INH prophylaxis which was discontinued upon 
presentation with CADR and in the remaining 8 patients there was insufficient evidence 
to support the TB diagnosis thus rechallenge was deemed unnecessary. Seventy-six of 
the 85 patients undergoing rechallenge (78% of the study population) were discharged 
on TB therapy, 34 of which were discharged on first-line TB therapy, with 42/76 (55%) 
requiring regimen adjustment to include second-line TB drugs.  Four patients were 
rechallenged to various degrees before the decision was taken that they had been 
unnecessarily treated for TB. Three patients absconded from the hospital ward after a 
weekend pass-out and were lost to follow up. Two patients died due to conditions 
unrelated to the CADR (Addisonian crisis due to high dose steroid use for chronic 





Table 4.2: Population rechallenged and outcomes of the rechallenge process for the study 
population.  
Patient group Number of patients 
(% of study population) 
Number of patients admitted with CADR 97 (100) 
Number of patients rechallenged 85 (88) 
Patients not undergoing rechallenge 
LDR 





8 (8)  
2 (2) 
1 (1) 
Number of patients discharged on TB therapy 
After rechallenge 


















Key: CADR=cutaneous adverse drug reaction, INH= isoniazid, LDR=lichenoid drug reaction, 
TB=tuberculosis 
 
4.1.2 Causative drugs 
Causative drugs of the CADR were confirmed with rechallenge in 64 of the 85 cases 
undergoing rechallenge (75%) (Table 4.3). A single drug was implicated in 46/64 
patients (72%). In 18/64 (28%) of patients there was more than one possible offending 
drug and in the remaining 22/86 patients (26%) a causative drug was not identified. 
Three of the population with DR-TB was found to have reacted to first-line TB drugs (2 
to pyrazinamide and 1 to isoniazid). 
 
Twenty-one of the 22 patients (95%), in whom a causative drug was not identified, were 
HIV-infected. Seven of these patients were on ART (tenofovir, lamivudine and 
efavirenz). In 3/7 cases the ART initiation was within 2 weeks of starting TB treatment 
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and the CADR developing. In a single case, ART was started a month after TB therapy, 
but 4 months before CADR. In 2/7 cases, ART had been started more than a year before 
the diagnosis and treatment of TB. In the remaining case, the patient reported symptoms 
of CADR before ART was initiated at the TB clinic. In a further 2 of the cases where the 
offending agent could not be identified the patients were known to be epileptic and on 
treatment for their epilepsy. 
 
Table 4.3: The frequency of first-line drugs identified as the causative drug of CADR in the 
study population. 
Suspected offending drug Number of cases identified 
(%) 
Rifampicin 11 (18) 
Isoniazid 11 (18) 
Pyrazinamide 10 (16) 
Ethambutol 9 (15) 
Rifampicin/Isoniazid  5 (8) 
Pyrazinamide/Ethambutol 4 (6) 
Rifampicin/Ethambutol 2 (3) 
Isoniazid/Pyrazinamide/Ethambutol * 1 (2) 
Rifampicin/Ethambutol/Pyrazinamide * 2 (3) 
Rifampicin/Isoniazid/Pyrazinamide * 1 (2) 
Rifampicin/Isoniazid/Ethambutol * 1 (2) 
* Multiple drug hypersensitivity 
 
Exclusion of the offending drug resulted in a regimen adjustment in 45/76 (59%) 
patients discharged onto TB therapy.  Four patients were rechallenged successfully with 
the four first-line drugs and discharged on a regimen containing all four drugs with no 
further documented reaction.  Pyrazinamide and ethambutol was the suspected causative 
agent in 2 each of these 4 cases.  
 
In the 22 patients where the causative drug was not known, 17 patients tolerated all the 
first-line TB drugs that were rechallenged. Fifteen of which had DS-TB and were 
restarted on first-line TB therapy (comprising 2 or more of the original 4 first-line drugs) 
without further reactions thus no additional investigations were required to identify the 
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offending drug. Three absconded from hospital during the rechallenge process and 2 
died before a drug could be identified and had not reacted to the any of the drugs during 
rechallenge.  
 
Overall, 34/76 (45%) patients were discharged on a regimen containing first-line TB 
drugs. Seventeen were discharged on a regimen comprising all 4 first-line drugs for 
various durations.  The other 17 (22%) were discharged on various combinations of 2 or 
3 first-line drugs only. The remaining 42/76 patients (55%) were discharged on regimens 
of TB therapy that included both first- as well as second-line TB therapy.  
4.1.3 Duration of hospitalisation and treatment 
Duration in each stage of the rechallenge process was calculated for all individuals of the 
study population. The average patient in the study population spent a median of 48 days 
in hospital (IQR 33; 73), the majority of hospitalisation, 41 days, was for the period of 
rechallenge. It would take the average patient in the study population a median of 255 
days (IQR 172; 342) from diagnosis of CADR, through management to final treatment 
completion (Table 4.4) 
 
Table 4.4: Duration in days that the study population spent in each stage of the rechallenge 
process.  
 Duration median days (IQR) 
Stabilisation period 8 (3;12) 
Rechallenge period 41 (28; 63) 
Optimised treatment period 180 (120; 270) 
Total days hopistalised 48 (33; 73) 
Duration from diagnosis to treatment 
completion 
255 (172; 342) 
 
4.1.4 Study population for cost comparison 
As our hypothetical alternate regimens would only be costed for use in patients with DS-
TB, the study population was separated into those with DS-TB (89 patients) and those 
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with DR-TB (8 patients) to allow for a more accurate cost comparison. Within the group 
of the population that had DS-TB, 2 were on INH prophylaxis and not rechallenged, 
while 12 lacked sufficient evidence for TB and thus were deemed to have been 
inappropriately treated for TB. Among those with confirmed DS-TB, there was a further 
division between those in the intensive phase and those in the continuation phase of 
treatment. Number of days in each stage of the process as well as days in hospital would 
be important for comparison and eventual costing. The differences in each group are 
shown in Table 4.5 below. Within the group of patients with DS-TB the average patient 
spent a median of 52 days in hospital (IQR 38; 79), the majority of hospitalisation being 
for the period of rechallenge. Within each population it is important to note that at 
various points during the rechallenge period patient were allowed a temporary discharge 
pass-out during which they could return home for a pre-determined period. This was 
typical done after patients were started on bridge therapy prior to the rechallenge period. 
In the DS-TB group patients were discharged for a median of 12 days (IQR 9; 14), and 
within the DR-TB group only 1 patient was allowed home for 20 days (Table 4.5). 
 
Table 4.5: Duration in days spent in each stage of the rechallenge process in DS-TB and DR-TB 
patients in the study population.  
Key: DS-TB=drug-sensitive TB, IQR=inter-quartile range, DR-TB=drug resistant TB, TB=tuberculosis 
 
Following discharge, the average patient with DS-TB would need to complete a further 
217 (IQR 180; 270) days of TB therapy, with DR-TB patients still having 437 (IQR 270; 
591) days of therapy after discharge. From presentation to completion of TB treatment, 
the average patient with DS-TB would have been in the CADR management programme 
for a median 239 days (IQR 159; 335), comparable with a regimen of second-line drugs 
for 9 months. DR-TB patients were in the programme for a median 537 days (IQR 310; 
710).  
Duration (median days) DS-TB  days (IQR) DR-TB days (IQR) 
Stabilisation period  11 (7, 19) 24 (11, 63) 
Rechallenge period 45 (32, 66) 42 (34, 64) 
Optimised Treatment Period 217 (180, 270) 437 (270, 591) 







4.2 Cost of current drug rechallenge process 
The 3 periods of the rechallenge process include; stabilisation, rechallenge and 
optimised treatment, which all contributed to the overall cost in varying degrees. In 
terms of the first aim of the study, calculating the total cost of CADR to first-line TB 
therapy, a total for the entire study population was calculated. Thereafter, the population 
was divided into those with DS-TB and those with DR-TB. Within these 2 subsets of the 
population totals and various results were presented to allow for a more accurate point of 
comparison for the hypothetical cohort for the second aim of the study. 
4.2.1 Total and per-patient cost of CADR management  
The total cost of managing CADR to first-line TB therapy in our population of 97 
patients admitted to GSH was $632,918 ($6,525 per patient).  
The majority of this total, $518,927 (82%) was made up from the cost of managing the 
CADR in the DS-TB patients in the CADR population. Within this group of the 
population the period of rechallenge was the most costly ($366,806; 71% of the total DS-
TB cost). However, the period of initial stabilisation and optimised treatment also 
contributed significantly to the overall cost $104,369 (20% of the total DS-TB cost) and 
$47,752 (9% of the total DS-TB cost) respectively. 
 
The remaining $113,991 amounted to the cost of managing the CADR in the patients 
with DR-TB. Within this group of the population the majority of the cost was made up 
by the optimised treatment period ($56,646; 50% of the total DR-TB cost). Within this 
population the initial stabilisation and rechallenge contributed $16,455 (14% of the total 
DR-TB cost) and $40,890 (36% of the total DR-TB cost) respectively (Figure 4.1 A). 
 
The average cost per patient was also determined for each group within the study 
population. The cost of managing a single patient with DS-TB and CADR was $5,831 
(95% CI 5134; 6527).  Once again, the major contributor was the rechallenge period at 
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$4,121 (95% CI 3521; 4722). The management of a single patient with DR-TB and 
CADR was more than double that of the DS-TB at $14,249 (95% CI 7257; 21240).  
The average cost per patient in the DR-TB population was greatest in the optimised 


















































Figure 4.1. Graphs showing (A) the total cost and (B) the average cost per patient of managing a 
CADR for the entire phase and for each stage of the rechallenge process in the patients with DS-
TB and DR-TB. In (A), values above each bar represent the total cost. In (B), values above each 
bar represent the mean cost and error bars show the 95% confidence interval. Values expressed 
in 2016 US $. 
 
4.2.2 Cost per subset within the DS-TB population 
The DS-TB patients within the study population could be further broken down into those 
who developed their CADR in the intensive phase of TB therapy (68; 76%), those in the 
continuation phase of TB therapy (7; 8%) and those unnecessarily treated for TB (14; 
16%).  
Patients in the intensive phase of TB therapy contributed $439,761 (85%) to the total 
CADR cost in DS-TB patients with 72% ($316,884) of this cost attributed to the 
rechallenge period. Patients in the continuation phase contributed $46,782 (9%), with the 
majority ($36,309; 78%) of this total also due to the rechallenge period. Those who were 
unnecessarily treated for TB, contributed a total of $32,383 (6%) to the overall cost. In 
this group the period of stabilisation was the greatest contributor to total cost for this 
group at $18,657 (58%) (Figure 4.2). The majority of this cost in the unnecessary 
treatment group (a total of $13,612; $3,403 per patient) was attributed to the 4 of the 14 
that underwent rechallenge to various degrees before the decision was made to 




Figure 4.2: Proportions of total cost of CADR in patients with DS-TB in the study population 
contributed to by the 3 different groups within the DS-TB group for each step of the rechallenge 
process. Costs are expressed in 2016 US $. 
 
The average cost of CADR for patients with DS-TB in the intensive phase of treatment 
was $6,467 (SD of mean 3,048) this is compared with $6,683 (SD of the mean 3,968) in 
the continuation phase and $2,313 (SD of mean 1,738) in those unnecessarily treated for 
TB. Of the patients who should have been in the continuation phase of treatment, 3 of 
the 7 underwent a more extensive rechallenge with pyrazinamide and ethambutol. In the 
confirmed TB groups, the greatest cost was incurred in the rechallenge period ($5,187 
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per patient in the continuation phase and $4,660 per patient in the intensive phase). The 
cost of rechallenging individuals in the continuation phase of TB therapy accounted for 
10% of the total cost for the whole DS-TB population (Figure 4.3).   
In those who were found to be unnecessarily treated for TB, 48% of the total cost was 
incurred in the stabilisation period at $1,333 per patient (SD of mean 617). In the 
optimised treatment period, these patients did not undergo TB treatment but were 
followed up at 6 weeks by a dermatologist to ensure resolution of the CADR symptoms, 
as is standard practice in the unit and ensure that they had not since developed TB. This 
amounted to a total cost of $114 ($8 per patient), equivalent to 0.2% of the study total 
for DS-TB at this stage (Figure 4.3). 
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Figure 4.3: Average per patient cost for the 3 different groups within the group of patients with 
DS-TB for each step of the rechallenge process. Values are expressed in 2016 US $.  
 
4.2.3 Components contributing to cost of CADR management 
Within the 3 periods of the rechallenge process several parameters influenced overall 
cost to varying extents. Within the period of stabilisation and rechallenge the greatest 
driver of cost was hospitalisation in the DS-TB patients in the study population. During 
stabilisation, the average cost per patient for hospitalisation amounted to $762 (65% of 
total stabilisation cost) whereas the cost of hospitalisation was $2,875 for the rechallenge 
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period (70% of the total cost for this period). Both consultations and investigations 
contributed almost equally during these 2 stages and were the second major contributors 
to total cost.  
 
After discharge, the main contributor to total cost became that of medication at $28,412 
($319/patient). Tests in this stage contributed to 19% of the total cost, more than they 
had in previous stages (10 % and 13% respectively) (Figure 4.4A).  
 
Within the group of patients with DS-TB, the influence of the various parameters on cost 
could also be seen amongst the 3 subgroups of this population subset. The group that 
was unnecessarily treated for TB had the highest average per patient cost for the 
stabilisation period with hospitalisation having the greatest contribution at $926. Patients 
in the intensive phase of TB treatment had the second highest per patient cost in the 
stabilisation period, with hospitalisation being $753 per patient and investigations being 
the second biggest contributor at $200. However, within the rechallenge period, the per 
patient cost was higher for the group in the continuation phase of treatment. In the 
optimised treatment phase, the average patient cost was again greater in the intensive 
phase group, with medication costs being the greatest contributor to overall cost at $392 
per patient (Figure 4.4B). 
 
In the group of patients with DR-TB, hospitalisation was the main contributor of total 
cost in the stabilisation ($1,381 per patient) and rechallenge period ($3,462 per patient,). 
Optimised treatment after discharge from hospital was largely influenced by the 
combination of TB drugs used with drugs costs amounting to a total of $51,872  or 









Figure 4.4: Breakdown of the per patient cost components contributing to each step of the 
rechallenge process in (A) the patients with DS-TB in the study population and (B) in the 
different 3 groups within the DS-TB population and (C) the patients with DR-TB in the study 
population. The cost values in each bar represent the cost of a particular component with the 
percentage representing the proportion contributed to the total cost in each step of the 
rechallenge process. Values expressed in 2016 US $. CP: DS-TB in the continuation phase of 
treatment, IP: DS-TB in intensive phase of treatment, UT; population unnecessarily treated for 
TB.  
 







































4.2.4 Medication cost breakdown 
Medication costs were further broken down for the entire rechallenge process into 
dressing costs, ancillary medications and TB drug costs. In patients with DS-TB total 
medication costs amounted to $18,431 and $207 per patient (95% CI: 126.7; 287.5). The 
greatest contributor to this total was the cost of TB drugs at $111 per patient (95% CI 
75.51; 146.3). Ancillary medications contributed $71 per patient (95% CI 0.46; 141.6).  
Dressings were the least costly at $26 per patient (95% CI: 19.04; 32.17).  
 
Medication cost was more than double in patients with DR-TB as compared to those 
with DS-TB ($461 per patient; 95% CI: 232.2; 690.5). TB drugs were, by far, the 
greatest cost contributor at $429 per patient (95% CI: 192.6; 664.4). This cost comprised 
93% of the total medication cost compared to the 54% in those with DS-TB. Dressing 
and ancillary drugs only amount to $28 (95% CI: 6.256; 49.83) and $5 (95% CI: 1.369; 





Figure 4.5: Breakdown of the total drug and dressing cost for the rechallenge period in patients 
with DS-TB and DR-TB. Values above each bar represent the mean cost and error bars show the 
95% confidence interval. Values expressed in 2016 US $. 
 
4.2.5 Test cost breakdown 
Within the study population test costs, comprising laboratory investigations and 
radiological examinations, contributed to a substantial proportion throughout the entire 
process. Radiological examinations were more commonly used in the diagnosis of extra-
pulmonary TB and had higher unit costs amongst the investigations carried out in the 
study population. CXR cost on average $13, with abdominal sonographs being $38, CT 
scans were by far the most expensive investigation at $182. Within the group of patients 
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with DS-TB the total cost of tests amounted to $588 per patient (95% CI 494; 682.7) and 
a total of $52,360. This contributed to 10% of the overall total cost (Figure 4.6A). 
Laboratory investigation costs for commonly used individual tests ranged from a white 
cell count (WCC) and haemoglobin at $1 to $4 for an AST or ALT. Less frequently used 
tests such as CD4 count cost $17. These less frequently used tests were used 
predominantly in the stabilisation period when evaluating a patient for all their baseline 
characteristics. Despite radiological examinations having higher unit costs as compared 
to typical laboratory investigations, the frequency at which the laboratory investigations 
were done contributed to a greater overall cost (86% of the total test cost). The greatest 
laboratory investigation costs were recorded during the rechallenge period ($475; 95% 
CI 387.9; 561.4). 
 
Amongst the patients with DR-TB the cost of tests per patient was higher at $827 (95% 
CI 601.6; 1052) for a total cost of $6,614 (6% of overall total cost). The highest 
laboratory investigation cost was incurred in the rechallenge period ($471 per patient; 
95% CI: 219.5; 723.1), but these costs were also significant in the optimised treatment 









Figure 4.6: Breakdown of the cost of investigations carried out in the patients with DS-TB (A) 
and patients with DR-TB (B) at the various stages of the rechallenge procedure for the average 
patient. Values above each bar represent the mean cost and error bars show the 95% confidence 
interval. Values expressed in 2016 US $. 
 
4.3 Estimated cost of the proposed alternative regimens 
The cost of a strategy where patients with DS-TB suffering from a CADR were 
immediately placed on second-line treatment as an alternative to rechallenge with first-
line TB drugs was determined. Patients with DR-TB with a CADR were not assessed in 
this model.  
 
It was assumed that the cost per patient for the stabilisation period in the hypothetical 
alternate regimen would be equivalent to that of a patient with DS-TB undergoing the 
rechallenge process ($1,173 per patient). All patients with CADR would be admitted and 
stabilised and then immediately initiated on specific second-line TB regimens rather than 
backbone therapy and avoid rechallenge. After therapy is started, patients would be 
discharged and continue treatment as outpatients with standard monitoring tests and 
follow up as per the South African NTP.   
4.3.1 Patients developing a CADR in the continuation phase of treatment 
For patients who had already completed the intensive phase (first 2 months) of first-line 
therapy at the onset of a CADR, we modeled a continuation phase regimen that would 
require an additional 4-month treatment period using the drugs rifabutin and 
ethionamide. This accounted for 7/75 (9%) patients with DS-TB in the rechallenge study 
cohort. Within this hypothetical population, the cost per patient was $681 from the 
period of stabilisation to treatment completion. TB drug costs accounted for 61% of this 
total cost. Rifabutin can be associated with hepatitis; neutropenia and thrombocytopenia 
thus screening tests included regular AST, ALT, and bilirubin with a white cell and 
platelet count. Ethionamide commonly causes gastrointestinal upset and does not require 
more specific monitoring. Investigations were the second greatest contributor to overall 
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cost with a total of $170 (25% of total cost). The cost breakdown is shown in Table 4.6 
below. 
 
Table 4.6: Component and total costs of a hypothetical alternative CADR management strategy 
using rifabutin and ethionamide for an average DS-TB patient who develops a CADR during the 
continuation phase of first-line treatment. The period of costings stated here includes from the 







Drug Dosage/Treatment length   
Rifabutin 300mg daily/4 months 1.71 205.20 
Ethionamide 750mg daily/4 months 1.77 212.40 
Follow up visits Frequency (total # of 
visits for treatment 
period) 
  
Dermatologist follow up 
visit 
6 weeks from treatment 
initiation (1) 
8.16 8.16 
Clinic visit (Facility cost) Weekly for the first month 
then monthly (7) 
5.27 36.89 
Appointment with doctor at 
clinic 
Weekly for the first month 
then monthly (7) 
6.94 48.58 
Tests Frequency (total # of tests 
for treatment period) 
  





Monthly (7) 4.31 30.17 
Alanine transaminase (ALT) Monthly (7) 4.31 30.17 
Alkaline phosphatase (ALP) Monthly (7) 4.31 30.17 
Total bilirubin Monthly (7) 3.85 26.95 
White cell count (WCC) Monthly (7) 1.30 9.10 
Eosinophil count Monthly (7) 1.30 9.10 
Platelet count Monthly (7) 1.30 9.10 




4.3.2 Patients with CADR within 2 months of starting first-line therapy 
In DS-TB patients who develop a CADR during the intensive phase of first-line 
treatment, we modeled 3 different regimens comprising second-line drugs to which the 
patients had never been exposed to be taken for 9 months. These regimens were 
developed based on clinical evidence from the literature and in consultation with experts 
in the field. With regard to laboratory investigations outlined in the methods chapter, 
some of the selected drugs required more specific monitoring as detailed in Table 4.7-4.9 
below. 
 
1) REGIMEN 1 comprised moxifloxacin, rifabutin and ethionamide for 9 
months. 
The total treatment period cost for regimen 1 was $1,478 per patient. TB drug costs 
accounted for the majority of this cost at $1,050 per patient (71% of the total cost). 
Monitoring is required for more severe adverse events such as hepatitis, neutropenia and 
thrombocytopenia and included regular AST, ALT, and bilirubin with a white cell and 
platelet count. These side effects are most commonly associated with rifabutin use. 
Moxifloxacin and ethionamide are generally well tolerated, but can cause gastro-
intestinal upset. These side effects are generally benign and don’t require any specific 
monitoring. Monitoring tests in this regimen was the second greatest contributor to 












Table 4.7: Component and total costs of a hypothetical alternative CADR management strategy 
using rifabutin, ethionamide and moxifloxacin for an average DS-TB patient who develops a 
CADR during the intensive phase of first-line treatment. The period of costings stated here 







Drug Dosage/Treatment length   
Rifabutin 300mg daily/9 months 1.71 461.70 
Ethionamide 750mg daily/9 months 1.77 477.90 
Moxifloxacin 400mg daily/9 months 0.41 110.70 
Follow up visits Frequency (total # of 
visits for treatment 
period) 
  
Dermatologist follow up 
visit 
6 weeks from treatment 
initiation (1) 
8.16 8.16 
Clinic visit (Facility cost) Weekly for the first month 
then monthly (12) 
5.27 63.24 
Appointment with doctor at 
clinic 
Weekly for the first month 
then monthly (12) 
6.94 83.28 
Tests Frequency (total # of tests 
for treatment period) 
  





At each clinic visit (12) 4.31 51.72 
Alanine transaminase (ALT) At each clinic visit (12) 4.31 51.72 
Alkaline phosphatase (ALP) At each clinic visit (12) 4.31 51.72 
Total bilirubin At each clinic visit (12) 3.85 46.20 
White cell count (WCC) At each clinic visit (12) 1.30 15.60 
Eosinophil count At each clinic visit (12) 1.30 15.60 
Platelet count At each clinic visit (12) 1.30 15.60 






2) REGIMEN 2 comprised rifabutin, levofloxacin and bedaquiline all for 6 
months then rifabutin and levofloxacin for a further 3 months. 
Along with investigations included in Regimen 1, bedaquiline requires additional 
monitoring tests due to the increased risk of QT interval prolongation. These tests 
include; an ECG as well as potassium, calcium and magnesium monitoring. ECG is 
performed at baseline and repeated at 2, 12 and 24 weeks while lab tests should be done 
at each visit. Bilirubin, AST, ALT, and alkaline phosphatase should be monitored at 
baseline and monthly to screen for potential hepatotoxicity. 
 
The overall cost of the treatment period used in this regimen was $1,746 per patient. The 
need for additional monitoring resulted in investigation costs being greater than in 
Regimen 1 at $339 per patient (19% of total cost). However, drugs still contributed the 




Table 4.8: Component and total costs of a hypothetical alternative CADR management strategy using 
rifabutin, levofloxacin and bedaquiline for an average DS-TB patient who develops a CADR during 
the intensive phase of first-line treatment. The period of costings stated here includes from the end of 







Drug Dosage/Treatment length   
Rifabutin 300mg daily/9 months 1.71 461.70 
Levofloxacin 500mg twice daily/9 months 0.42 113.40 
Bedaquiline (BDQ) 400mg daily for 2 weeks then 
200mg 3xweek for 22 weeks 
3.60  677.17 
Follow up visits Frequency (total # of visits 
for treatment period) 
  
Dermatologist follow up 
visit 
6 weeks from treatment 
initiation (1) 
8.16 8.16 
Clinic visit (Facility cost) Weekly for the first month 
then monthly (12) 
5.27 63.24 
Appointment with doctor at 
clinic 
Weekly for the first month 
then monthly (12) 
6.94 83.28 
Tests Frequency (total # of tests 
for treatment period) 
  





At each clinic visit (12) 4.31 51.72 
Alanine transaminase (ALT) At each clinic visit (12) 4.31 51.72 
Alkaline phosphatase (ALP) At each clinic visit (12) 4.31 51.72 
White cell count (WCC) At each clinic visit (12) 1.31 15.60 
Eosinophil count At each clinic visit (12) 1.31 15.60 
Platelet count At each clinic visit (12) 1.31 15.60 
Creatinine Monthly while on BDQ (6) 2.93 17.58 
Potassium Monthly while on BDQ (6) 2.93 17.58 
Calcium Monthly while on BDQ (6) 2.18 13.08 
Magnesium Monthly while on BDQ (6) 2.18 13.08 
Electrocardiograph (ECG) At weeks 2, 12 and 22 from 
starting BDQ (3) 
16.88 50.64 




3) REGIMEN 3 comprised delamanid, levofloxacin and rifabutin for 6 months, 
followed by levofloxacin and rifabutin for an additional 3 months.  
Similarly, to bedaquiline, delamanid carries the risk of QT prolongation. As such, the same 
monitoring tests used in Regimen 2 should also be used in Regimen 3 including liver function 
tests, ECGs and electrolytes that can contribute to cardiac abnormalities (sodium, potassium 
and magnesium). Intervals for tests were the same as those used for Regimen 2. Test costs in 
this regimen still accounted for the second highest component cost at $339 per patient (16% of 
total cost). The higher drug cost of delamanid reduced the proportion of test contribution in 
this regimen. TB drug costs were $1,610 per patient, which was 77% of the total cost for 
Regimen 3 (Table 4.9). The total cost of this regimen from stabilisation to treatment 






















Table 4.9: Component and total costs of a hypothetical alternative CADR management strategy using 
rifabutin, levofloxacin and delamanid for an average DS-TB patient who develops a CADR during the 
intensive phase of first-line treatment. The period of costings stated here includes from the end of 
stabilisation to treatment completion. Costs are expressed in 2016 US $. 






Drug Dosage/Treatment length   
Rifabutin 300mg daily/9 months 1.71 461.70 
Levofloxacin 500mg twice daily/9 months 0.42 113.40 
Delamanid 100mg twice daily/6months 5.74 1034.44 
Follow up visits Frequency (total # of visits for 
treatment period) 
  
Dermatologist follow up 
visit 
6 weeks from treatment initiation 
(1) 
8.16 8.16 
Clinic visit (Facility cost) Weekly for the first month then 
monthly (12) 
5.27 63.24 
Appointment with doctor at 
clinic 
Weekly for the first month then 
monthly (12) 
6.94 83.28 
Tests Frequency (total # of tests for 
treatment period) 
  





At each clinic visit (12) 4.31 51.72 
Alanine transaminase 
(ALT) 
At each clinic visit (12) 4.31 51.72 
Alkaline phosphatase 
(ALP) 
At each clinic visit (12) 4.31 51.72 
White cell count (WCC) At each clinic visit (12) 1.30 15.60 
Eosinophil count At each clinic visit (12) 1.30 15.60 
Platelet count At each clinic visit (12) 1.30 15.60 
Creatinine Monthly while on delamanid (6) 2.93 17.58 
Potassium Monthly while on delamanid (6) 2.93 17.58 
Calcium Monthly while on delamanid (6) 2.18 13.08 
Magnesium Monthly while on delamanid (6) 2.18 13.08 
Electrocardiograph (ECG) At weeks 2, 12 and 22 from 
starting delamanid (3) 
16.88 50.64 




4.3.3 Total cost estimates of alternate arm options 
The treatment period costs for each of the alternative regimens are provided in Tables 4.6-4.9 
above. In order to determine the total cost of each regimen, the period of stabilisation, the per-
patient cost of which is assumed to be the same as in the rechallenge process, was added to the 
treatment costs of each regimen. This total cost then reflects the cost of each regimen from the 
period of CADR diagnosis to treatment completion. Management of CADR occurring in the 
continuation phase would be $1,854 per patient. Intensive phase regimens remain more costly 
and are reflected below (Table 4.10). 
 
Regimen 3 was the most costly ($3,276 per patient) due to the higher cost of delamanid.  Both 
Regimen 1 and 2 had similar costs at $2,651 and $2,919 per patient respectively. In the next 
section, the cost per patient of the rechallenge process was compared to each of the alternative 
regimens 
 
Table 4.10: Total costs of the hypothetical alternative CADR management strategies for an average 
DS-TB patient who develops a CADR during the intensive phase of first-line treatment. The period of 
costings stated here includes from the start of stabilisation to treatment completion. Costs are 
expressed in 2016 US $. 
 Regimen 1 Regimen 2 Regimen 3 
Stabilisation Period $1,172.69 $1,172.69 $1,172.69 
Optimised 
Treatment Period 
$1,478.12 $1,745.85 $2,103.12 
Total cost/ patient 
(US $) 





4.4 Cost comparison of the drug rechallenge strategy to alternative 
treatment strategies 
A cost comparative analysis was performed to compare the per patient cost of managing 
a first-line TB therapy-associated CADR in patients with DS-TB using the current 
strategy of drug rechallenge to the proposed alternative second-line treatment regimens.  
 
In the rechallenge strategy, and assumed to be the same with the alternative strategies, all 
patients were admitted to the GSH Dermatology ward upon presentation with their 
CADR. Following admission, patients were offered supportive therapy and symptomatic 
management until all clinical and biochemical parameters had stabilised (stabilisation 
period). In the rechallenge strategy, this initial period of stabilisation cost $1,172.69 per 
patient with DS-TB and was assumed to be equivalent in each of the alternative 
strategies. However, CADR patients undergoing rechallenge in terms of current practice 
incurred a cost of $4,121.41 for the rechallenge phase and $536.54 for optimised 
treatment and follow up.  
 
Following stabilisation, our hypothetical cohort was assumed to initiate treatment on the 
alternative regimens immediately and subsequently be discharged to continue treatment 
and follow up as outpatients (Figure 4.7). All patients were assumed to complete a full 
course of the prescribed treatment in both strategies. 
 
In the current drug rechallenge process, 9% of patients presented with a CADR in the 
continuation phase of treatment and were subsequently discharged on rifampicin and 
isoniazid only. The cost when using the proposed alternate continuation phase regimen 
in this population subset cost $1,854 per patient compared with $10,983 per patient in 
the current rechallenge process (83% and $9,130 per patient saving). When estimating 
the costs of the alternate arms, the same proportion of patients (9%) was assumed to only 




The total cost of the drug rechallenge strategy was $5,831 per patient. In the alternative 
strategy, the cost per patient for Regimen 1 was $2,651 (45% less than current practice) 
with an incremental saving of $3,180. Although Regimens 2 and 3 were more costly at 
$2,919 and $3,276 per patient respectively, they were also associated with significant 
saving compared to drug rechallenge, with an incremental cost of $2,912 (Regimen 2) 




Key: BDQ=bedaquiline, CADR=cutaneous adverse drug reaction, DLM=delamanid, DS-TB=drug-sensitive TB, E=ethambutol, ETO=ethionamide, H=isoniazid, 
LFX=levofloxacin, MFX=moxifloxacin, R=rifampicin, RFB=rifabutin, Rx=treatment, TB=tuberculosis, Z=pyrazinamide. 





Hospitalisation was the primary driver of costs in drug rechallenge at $2,875 per patient (49% of 
total cost). Despite TB drug costs being much higher in our proposed alternatives compared to 
drug rechallenge, these costs still remained lower than that of hospitalisation. TB drug costs 
amounted to $1,050 per patient (40% of total cost) in Regimen 1, whereas these costs were 
higher in Regimen 2 at $1,252 per patient (43% of the total cost). Regimen 3, which included 
delamanid, incurred the highest drug cost at $1,610 per patient (49% of the total cost). 
Healthcare personnel and test costs were also much lower in the alternative regimen strategies as 
these patients were primarily treated as outpatients. The cost breakdown of each strategy is 
shown in Table 4.11. 
 
Table 4.11: Breakdown of parameters contributing to total cost per patient in the drug rechallenge 
strategy and the alternative treatment strategies. Costs were expressed in 2016 US $. 
 Current practice Alternative treatment strategies 
Component Drug rechallenge Regimen 1 Regimen 2 Regimen 3 
Stabilisation period $1,172.69 $1,172.69 $1,172.69 $1,172.69 
Hospitalisation $2,875.18 $0.00 $0.00 $0.00 
Clinic visit  $47.13 $60.91 $60.91 $60.91 
Healthcare personnel $596.12 $88.37 $88.37 $88.37 
Tests $613.19 $264.00 $323.85 $323.84 
TB drugs $526.32 $993.77 $1,177.57 $1,502.68 





4.5 Patient costs 
The cost incurred directly by patients in the study cohort suffering from a CADR to TB 
therapy was also determined. The majority of patients, (61/97, 63% of the study 
population), were classified as being unemployed, or being employed in jobs earning 
close to minimum wage. Unemployed patients were assigned an income of $221/month. 
Conversely, thirty patients were employed and their specific annual incomes were 
obtained from hospital records. The average annual income was $2,057 ($2,087 in 
patients with DS-TB and $1,716 in patients with DR-TB) with a daily income of $8 and 
$6.50 in the DS-TB and DR-TB patients, respectively. Patients admitted with DS-TB 
and a CADR spent a mean of 54 days in hospital with 39 of those days being working 
days, while patients with DR-TB and a CADR spent a mean of 65 days in hospital of 
which 46 days were determined to be working days.  
4.5.1 Medical expenses 
Patients accessing government healthcare services are liable to pay a portion of their 
medical bills based on their annual individual or household income. Within the study 
population, the majority of patients fell into the H1 category of partial subsidisation with 
an annual income of less than $2,450 (single income) or $3,403 (family income). Five 
individuals (4 DS-TB, 1 DR-TB) had an income of more than $3,403 but less than 
$4,900 falling into the H2 category. Within the study population there were 6 individuals 
who earned more than $4,900 per year and they were classified as H3. This group 
incurred higher hospitalization costs of $54/day and was liable for 75% of the total cost 
of laboratory tests and ancillary medications. As TB services in South Africa are free, all 
costs related to TB diagnosis and treatment was not included in the patient costs.  
 
The average patient in the H1 category incurred a mean cost of $38 up to the point of 
treatment completion (95% C1 17.74; 58.40).  H2 patients incurred a mean cost of $420 
(95% CI 171.4; 667.9), while H3 patients incurred the greatest cost of $3,058 (95% CI 




Figure 4.8: Medical expenses incurred by each patient being managed for a CADR by drug 
rechallenge stratified by the hospital subsidization categories, which were based on the patient’s 
annual income. Values above the graph represent the mean cost per patient with error bars 
representing the 95% confidence intervals. Values are expressed in 2016 US $. 
 
4.5.2 Patient loss and expenses 
The average loss of income due to hospitalisation was $303 (15% of total annual 
income) in the patients with DS-TB in the study population (95% CI: 228.2; 377.9) and 
$308 (18% of total annual income) in those patients with DR-TB (95% CI 137; 479.7). 
In the study population the loss of income due to hospitalisation contributed to the 
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Overall patients not only lost a substantial portion of their annual income due to 
hospitalisation, but also were further subject to a debt of $227 in the patients with DS-
TB (95% CI 48.64; 405.9) and $154 in the patients with DR-TB (95% CI 108; 416.6) as 
a result of medical expenses that were incurred due to the CADR. The majority of these 
expenses in were incurred in the rechallenge phase. In those with DS-TB, the mean 
patient expense for this phase was $148 (68% of total expenses) and $77 (50% of total 
expenses) in the DR-TB patients in the study population. The stabilisation period was 
the second most expensive period for the patients with DS-TB in terms of expenses at a 
mean of $71, whereas in those with DR-TB the optimised treatment phase was the 
second most expensive period at a mean of $41 per patient. 
 
By the time of treatment completion an average patient with DS-TB in the study 
population would have lost 25% of their annual income, equating to a mean of $530 
(95% CI 288.3; 772.3). An average patient with DR-TB experienced a loss of $462 (95% 





Figure 4.9: Costs incurred by study and hypothetical patients using alternate regimens suffering 
from a CADR and expressed as a percentage of their annual income. Values above the graph 
represent the mean annual salary per patient within each group. Percentages shown in red 
represent the proportion of the annual patient income that is assigned to each component. Values 
are expressed in 2016 US $. 
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4.6 Estimated patient costs for alternate regimens 
Using the same proportions of patients employed and their average annual incomes. As 
well as the proportion on each payment subsidy of the patients with DS-TB within the 
study population (89% H1, 4% H2, 7% H3), an estimate of the loss of annual income 
and costs for the alternate regimens was calculated. Costs included the costs incurred in 
the original period of stabilisation and the optimised treatment phase as per the alternate 
treatment regimens outlined earlier in this chapter. 
 
The annual income for this population amounted to $1,630 ($5.72/day). Loss of income 
due to hospitalisation for a total of 11 days (equivalent to that of patients with DS-TB in 
the study population) in the period of stabilisation was $63. Patient costs relating to each 
regimen are shown in Figure 4.9 above.  
 
 
Overall the alternate regimens therefore resulted in a total patient loss of $154 for 
Regimen 1 and $155 for Regimen 2 and 3. This amounted to 10% of the total annual 
income in both groups.  
 
4.7 Societal costs 
The rechallenge process amounted to a total societal cost of $545,898 equivalent to 
$6,134 per patient with DS-TB who developed a CADR to first-line TB therapy (95% CI 
5401; 6866). This cost was lower in the alternate regimens. Regimen 1 cost $2,643 (43% 
of current practice) per patient, with regimen 2 and 3 costing $2,982 (47% of current 









Table 4.12: Breakdown of the societal costs for the rechallenge practice and alternate regimens.  
 Rechallenge Regimen 1 Regimen 2 Regimen 3 
Healthcare 
Provider costs 
$5,831 $2,580 $2,823 $3,148 
Patient costs $303 $63 $63 $63 
Total $6,134 $2,643 $2,886 $3,211 
 
4.8 Sensitivity analysis 
A univariate sensitivity analysis was performed to determine the uncertainty around the 
assumptions and values of each variable used to estimate the costs of drug rechallenge 
and alternative treatment strategies. Hospitalisation, TB drugs and ancillary drug costs 
were either doubled or halved and test costs were increased or reduced by 50%. 
Additionally, the influence of outpatient stabilisation for eligible patients was considered 
and the consultation times (halved and doubled) and frequency (daily and weekly) was 
varied as well as the percentage of patients who developed a CADR during the 
continuation phase of treatment. Figure 4.10A-D shows the effects of changing these 
parameters on the overall cost per patient of each strategy. 
 
In the drug rechallenge strategy; variation in hospitalisation costs had, by far, the 
greatest influence on the overall cost likely due to extensive length of hospitalisation that 
is required for these patients.  When costs were halved, this resulted in a 30% reduction 
in overall cost, with rechallenge costing $4,067 per patient. Doubling these costs brought 
the total per patient to $12,884 (2,2 times more than current cost). Outpatient 
stabilisation resulted in a $154 saving per patient, which was an overall saving of 
between 2.6% in current practice to 5.9% in Regimen 1 (5.4% Regimen 2 and 4.8% 
Regimen 3). Alternatively, if this period were carried out at a secondary level it would 
result in a $145 saving equivalent to 2.8% in current practice and up to 5.5% in Regimen 
1. Consultation time and TB drug costs also had a significant influence on overall cost 
within the rechallenge population. Longer consults with patients while admitted resulted 
in a 12% increase in cost per patient. Conversely, when consultation time was halved, 
cost was reduced by 6% ($5,494). TB drug costs when doubled resulted in a 19% 
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increase in rechallenge total per patient at $6,938, when halved the cost was reduced by 
9% to $5,277 per patient. Due to the similar cost of the optimised treatment period, 
whether patients develop a CADR either in the intensive or continuation phase, altering 
the percentage of patients developing a CADR in the continuation phase had very little 
impact on the overall cost per patient in this strategy ($1, Figure 4.10A). 
 
Conversely, the biggest impact on overall cost per patient in the alternative treatment 
strategies was TB drug costs. Doubling the costs of TB drugs resulted in a substantial 
increase in the alternative regimen costs ($3,630; 41%, $4,076; 44% and $4,758; 51% 
for Regimens 1-3, respectively). Halving theses costs resulted in a reduction of costs 
from 20-26% for the alternate regimens as seen in Figures 4.10 B-D. Within the alternate 
regimens, hospitalisation still had a significant influence on overall cost. Doubling the 
cost of hospitalisation resulted in a 16-19% increase in overall cost, whereas halving this 
cost resulted in an 8-10% saving on the total cost. Implementing an additional month of 
inpatient hospitalisation in alternate regimens increased costs by 61-75%. Regimen 1 
cost $4,504 per patient with Regimen 2 and 3 costing $4,747 and $5,072 per patient. 
Test costs also impacted overall costs due to the more intensive monitoring required for 
the second-line drugs. This increase and decrease in the cost in all alternate regimens 
was between 9 and 10%. Varying the percentage of patients developing a CADR in the 
continuation phase had a greater impact on overall costs in these strategies, particularly 
at the higher estimate, as the continuation phase treatment regimen (rifabutin & 
ethionamide) were much cheaper than the full second-line treatment regimens 
(Regimens 1-3). Regimens 1-3 exhibited sensitivity to similar components in the 
sensitivity analysis. 
 
Using the lowest reported ZAR to USD exchange rate for the period of R13.26=1USD 
resulted in a 10% decrease in the overall costs of the current as well as the alternate 
regimens with current rechallenge practice costing $5,263 per patient with Regimen 1, 2 
and 3 costing $2,329, $2,549 and $2,842 per patient respectively. However, using the 
higher rate of R16.86=1USD reported for the 2016 period resulted in a 15% increase in 
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the overall per patient cost. Rechallenge practice would then cost $6,692 with alternate 

























Figure 4.10: Tornado diagram showing the effect of changing specific parameters on the cost per patient for managing a CADR case in 
(A) the current practice of drug rechallenge and in (B) regimen 1, (C) regimen 2 and (D) regimen 3 of the alternative second-line 




4.8.1 Sensitivity analysis of patient costs 
By doubling the annual incomes of the study population societal costs were also 
increased due to the higher patient costs. Societal costs for the rechallenge process were 
$6,407 (5% higher), with Regimen 1, 2 and 3 costing $2,706, $2,949 and $3,274 per 
patient respectively (2% greater than current costs). Should patient have a lower than 
estimated annual income, societal costs would decrease accordingly. Halving the annual 
income resulted in a 5% decrease to $5,801 per patient in the rechallenge group and a 
2% decrease in the alternate regimens at $2,508, $2,823 and $3,148 respectively.  
4.8.2 Scenario analysis 
A scenario analysis was also performed where a number of variables were varied 
simultaneously to determine the effect on the overall cost of each strategy. The specific 
variables that were altered in the “best” and “worst” case scenarios have been described 
in detail in the methods chapter (Chapter 3).   
 
The cost per patient in the “best” case scenario ranged from $1,640 to $3174, with 
savings from 54% (in the current strategy) to 37% (in the alternative second-line 
treatment strategies) compared to the baseline. Conversely, the “worst” case scenario 
almost doubled the cost of each strategy compared to the baseline ($5,981- $8,027). 
When the “best” and “worst” case scenarios were compared between the different 
strategies, the alternative treatment option was cheaper than drug rechallenge strategy. 
However, “worst case” scenario for the alternative treatment options was more costly 
than baseline rechallenge strategy cost, but still cheaper than the worst case of the 




Figure 4.11: Scenario analysis showing the cost per patient of the “best” and “worst” case 
scenarios for managing a CADR case in the current practice of drug rechallenge and regimens 1, 
2 and 3 of the alternative second-line treatment strategies. Values are expressed in 2016 US $.  
 
When costs were broken down into their components, hospitalisation was again the 
greatest cost driver for the drug rechallenge strategy. This was also the case in the 
alternative treatment strategies, but to a lesser extent. Drug costs had the greatest 
influence on the overall cost of Regimens 1-3. A full breakdown of costs in the “best” 










































































Table 4.13: Scenario analysis showing the cost breakdown per patient of the “best” and “worst” 
case scenarios for managing a CADR case in the current practice of drug rechallenge and 
regimens 1, 2 and 3 of the alternative second-line treatment strategies. Values are expressed in 



















Component Baseline Best case Worst case 
Hospitalisation $3,637.55 $1,763.30 $5,257.84 
Clinic visits $47.13 $47.13 $47.13 
Tests $809.98 $465.42 $809.98 
Specialist consultations $776.16 $553.29 $921.85 
TB drugs $430.15 $215.08 $860.30 
Ancillary drugs $129.67 $129.67 $129.67 
































Hospitalisation $762.37 $381.19 $2,685.97 
Clinic visits $60.91 $60.91 $60.91 
Tests $460.89 $409.39 $921.78 
Specialist consultations $268.51 $257.66 $291.20 
TB drugs $993.87 $496.94 $1,987.74 
Ancillary meds $33.49 $33.49 $33.49 







Hospitalisation $762.37 $381.19 $2,685.97 
Clinic visits $60.91 $60.91 $60.91 
Tests $520.73 $469.23 $1,041.26 
Specialist consultations $268.51 $257.66 $291.20 
TB drugs $1,177.68 $588.84 $2,355.36 
Ancillary Meds $33.49 $33.49 $33.49 







Hospitalisation $762.37 $381.19 $2,685.97 
Clinic visits $60.91 $60.91 $60.91 
Tests $520.73 $469.23 $1,041.26 
Specialist consultations $268.51 $257.66 $291.20 
TB drugs $1,502.38 $751.19 $3,004.76 
Ancillary meds $33.49 $33.49 $33.49 






5.1 Study objective 
Tuberculosis remains an epidemic in South Africa with a reported annual incidence of 
834 per 100,000 in 2016, with up to 50% of patients being co-infected with HIV [1]. 
Fortunately, the implementation of TB and HIV management programmes has enabled 
infected individuals access to effective, affordable care with resultant improved case 
detection and treatment initiation rates. However, first-line TB therapy can be associated 
with severe adverse events requiring treatment interruption and even cessation. As a 
result, a balance of appropriate, effective treatment while preventing patient exposure to 
potentially toxic therapy must be maintained.  
 
Until now, drug rechallenge has been the method of choice for identifying the offending 
drug/s in cases of CADR to TB drugs. Drug regimens are then subsequently modified to 
exclude offending drug/s while providing effective treatment. No standard guidelines 
exist as to how the rechallenge process should be carried out. Current practice within the 
study population required prolonged hospitalisation imposing a financial burden on both 
the healthcare system and the patient. The extent of which has not previously been 
quantified. Alternative strategies using second-line drugs for the treatment of DS-TB 
have only been used experimentally and too have not been completely evaluated in terms 
of their efficacy or estimated costs. Parameters contributing to the cost of CADR 
management have varying influences on the overall total and highlight potential areas 
for adjustments that could result in cost saving. Aspects affecting healthcare and patient 
costs, though evaluated in other literature, have not been analysed in the context of 
CADR to first-line TB drugs. Within our study we not only estimated healthcare costs, 
but also estimated patient level costs in terms of loss of income and medical expenses as 




5.2 Key study findings 
Estimated costs of the current practice of rechallenge in cases of CADR to TB drugs are 
significant amounting to $6,525 (95% CI 5612; 7438) per patient. The majority of this 
cost (82%) was contributed to by CADR management in patients with DS-TB, $5,831 
(95% CI 5134; 6527) per patient. This total includes the cost of the rechallenge process, 
as well as subsequent outpatient management up to the point of treatment completion. 
Patient level costs place a substantial personal burden on affected individuals amounting 
to 25-27% of their annual income. With the proposed hypothetical alternative strategy, 
using newer second-line drugs, we have shown a more affordable option for CADR 
management and subsequent treatment. All three of the alternative treatment regimens 
are associated with significant estimated provider and patient cost saving. Alternative 
regimens were estimated to cost between 45% and 55% of the current practice, despite 
the higher TB drug costs, which were found to have the greatest influence on overall 
cost. Patients experienced a lower 10% loss of annual income in the alternative treatment 
strategy as compared to the current drug rechallenge strategy. Savings to both the patient 
and provider in the alternative regimens was attributed to the shorter period of 
hospitalisation.  
 
5.3 Study findings in view of the current literature 
5.3.1 Study population 
Among our population of 97 individuals admitted to the GSH dermatology ward in Cape 
Town, with a significant HIV prevalence (88%), 87 (89%) were assumed to have DS-TB 
at presentation, 14 of which were later determined to have been unnecessarily treated for 
TB. Of the remaining 10 patients, 2 were receiving only INH prophylaxis and 8 were 
classified as having DR-TB (4 MDR-TB and 2 each INH- and rifampicin (RIF) mono-
resistance). Within this population, the prevalence of DR-TB amongst patients with TB 
was 8.5%, much higher than the National Institute for Communicable Diseases estimated 
prevalence of 2.8% for South Africa [175]. This is likely due to selection bias as the 
study cohort consisted of inpatients in a tertiary hospital, thus not a true representation of 
the general population affected by TB who are typically managed at community-based 
 
 117
TB clinics. Tertiary hospitals are referral centres for more complicated medical cases 
and the higher number of DR-TB cases is therefore expected. Furthermore, this 
population consists of individuals with an ADR. The management of milder ADR may 
be attempted at TB clinics, but ADR in cases with MDR-TB are more likely to be 
referred onto specialist referral centres such as GSH.  
  
Despite low CD4 counts (median of 130 cell/mm3) only a third (29 patients) of the total 
HIV-infected population was on ART. Regardless of changing ART guidelines within 
the period spanned by the study, all HIV-infected individuals were eligible for ART [54-
56]. In most of the cases in the study, as is commonly reported; TB diagnosis was the 
indication for HIV testing. TB is often the initial opportunistic infection heralding HIV-
seroconversion [38, 41]. ART in this subset of HIV-infected individuals is therefore 
delayed to reduce the risk of TB-IRIS, as was seen in 19 patients who were within the 2 
weeks of starting TB treatment [6, 38, 40]. However, 37 patients (44%) had been on TB 
therapy for more than 2 weeks and should have been initiated on ART. The delay in 
initiation of ART has been shown to further negatively impact treatment outcomes 
related to TB and HIV [43, 44]. It is not clear why the ART was not yet started in these 
eligible individuals. 
 
Despite the low median CD4 count, the majority of patients had PTB and not the 
disseminated form of disease, as would be expected [42]. Within our population, the 
type of TB (pulmonary vs. extra-pulmonary or disseminated) was based on the first 
diagnostic test used that produced a positive result, i.e. a positive sputum smear, a CXR 
or abdominal ultrasound suggestive of TB or a positive culture from a biopsied sample. 
As such, not all patients were screened for further sites of TB resulting in cases of extra-
pulmonary or disseminated TB perhaps being missed and classified as PTB.  
 
In all cases of CADR, the diagnosis of TB needs to be definitive before patients undergo 
rechallenge. Following this, within our study population if TB was unconfirmed prior to 
rechallenge, more extensive investigations were undertaken to prove TB. In cases where 
TB could not be proven, infectious diseases specialists were consulted to advise if there 
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were enough grounds to treat for TB. In 14 individuals (16%) in our study population 
who were assumed to have DS-TB, their opinion was that there were insufficient 
grounds to re-initiate TB treatment. However, four patients within this group still 
underwent drug rechallenge according to standard rechallenge practice before treatment 
was discontinued as a result of differing opinions by consulting specialists. These 
individuals highlight the challenges experienced in diagnosing TB in a high HIV 
prevalence setting including; atypical CXR features of multi-lobar as compared to apical 
consolidation, and negative smears for microscopy [40, 48]. As a result, diagnosis of TB 
in HIV-infected persons is usually more costly. Of the 14 patients, 6 (43%) were started 
on treatment based on CXR findings thought to be suggestive of TB, whereas 2 had been 
initiated on TB treatment based on clinician opinion alone. The practice of “empiric” TB 
treatment is commonplace in high incidence setting of HIV and TB co-infection [19, 
176]. HIV not only increases the risk of developing TB, but also alters the clinical course 
of TB, with co-infected patients having an increased mortality [40]. South African TB 
guidelines include the practice of empiric therapy or rather treatment initiation based on 
suggestive symptoms and radiological features without the more sensitive 
bacteriological confirmation in order to avert the morbidity and mortality associated with 
untreated TB [40] [87].  
 
Smear microscopy has a high specificity for TB, but low sensitivity in patients who have 
non-cavitatory pulmonary disease or low sputum bacillary load [40]. Within the HIV-
infected population, especially at lower CD4 counts, sputum smear results are often 
negative [40]. The more sensitive Xpert® MTB/RIF assay was not yet available at 
periods during the study [45]. Xpert® MTB/RIF still has a lower sensitivity in HIV-
infected compared to HIV-uninfected individuals but is more sensitive than smear 
microscopy [40, 177].  
5.3.2 CADR 
In the study cohort, CADR occurred a median of 26 days after initiating TB therapy. 
This is comparable to other studies reporting that majority of CADR and hepatotoxicity 




The majority of patients (60/97, 62%) were diagnosed as having DRESS, with the 
remaining patients having SJS (22/97, 23%), SJS/TEN overlap (4/97, 4%) and TEN 
(10/97, 10%) and a single patient diagnosed with LDR (1%). Literature reports that 
>90% of TB-associated CADR in HIV-infected patients are classified as being DRESS, 
SJS and TEN as was the finding in our population [65, 178]. All our patients were 
admitted to hospital as no standard guidelines exist for the management of CADR and 
South African TB guidelines recommend hospital admission for all severe CADR, 
defined as those with erythematous rash and fever, blistering, mucosal involvement or 
hepatitis, for expert rechallenge [40]. Milder pruritic rashes without blistering, mucosal 
or systemic involvement are managed supportively at TB clinics with antihistamines 
[40].  
5.3.3 Offending TB drug 
The decision to rechallenge drugs was based on the Naranjo probability scale with 
offending drugs being identified through the rechallenge process [84]. Only first-line TB 
drugs were rechallenged. In cases where patients were on second-line TB therapy or 
ART, based on the Naranjo probability score, these drugs were changed to appropriate 
alternatives as needed and if using therapy for opportunistic infections this was 
discontinued. The offending drug was identified in 64/86 (74%) cases undergoing 
rechallenge. First-line drugs were implicated in 57/64 (89%) cases, with 16/57 cases 
developing a rechallenge reaction to more than one of the first-line TB drug. First-line 
drugs were identified as the offending drug in 3/8 cases of DR-TB. Although not key to 
the second-line drug regimens for DR-TB, this finding highlights the value of 
rechallenging first-line drugs. If identified as the offending drug, regimen adjustments to 
exclude the drug are straightforward, but if not, it allows for the use of an effective, well 
tolerated more affordable agent as compared with the D2 and D3 options of bedaquiline 
and delamanid (D2) and meropenem, imipenem, PAS and amoxicillin-clavulanate (all 
D3) in the DR-TB regimen. In one case within the population co-trimoxazole was 
identified as being the offending drug rather than first-line TB therapy following 




The causative drug was not identified in 22 patients. This was a result of a number of 
reasons including; 1) drug rechallenge with only rifampicin and isoniazid in those who 
had already completed or were about to complete intensive phase of therapy, 2) 
pyrazinamide not being rechallenged in individuals with severe hepatitis due to the 
drug’s direct liver toxicity, 3) patients absconding from the hospital before completion of 
rechallenge or 4) successful rechallenge of the TB drugs in those only on TB therapy or 
in those on another drug that was concurrently taken with TB drugs e.g. anti-epileptics 
or ART that could have been the offender.  
 
Seven patients in the group who developed a CADR to more than one drug, or where the 
drug could not be identified were on ART. In 3 of the 7 cases the ART had been started 
within 2 weeks of the TB therapy and the subsequent CADR. The incidence of ADRs in 
HIV-infected individuals is 26.7% higher than uninfected individuals. It is well 
established that ART and co-trimoxazole are associated with CADR in their own right 
[80, 111].  It is therefore possible that the individuals could have developed their CADR 
to ART rather than first-line TB therapy where these individuals were successfully 
rechallenged. In the case of one HIV-infected patient in the cohort, who was later 
deemed to have been unnecessarily treated; nevirapine or TB therapy was thought to 
have been equally likely to be the causative drug. ART was only stopped or changed 
within our population if the Naranjo probability score indicated a high probability of it 
being the offending drug at presentation. Thus if not stopped or changed and CADR 
improved with the withdrawal of TB therapy, the TB drug/s was the more likely 
causative agent.  
 
No consensus as to the most common offending TB drug has been reached with all four 
first-line TB drugs having the potential to result in CADR. Authors have reported 
various likelihoods of pyrazinamide and rifampicin being the most common culprits [11, 
65, 68]. In this study, we found that all 4 drugs were implicated almost equally in cases 
where a single offending drug was identified (11 for rifampicin and isoniazid, 10 for 
pyrazinamide and 9 for ethambutol). This finding highlights the danger of assuming that 
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any one of the 4 drugs is benign. All drugs need to be treated equally as potential 
offenders in first-line TB drug-associated CADR. First-line drug regimens cannot be 
altered without going through the rechallenge process, as even if there is a high index of 
suspicion of a causative drug with the Naranjo score, one is never sure if the patient may 
have multiple drug hypersensitivities as was seen in our population (11/64 reaction to 
more than 1 first-line drug and 5/64 having multiple drug hypersensitivities, 8%).  
5.3.4 Rechallenge 
In South Africa, drug rechallenge ensures infection control and prevents monotherapy 
through the use of bridging therapy, comprising three second-line drugs to which the 
patient has never been exposed for 2 weeks [65]. The first-line TB drugs are then 
rechallenged, sequentially and additively every 4 days, with rifampicin and isoniazid 
being the most effective drugs, rechallenged first [6, 17, 65]. The 4-day interval between 
subsequent drug introductions is used based on the premise that most rechallenge 
reactions will occur within 72 hours of repeat exposure [16, 65].  
5.3.4.1 Rapidity of rechallenge 
Interruption of TB treatment in the intensive phase is associated with a three times 
increased risk of mortality. This risk increases to an almost 4 times higher risk of 
mortality in those who are TB/HIV co-infected [3, 6, 11, 16]. Re-initiation of TB therapy 
should therefore happen as soon as possible. Limiting the length of the rechallenge 
process ensures that patients begin an optimal TB treatment regimen sooner thereby 
reducing the mortality risk [6]. However, the 96-hour interval between drug rechallenge 
cannot be shortened.  
 
The duration of bridging therapy has the potential to be shortened, regardless of the 
severity of the index CADR. Two weeks was reported as the duration in Lehloenya et 
al.’s population whereas 17-21 days was reported in the Sharma et al. population [17, 
65]. Our population had comparable average time to stabilisation in the DS-TB 
population with the literature (11 days; IQR 7; 19). The possibility of a shorter 
stabilisation period was not assessed in this study. Further studies are needed to 
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determine the optimum duration of the bridging therapy considering the relatively high 
frequency of multiple drug hypersensitivity in this setting [179].  
 
The most easily implementable cost-reducing change to the rechallenge process would 
be the use of an outpatient stabilisation period. No clear guidelines exist as to what 
would make a patient eligible for outpatient management and this option would need to 
be assessed on an individual patient basis. However, we estimated, based on specialist 
clinical opinion and literature that patients with DRESS and ALT of <100U/L could 
potentially be stabilized as outpatients and this would therefore apply to 26 (29%) of the 
study population [62]. Within our population 45 of the patients were given temporary 
discharge pass-outs, with a median of 12 days in the stabilisation period, further 
highlighting the possibility of outpatient management in this stage for patients with DS-
TB. As duration of stabilisation is patient dependent, measures could be put in place for 
regular assessment of these patients to allow for a perhaps sooner initiation of 
rechallenge.  
 
The period of rechallenge was associated with a significant duration of hospitalisation 
with the average patient spending a median of 41 days (IQR 28; 63) in hospital.  Those 
with DS-TB had an expected longer median of 45 days, as compared to those with DR-
TB (42 days) as a result of more drugs needing to be rechallenged in cases where 
second-line drugs were suspected as causing the CADR. The duration of hospitalisation 
was comparable with Lehloenya et al.’s experience with a median of 50 inpatient days 
[6]. The extensive hospitalisation period was attributed to the practice of rechallenge 
employed. Hospitalisation was further prolonged in patients that developed rechallenge 
reactions to reintroduced TB drugs. Following a rechallenge reaction, the patient would 
be allowed to once again reach their baseline before the process could continue. In 
addition, some patients developed more severe reactions upon rechallenge where the 
causative drug was not apparent, resulting in all drugs having to be stopped and the 




Outpatient based rechallenge is employed in specialised community TB clinics in cases 
of less severe CADR that require only supportive therapy [87]. This practice would 
result in the greatest cost saving.  However, with the documented mortality associated 
with CADR reported in our typical population, a more appropriate alternative could be 
the use of secondary level hospitals for rechallenge. The lower level of hospitalisation 
would result in the daily cost of hospitalisation being halved ($27 per day compared to 
current cost of $64 per day). In order to ensure patient safety, clear guidelines would 
have to be developed based on current knowledge and the staff in these hospitals trained 
appropriately. As estimated previously about 30% of the population could be eligible for 
this alternative, but this estimate is based on expert opinion. 
 
Upon discharge, an average treatment course of 217 days (IQR 180; 270) was 
anticipated in the patients with DS-TB, which is comparable to a 9-month course of 
second-line TB therapy. In the patients with DR-TB the expected duration to completion 
of treatment was a median of 437 days (IQR 270; 591).  
5.3.5 Patient outcomes 
The majority of patients (85) were rechallenged. Most patients (76/85, 89%) were 
discharged on TB therapy. TB treatment was continued in the patient with the LDR 
throughout the resolution of the reaction and upon discharge. Thirty-four of the 85 
patients (40%) were successfully rechallenged and discharged onto regimens comprising 
first-line TB drugs. Four of the individuals were discharged on a regimen comprising all 
four first-line drugs. Forty-two of the rechallenged patients (49%) required 
individualised regimens comprising both first and second-line therapy to optimise their 
treatment. The remaining 9 patients, who were rechallenged, were not discharged onto 
TB therapy as 4 were deemed to have been unnecessarily treated for TB, 3 absconded 
and the other 2 died. Drug regimens as well as expected durations of treatments in this 
population cannot be standardised. Regimens are built around suspected offending 
drug/s, duration of treatment prior to CADR, drug sensitivities, potential drug 
interactions and patient co-morbidities [16]. In our population, discharge drug regimens 
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were devised based on expert opinion of both the treating dermatologists and infectious 
disease specialists with extensive experience in managing TB.  
5.3.5.1 Morbidity and mortality associated with rechallenge 
The majority of patients were discharged successfully. Three individuals in the study 
population failed to return to the dermatology ward during the study period following a 
temporary discharge pass. In these individuals, we have no information as to whether 
they received further treatment. In hospital mortality associated with rechallenge was 
2%. Unfortunately, patients were not followed up beyond the 6-week dermatologist 
review post discharge. Patients continued their treatment at local clinics and did not 
usually return to the hospital. Attempts were made to follow up information after 
discharge via clinics. This was largely unsuccessful due to changing contact details and 
migration to other provinces or areas of the Western Cape. As such, it is unknown if 
patient completed treatment, absconded or demised. This missing patient information 
could potentially contribute to a higher overall morbidity as well as mortality rate for the 
overall population. The rate of treatment completion and subsequent cure, or the 
potential number of inadequately treated and relapsed patients as well as those who 
potentially developed drug-resistance is not known.  
5.3.6 Cost of CADR 
According to cost analysis studies in the literature, treatment of DS-TB costs $257 per 
patient ($334.85 once inflated to 2016 cost) in South Africa [28]. Costs of treating DS-
TB vary greatly in the literature due to different geographic regions as well as 
differences in clinical practice. Health service related costs are usually dependent on 
GNI per capita. Costs are thought to be less in lower income countries such as 
Zimbabwe where the average cost per patient was $45-$57.60 per patient in a US study 
[173, 180, 181].  
 
Within our population the average cost for treating a CADR to TB treatment was $6,525 
per patient (25 times greater than an uncomplicated case). The higher cost is not 
surprising, as uncomplicated cases are managed as outpatients, with initially weekly than 
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monthly appointments at community-based primary care clinics requiring only standard 
monitoring and investigations. Costing within the study population was analysed in 
terms of the 4 subgroups mentioned previously. The authors wished to determine the 
cost of CADR to TB therapy in all patients regardless of sensitivities. However, 
development of an alternate regimen was only possible for cases with DS-TB. The 
alternate regimen was derived on the premise that only drugs to which the patient had 
never been exposed would be used thus avoiding the need for rechallenge. This same 
principle could not be applied to DR-TB patients who represent a unique subset of the 
population, with regimens containing a wide variety of combinations based on 
sensitivities. It is therefore impossible to derive a regimen that avoids all drugs that 
patients DR-TB could potentially be on. After the initial costing of the whole population, 
the population was divided into those with DS-TB and DR-TB. Costing of the separate 
groups allowed for a more accurate comparison of costs with the alternate regimens. It is 
well documented that costs of managing DR-TB are much greater and thus we 
anticipated that complicated cases would have an even greater cost thus overinflating our 
estimate of current practice.   
 
Patients in our population with DS-TB that were managed for CADR cost $5,831 per 
patient (95% CI 5,134; 6,537) (23 times greater than an uncomplicated case). MDR-TB 
case treatment costs $6,772 ($8,836 once inflated to 2016 cost), with our patients with 
DR-TB cost being $14,249 (95% CI 7,257; 21,240) per patient (double that of an 
uncomplicated case) [28]. This relatively smaller increase is likely due to the fact that 
TB drug costs in DR-TB have the greatest influence on cost, which remains high 
whether or not the patient develops a CADR. Hospitalisation and in-patient 
investigations contribute in this instance to the greater cost in light of the CADR.  
 
A wide range of costs of CADR management is reported in the literature from $1,920-
$8,452 [128, 129, 136-138]. Although the cost within our study population falls within 
this range it is difficult to make meaningful comparisons as studies not only span a range 
of periods, but also have been conducted in varying geographical locations, with varying 
management practices and various costs being included in the different totals. Many 
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include just the direct medical costs, whereas the Gyllensten et al. population included 
the societal cost as their average cost per patient ($6,325) [136]. 
 
CADR was associated with significant cost to the healthcare system. Costs within each 
period varied greatly with the period of rechallenge clearly being the most costly (71% 
of the total cost) in the patients with DS-TB, and the optimised treatment period (50% of 
the total cost) in the patients with DR-TB.   
5.3.7 Cost of CADR amongst subgroups of patients with DS-TB  
As can be expected patients in the intensive phase of TB therapy (68 patients) at the time 
of CADR contributed the majority (85%) of the total cost for the patients with DS-TB. 
This was equivalent to $6,467 per patient. The greatest cost within this group was 
encountered during the rechallenge period at $4,660 per patient ($316,884 total for the 
rechallenge period). The individuals who demised and those who did not return 
following their temporary discharge pass-outs may lower the total cost per patient in this 
group as there is incomplete data for these patients related to the varying periods of the 
rechallenge process. 
 
For those in the continuation phase of TB therapy at the time of CADR (7 patients), the 
cost of the rechallenge process was $446,782 ($6,683 per patient). As this group of 
patients only needs to tolerate rifampicin and isoniazid, this higher average is 
unexpected. Four of the patients were only rechallenged with rifampicin and isoniazid, 
resulting in a very affordable rechallenge and optimised treatment phase. However, 3 of 
these individuals underwent a prolonged rechallenge. One individual was rechallenged 
with ethambutol for 4 days before it was discontinued, with another 2 patients 
rechallenged with both ethambutol and pyrazinamide contributing to an additional 17 
and 121 days in hospital respectively. However, some of these patients had not sputum-
converted at the end of the intensive phase of treatment and would benefit from 
treatment with four drugs beyond the two months should the drugs not be the offending 
drug. Others had interrupted therapy during the intensive phase and it was felt they had 
not had enough treatment. These 7 patients were in the minority in terms of the 
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population yet contributed to 9% of the total cost for the DS-TB group. Much like those 
in the intensive phase of therapy, the rechallenge period was the greatest contributor to 
overall cost at $5,187 per patient ($36,309 total for rechallenge period). 
 
At the outset of rechallenge individuals need to be assessed in terms of how far they are 
in to their treatment regimen to prioritise which agents need to be available for continued 
use. This assessment needs to consider whether the patient was compliant to medication 
and whether sputum conversion has occurred qualifying the patient for the continuation 
phase of TB therapy. Provided parameters are met, rechallenging these individuals with 
only rifampicin and isoniazid could result in cost saving through reduced number of days 
in hospital as well as fewer drugs used. 
 
Another group within the DS-TB patients were the 14 who were admitted with CADR 
and managed to various degrees before it was decided that they had been incorrectly 
diagnosed and unnecessarily treated for TB. Four of the 14 were rechallenged for a total 
of $972 per patient for the rechallenge period, which contributed to 4% of the total cost 
of the rechallenge period in the patients with DS-TB. Despite 4% being a relatively 
small proportion, this cost becomes significant on a population level and detracts from 
the budget available for treating confirmed TB cases. Not only is there an increased cost 
with empiric TB, but also a danger with these individuals having developed potentially 
life-threatening reactions to treatment that was unnecessary. On the other hand, this has 
to balance against the need for empiric TB treatment, a strategy recommended by the 
WHO in settings of high HIV prevalence. The strategy has been shown to improve 
survival in severely ill HIV-infected person with presumed TB [182]. The practice of 
initiation of TB therapy based on clinical symptoms and radiology without biological 
evidence is also supported as a recommended approach by the South African TB 
guidelines and as such cannot be faulted by the clinicians treating the study population 
[40]. Within this group the stabilisation period expectedly made the largest contribution 
to the total cost $18,657 ($1,333 per patient). This is due to the more extensive 
investigations that were carried out to determine whether or not the patients had TB prior 
to initiating the rechallenge process.  
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5.3.8 Components contributing to costs 
Hospitalisation, personnel costs, TB drugs and ancillary medication as well as laboratory 
investigations and radiology contributed in varying degrees to the total cost of the 
periods of the rechallenge process. Parameters influence varied amongst periods of the 
process as well as between the 3 subgroups (intensive, continuation and unnecessary 
treatment) of the patients with DS-TB, highlighting the absence of standardised 
management guidelines for CADR.  
5.3.8.1 Hospitalisation 
Among the patients with DS-TB, the greatest contributor to cost was hospitalisation in 
both the stabilisation (65% of total stabilisation period cost, $762/patient) and 
rechallenge period (70% of total rechallenge period cost, $2,875/patient). In all 3 
subgroups of the DS-TB patients, hospitalisation was the greatest contributor in the 
stabilisation period. In the case of the unnecessary treatment group, the per patient 
hospitalisation cost ($926 per patient) was higher than those who had proven TB. Within 
the stabilisation period, hospital costs are substantial considering that the study 
population had temporary pass-outs for a median of 12 days. Hospitalisation costs in the 
rechallenge period for patients with proven TB accounted for 70% of the rechallenge 
period cost in both subgroups. A similar trend was observed in the patients with DR-TB 
where hospitalisation was the main cost contributor in the stabilisation (67% of total 
stabilisation period cost, $1,381/patient) and rechallenge period (68% of total 
rechallenge period cost, $3,462/patient). The rechallenge period was also associated with 
a significant duration of hospitalisation due to the 72-hour interval between subsequent 
first-line TB drug reintroduction. With the identification of causative drugs, alternative 
treatment options were derived which too contributed to the duration as patients were 
observed ensuring tolerance of the new regimens.  
 
The significant contribution to total cost by the cost of hospitalisation is in keeping with 
literature findings. Pooran et al. demonstrated in a cost analysis that cost of 
hospitalisation had the most significant influence on XDR-TB costs [28]. A fully 
decentralised model of care was found to reduce treatment costs in MDR-TB by 42%, 
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with the reduced number of days in hospital being the key contributor [26, 27]. Costs of 
ADR vary in literature reports likely related to prolonged hospitalisation, with one study 
reporting a cost of $2,262/ADR [134]. Within the USA in 1997 Cullen et al. found 
inpatient costs related to ADRs to be as high as $19,685 in an ICU setting and $13,994 
in a non-intensive care unit [183]. In a systemic review by Laurence et al. of 59 studies 
related to DS-TB costs, hospitalisation was found to contribute to 74% of the total cost 
($11,283 in high income countries and $128 in low income countries) [173].  
 
Within our population the cost of hospitalisation could once again be reduced through 
the use of a step-down approach in which patients are transferred to secondary or district 
level hospitals to complete rechallenge. Patients could be managed in conjunction with 
specialist dermatologists and referred back should they once again become unstable. 
This option offers potential further benefit to patients, as secondary or district hospitals 
are often closer to areas in which they live resulting in lower transport costs incurred by 
the patient household. 
5.3.8.2 TB drugs 
TB drugs comprised the majority of medication costs in the study population and were 
the greatest contributor to overall cost within the patients with DR-TB. Drug costs are 
determined by a number of prices including customs duties, registration fees as well as 
local and international taxes [174]. DR-TB patients were discharged on regimens 
comprising second-line therapy for much longer periods compared to those with DS-TB, 
the longest being 36 months with a median of 437 days (IQR 270; 591) of treatment post 
discharge. The costs of many of the second-line drugs are much greater than first-line 
drugs. Cost of the first-line drugs range from $0.02-$0.10, with the combination drug 
Rifafour™ costing $0.05/tablet. In comparison second-line drugs have an average cost 
of $4 (range $0.09-$22/tablet). Overall drug costs are reported to account for about 5% 
of the total cost of treating DS-TB, though this can vary greatly [173]. In a study by 
Burman et al. drug costs were shown to account for $311 per DS-TB patient, but could 




In an analysis by Laing et al. it was found that costs of TB therapy were generally higher 
in the developed as compared to the developing world, with the average price of first-
line drugs increasing by 10.7% per year in the private sector and 4.1% in the public 
sector [174]. Whereas in the developing world prices rise at a rate of 2% per year [174]. 
A systemic review illustrated these differences with average costs of treating DS-TB 
patients in high-income countries at $14,659 (SD 13,594) as a result of these drug costs, 
compared with $258 (SD 352) in the low-income countries [173]. 
 
Within Pooran et al.’s cost analysis, TB therapy contributed to 49% of the total cost of 
treatment in MDR-TB. MDR-TB treatment costs were found to be 26 times greater than 
those for DS-TB [28]. Furthermore, DR-TB cases accounted for only 2.2% of total TB 
cases, yet the treatment of these cases cost 32% of the annual TB budget. This is 
comparable to our study population where patients with DR-TB made up 8% of the total 
study population but contributed to 18% of the total cost. However, the average cost per 
patient in the DR-TB group was only 2.5 times greater than the cost per patient in the 
DS-TB group. The relative similarity in cost is likely accounted for by the prolonged 
hospitalisation that occurred in the groups (DS-TB median 56, DR-TB median 69), with 
the greater number of DS-TB patients, which diluted out the effects of the higher drug 
costs in the DR-TB group. 
 
TB drug cost reductions will have a substantial impact on the overall cost of potential 
alternative regimes. The affordability of currently used first-line drugs enhances the 
appeal of the rechallenge process to re-establish conventional first-line treatment. 
However, within our population in many instances the cost of hospitalisation outweighed 
the cost saving achieved through the use of first-line TB drugs. 
5.3.8.3 Investigations 
Investigations made up of both laboratory investigations as well as radiological 
examinations contributed significantly throughout the drug rechallenge procedure (11% 
of total cost in DS-TB and 6% in DR-TB patients). The higher per patient costs amongst 
those with DR-TB was mainly due to the higher drug costs, which diminished the % of 
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costs that were attributable to investigations in these patients. Costs of investigations 
prior to rechallenge in the patients with DS-TB include tests needed to confirm TB in 
cases where the diagnosis was not evident. This is highlighted by the higher cost of 
investigations in the group unnecessarily treated for TB where stabilisation phase 
investigation costs were the highest at $210 per patient. 
 
There is no standard protocol for how frequently investigations should be carried out in 
individuals who develop a CADR. Laboratory investigations as well as radiological 
examinations, particularly tests relating to detection of hepatic dysfunction or 
eosinophilia (a rise in the eosinophil count associated with DRESS), are generally done 
as screening. In instances where patients are symptomatic i.e.; a rash develops, 
gastrointestinal upset ensues or they develop another systemic symptom, investigations 
are likely to be more specific and guided by the clinical presentation or complaint [6, 
65]. In our population, screening tests were done at varying intervals, particularly during 
the period of rechallenge to detect possible rechallenge reactions. Although all 
individuals were managed within the same unit, differences in the practice of treating 
dermatologists, as well as inter-patient variability influenced the frequency and the 
extent to which investigations were carried out. Having a standardised guideline as to the 
use of screening tests would not only limit the cost in our population, but also contribute 
to the development of management guidelines for CADR, which would assist in the 
implementation of decentralised management. 
 
The selection of laboratory investigations ordered by the treating clinician also has a 
potential for cost saving. For example, liver function tests include a combination screen 
of AST and ALT. Both aminotransferases are highly concentrated in the liver but, ALT 
is more liver-specific with elevated serum levels being more indicative of liver damage 
[186]. Use of ALT alone could enable detection of hepatotoxicity and potentially 
decrease investigation cost. The same could be said for ordering combination tests of a 
full blood count (FBC) ($8) and differential count ($5) when assessing for an elevated 
eosinophil count as is commonly seen in DRESS. The FBC provides the white cell count 
(WCC), haemoglobin, mean cell volume and platelets, when one only needs the WCC 
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($1.30) to determine the eosinophil count. This amounts to a 50% reduction in cost of 
this test alone at $6.30 rather than $13. 
5.3.9 Alternatives to rechallenge 
Drug rechallenge can be contra-indicated in cases of severe comorbidities, pregnancy 
and in those where there is an unacceptable risk of life threatening rechallenge reactions 
[6, 14, 15, 88]. As such, a set of alternative regimens was devised using second-line 
therapies based on the needs of these groups, but applicable to an average population 
with DS-TB that develop CADR enabling the rechallenge process to be avoided. 
Disadvantages of using second-line drugs are attributed to their presumed lower efficacy 
(47-60% success rate), greater rate of adverse events, longer treatment duration (18-
24months) and greater cost of medications [26, 27, 30].  
 
Nonetheless, there are new second-line drugs becoming available. Based on clinical trial 
data, these drugs have efficacies that seem to match their first-line counterparts 
translating to improved treatment outcomes and shorter durations of therapy for DR-TB. 
Regimens using these drugs have been trialed further demonstrating the efficacy of these 
agents in the treatment of DS-TB [113, 117]. The proposed regimen consists only of 
drugs taken orally avoiding the use of typical second-line injectable drugs. This further 
reduces not only patient discomfort in receiving a daily injection, but also cost in terms 
of daily clinic visits for both the healthcare services and patients. In addition, avoidance 
of daily clinic appointments does not limit patients in their ability to continue or seek 
employment. A further benefit is that proposed alternate regimens have monitoring 
based on the current NTP, thus placing no additional burden on the healthcare system. 
Furthermore, with the use of drugs for DS-TB one could argue that the duration of 
treatment could be shorter at 9 months matching regimens in the literature [96, 97]. 
 
Perhaps of greatest concern with use of traditional as well as newer second-line TB 
therapy for DS-TB, is the risk of resistance to these drugs developing as a result of 
increased use. This not only translates to a greater individual as well as community risk, 
with increased numbers of drug-resistant strains of TB, but also a further decrease in 
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available treatment options for individual patients should they develop or contract DR-
TB requiring treatment with second-line drugs. Acquired drug resistance occurs when 
the patient does not take or absorb the medication thus selecting for a bacterial 
population, which is now resistant to the drug as a result of prior exposure [187]. 
Although the risk or rate of development of resistance can’t be determined, mechanisms 
of development of resistance for the various drugs are being explored. A study by Li et 
al. found that the rate of acquired rifampin resistance was equivalent with rifampicin and 
rifabutin [151].  Resistance to fluoroquinolones (moxifloxacin) occurs as a result of 
mutations of genes in the quinolone resistance-determining region [187]. The risk of 
acquiring a primarily resistant strain in cases of fluoroquinolones is marginally further 
increased as a result of prior exposure with fluoroquinolones commonly being used to 
treat community acquired pneumonia or urinary tract infections [188]. Literature has 
shown a potential cross-resistance between isoniazid and ethionamide. Patients who 
have isoniazid-resistant TB may also have resistance to ethionamide making DR-TB 
regimens less effective [154]. What is not clear is whether increased ethionamide 
exposure with risk of resistance will result in increased isoniazid resistance by the same 
mechanism. Delamanid and bedaquiline, have longer half-lives. If there is premature 
continuation of the accompanying drugs there is an increased risk of development of 
resistance due to the residual low plasma levels of drug [189]. 
 
In modeling our alternative regimens, newer drugs were used based on clinical evidence 
from literature as well as personal meetings with experts in the field including Professor 
Gary Maartens and Associate Professor Helen Cox. Second-line drugs were used for DS-
TB CADR cases based on the assumption that fewer drugs in combination would be 
effective to eliminate the disease while avoiding unnecessary side effects of multiple 
second-line therapies as well as the overwhelming drug costs.  
 
By using rifabutin as a tolerable substitute for rifampicin, we were able to cost shorter 
durations of therapy, while still maintaining regimen strength of a rifamycin, with 
potentially fewer adverse events [5, 22, 23, 53, 190]. Furthermore, despite being from 
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the same drug class, 80% of individuals who react to rifampicin are documented to be 
able to tolerate rifabutin [22, 99, 100].  
Newer second-line alternatives in bedaquiline and delamanid have been shown to have 
great potential. Bedaquiline has shown a 48% rate of sputum-culture conversion when 
compared to placebo as well as a faster time to conversion of 83 days compared with 
125 days (p<0.001), while delamanid showed increased rate and proportion (45.4% vs. 
29.6%, p=0.008) of sputum culture conversion in the population receiving delamanid 
compared to placebo [24, 106, 117]. Both these new drugs have been documented to 
cause QT prolongation, adding not only to the risk of use, but also to the increased cost 
of monitoring that is necessary [106, 191]. Despite this proven efficacy, use in South 
Africa requires regulatory approval and confined to MDR-TB cases. 
 
These alternatives like their first-line counterparts have the potential to cause ADR 
resulting in hospitalisation and interruption of treatment, which would increase the 
estimated costs. Drug-drug interaction with ART, much like was described in the index 
population with first-line TB therapy, is also a possibility. Complications of further 
CADR to second-line alternatives or ART in this population was not accounted for and 
would need to be evaluated as not only a contributor to cost, but as a risk to use.  
5.3.10 Costs of alternative arms of therapy 
5.3.10.1 CADR in the continuation phase 
Within our study cohort, 7/75 (9%) individuals with DS-TB had already completed the 
intensive phase of first-line 4-drug therapy at the time their reaction occurred. They 
therefore only required tolerance to rifampicin and isoniazid to complete their treatment. 
An alternate 2-drug regimen using rifabutin and ethionamide was derived to account for 
this proportion of the population. From onset of CADR to treatment completion using 
the devised regimen, the cost was $1,854 per patient. This equates to 17% of the actual 
cost in current rechallenge practice for a total cost saving of $9,130 per patient. The 
significant savings in this group is attributed to the avoidance of hospitalisation costs 
during the rechallenge period as well as investigation costs that were included as part of 
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the management of the 3 patients within this group that underwent rechallenge with 
more than just rifampicin and isoniazid.   
5.3.10.2 CADR within the intensive phase 
The majority of the study population, compatible with literature findings developed their 
CADR within the first 2 months of TB therapy. Three alternative regimens were derived, 
comprising various combinations of second-line TB drugs. The first alternative made use 
of drugs commonly used in the treatment of MDR-TB, moxifloxacin and ethionamide, 
combined with rifabutin as a new alternative. Regimen 1 required less intensive 
monitoring (for a cost of $273/patient) and had lower TB drug costs ($1,050) than the 
alternatives that used newer drugs. The total cost per patient in this regimen combining 
the initial stabilisation cost was $2,651. Although rifabutin was a newer addition it has 
relatively lower drugs costs compared to other newer drugs employed for the treatment 
of drug resistant TB ($1.71 compared with $3.60 for bedaquiline and $5.74 for 
delamanid). Moxifloxacin and ethionamide, already fairly widely used, are very 
affordable options for treatment, $0.41 and $1.77 per dose respectively. This regimen is 
one that is not only potentially effective, but is also the most affordable and readily 
available. Making use of already circulating freely available medications makes access 
to this regimen unrestricted.  
 
For the second and third option, we elected to use drugs that have been approved and are 
in clinical use, though requiring regulatory approval for use. These newer TB drugs are 
proving to be promising and should be incorporated into protocols for use to not only 
improve patient outcomes, but also potentially increase use, decreasing costs of the 
individual drugs [24]. Often increased use and demand can result in decreased costs of 
individual drugs with increased competition for tenders, which drive costs, as well as 
development of generic drugs as was seen in the HIV epidemic with rollouts resulting in 
decreased costs of ART [141].  In using bedaquiline there are serious concerns about 
adverse events related to QT prolongation leading to sudden cardiac death [104]. Use 
therefore requires more intense electrolyte and cardiac monitoring accounted for in the 
costing of this regimen ($339/ patient for investigations). Drug cost in this regimen was 
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$1,252, making up 43% of the total cost ($2,919). Although only used for the first 6 of 
the total 9 months of treatment the cost of bedaquiline, at $3.60 per dose, is substantial 
and almost double that of the cost of the other drugs used in this regimen, which were 
only $2.13.  
 
The final alternative option made use of delamanid with rifabutin and levofloxacin. Like 
bedaquiline, delamanid is associated with the risk of QT prolongation [25, 191]. 
Monitoring in this population was therefore equivalent to Regimen 2, with the difference 
in drug costs driving the difference in cost between these two regimens. The higher cost 
of delamanid, $5.74 per dose, contributed significantly to the overall drug cost of $1,610 
in this regimen. The total cost for Regimen 3 was estimated at $3,276 per patient, 48% 
of which was TB drug cost.  
 
All 3 of the alternative regimens were found to cost less than the current drug 
rechallenge practice despite higher second-line drug costs and more intense drug specific 
monitoring required. The first regimen comprising rifabutin and ethionamide was the 
most affordable of the 3 alternate regimens. This is due to the use of more readily 
available and affordable second-line drugs. Moreover, these drugs had relatively few 
side effects making fewer screening investigations during the course of treatment 
necessary, for a lower overall cost of investigations at $273 ($66 less than Regimen 2 
and 3 per patient). This regimen cost 45% of that of the current rechallenge practice with 
an incremental cost saving of $3,180 per patient.  
 
Regimen 2 and 3 made use of newer TB drugs. Nevertheless, both regimens, which 
included more expensive drugs in bedaquiline ($3.60 per dose), levofloxacin ($0.42 per 
dose) and delamanid ($5.74 per dose), proved to be more affordable that the traditional 
rechallenge practice (50% and 56% of the cost of current practice respectively). Even 
with the more intensive monitoring required, the costs of monitoring were still lower 




Regimen 3 using delamanid, levofloxacin and rifabutin was estimated to account for an 
incremental cost saving of $2,555 per patient, with drug cost accounting for 48% of the 
total regimen cost. This was comparable with literature reports of the large proportion 
that second-line drugs typically contribute to overall cost [26, 27, 30]. Delamanid is not 
yet freely available and pricing is therefore not well established. We costed delamanid in 
our alternative regimen based on literature reported costs at which the drug will be made 
available by the Japanese pharmaceutical company Otsuka [146, 147]. It is anticipated 
that costs should be lower in the developing world as has been the reported trend of drug 
costs and developing countries are unlikely to pay the exorbitant amounts that the drug is 
costing in more developed countries [25]. Furthermore, once trials have completed and 
drugs are more readily available one would expect this cost to decrease making this 
regimen more feasible.  A cost-effectiveness analysis by Diel et al. reported a course of 
delamanid (168 days) to be €25 200 [192]. Despite the high drugs costs and the 
contribution added to the total overall cost of treating MDR-TB, delamanid use was 
deemed cost-effective. The efficacy of the drug resulted in cost savings that outweighed 
the increased drug costs in terms of incremental cost per quality adjusted life year 
(QALY) and disability adjusted life year (DALY) avoided [192]. 
 
Regimens containing the newer drugs are seemingly more expensive based on drug 
costs. Hospitalisation costs in our study population and in the literature have been shown 
to be the major contributor to cost of TB treatment [26-28]. Outpatient use and 
monitoring of these drugs, with the avoidance of hospitalisation seems to negate the 
additional expected drug costs.  
 
It is well documented that second-line TB drugs carry a high risk of ADR [16, 65, 80]. 
All the above hypothetical regimens could at any time be complicated by the 
development of an ADR, which would potentially result in hospitalisation and increased 
cost of the regimen. The frequencies of reactions are not well established and using new 
combinations and regimens makes this estimation problematic. All estimates of costs in 
the hypothetical populations using the new regimens are based on uncomplicated well-
tolerated cases.  
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5.3.11 Patient costs 
TB and HIV are for the most part diseases of the developing world, with poverty playing 
an integral role in the disease momentum [1]. Poverty and poor socio-economic 
circumstances are risk factors for contracting TB and hindering treatment completion. 
While TB exacerbates poverty by limiting the affected individuals’ ability to work as 
well as increasing out-of-pocket expenditure with hospital visits, as well as transport and 
nutritional supplementation costs. Poverty often delays health seeking and ultimately 
diagnosis resulting in poorer disease outcomes.  
 
Within our population of largely unemployed individuals or those earning minimum 
wage the average loss of income due to hospitalisation was 15% in patients with DS-TB 
and 18% in those with DR-TB. The Western Cape government payment schedule 
classifies healthcare users according to their annual income in terms of their ability to 
contribute to the cost of their healthcare. The majority of our population fell into the H1 
category making the vast majority of their care subsidised with patients being 
responsible for $4 per 30 days hospitalised which included all tests, medications and 
procedures the patient may have required. Following discharge, patients would be billed 
$1.22 per clinic visit. All individuals received TB medication for free, with the cost 
being carried by the NTP. Despite the seemingly small individual burden the total billed 
amount for the period cost the average patient $227 (DS-TB) and $154 (DR-TB). This 
combined with the income lost for the period of hospitalisation meant that patients with 
DS-TB would have lost 25% of their annual income and 27% in those with DR-TB. 
Literature estimates that while on TB therapy patients can lose up to 30-40% of their 
annual income [32].  
 
Estimated loss using the alternate regimens amounted to 10% of patients’ annual income 
in all 3 of the alternate regimens. This is likely due to the shorter period of 
hospitalisation (11 days in the period of stabilisation), theoretically enabling patients to 
have very little time away from work as compared with the traditional process. Although 
these regimens make use of more expensive drugs, most of the expense in these 
regimens is related to TB treatment and will be borne by the NTP. However, what is not 
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clear is whether the regimens, which depart from standard treatment guidelines, would 
be covered under the NTP, potentially resulting in greater patient costs if they were not 
included.  
 
Due to the retrospective nature of the study we were unable to account for more specific 
patient level costs attributed to transport, nutritional supplementation as well as potential 
employment finding difficulty and the cost beyond the period of hospitalisation. Taking 
all this into account it is likely that our estimates of patient loss are likely to be much 
higher.   
 
Gospodarevskaya et al. within their populations in Tanzania and Bangladesh found 
patient costs, although lower in the continuation phase than the intensive phase, 
represented a significant proportion of annual income (89% and 77% respectively) [31]. 
Within our population during the optimised treatment phase patients would be liable for 
a further $25 (DS-TB) and $43 (DR-TB) up until completion of treatment. This cost 
would only be related to clinic visits and ongoing investigations, with the higher cost in 
patients with DR-TB group being attributed to the longer proposed duration of TB 
treatment until completion.  
 
It is expected that in the further treatment phase that there would be ongoing loss of 
income as monthly clinic visits and disease place a strain on individuals trying to find 
permanent employment. Ramma et al. who reported a drop in proportion of income 
earners from 37%-3% while on treatment in their MDR-TB treatment cohort support this 
assumption [32]. Within a population earning largely minimum wage, with many 
households reliant on a single income, a 15-17% higher loss of the annual income is 
substantial. This loss is even more catastrophic as it is likely to be higher due to the 
inability to commit to employment in the optimised treatment phase. Society helps these 
individuals by providing temporary disability grants. Although this provides personal 




Within both the rechallenge process and alternative regimens, the societal cost incurred 
was significant. The cost of rechallenge amounted to $6,134 per patient. The alternate 
regimens were more economical as costs were 46-56% lower than that of the current 
practice. This substantial saving allows for resources to be made available to other areas 
of social importance.  
5.3.12 Sensitivity analysis 
Within our population hospitalisation was found to have the greatest influence on overall 
cost. The effect of hospitalisation on the overall cost was demonstrated by increasing 
both hospital cost and the duration of hospitalisation. These findings are consistent with 
literature reports of hospitalisation being the main contributor to cost in the case of TB 
therapy and drug reactions [26, 27, 30]. A variation of hospital cost, i.e. half and double 
enables the cost to be viewed in terms of the effect secondary level hospitalisation (half 
the cost, 30% reduction in total cost) as well as perhaps cost at a more costly centre 
(private, 2.2X increase in total cost) would have on the overall cost of the rechallenge 
procedure. In addition, increasing the current 4-day interval between rechallenge of 
subsequent TB drugs to a more conservative interval of 8 days (as reported in the 
literature) significantly increased the per patient cost of the rechallenge process [6, 19, 
65]. Furthermore, making use of outpatient stabilisation for eligible patients (DRESS 
with ALT <100U/L) resulted in cost saving despite these patients being in the minority 
(2.6% reduction in total cost). These findings are consistent with literature reports of 
inpatient day costs having the greatest influence on cost of treatment of XDR-TB [28]. 
Regimen 1, with lower drug costs, was largely influenced by the cost of hospitalisation. 
This was highlighted in the worst case where an additional month of hospitalisation after 
initiation of alternate regimen was added prior to discharge (discussed later).  
 
It is well documented that second-line TB drugs are more costly than first-line 
alternatives [28]. Pooran et al. found treatment of MDR-TB to be 26 times greater than 
the treatment of DS-TB with 49% of this cost being due to TB drugs [28]. Potential 
generic options of second-line TB drugs were found to decrease overall treatment costs 
by 41-97% [141]. Current practice cost increased by 19% when drug costs were doubled 
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and as Regimen 1 starts to make use of more costly second-line drugs the effect of 
increased costs in increased with a 41% increase in total per patient cost. This is even 
more pronounced in Regimen 2 (44% increase in total cost) and 3 (51% increase in total 
cost), which make use of newer, even more costly, second-line drugs.  
 
The impact of drug costs, as well as hospitalisation to various extents as shown by the 
sensitivity analysis was further demonstrated through the scenario analysis. In changing 
multiple variables simultaneously, the overall costs increased and decreased as expected. 
Within the current rechallenge process hospitalisation costs have been a major 
contributor to the total cost in all stages. This influence was further highlighted in the 
“best” scenario, where reduced component costs resulted in a 56% decrease in total costs 
at $3,174 per patient. In the alternate regimens, the length of hospitalisation was minimal 
and drug costs are the greatest driver of costs. Making the drugs more affordable, along 
with the reduction in the aforementioned parameters contributed to a 36% reduction in 
Regimen 1 ($1,640 per patient) and 2 ($1,790 per patient) and a 38% reduction in 
Regimen 3 ($1,954 per patient).  
 
Conversely, in the “worst” case scenario where costs of drugs and hospitalisation were 
doubled, patients were seen more frequently and lab tests done more regularly, there was 
a 38% increase in the total cost per patient for the drug rechallenge strategy ($8,027 per 
patient). Interestingly, increasing drug costs in the alternative strategies has a more 
profound influence on regimen costs than reducing them. Higher drug costs increased 
regimens costs by 1,3 times on average (Regimen 1; $5,981 Regimen 2; $6,468 and 
Regimen 3; $7,118 per patient respectively). In the “worst” case scenario, the increase is 
not solely due to the drug costs, but also contributed to by the additional hospitalisation. 
This again highlights the influence of inpatient management on cost. 
 
The $US to ZAR exchange rate fluctuated widely in 2016. In order to account for this 
fluctuation, the impact of the lowest as well as the highest 2016 rate on overall cost per 
patient was assessed. Using the higher rate of R16.86=1USD resulted in a 15% increase 
in rechallenge as well as alternate regimen total costs. Conversely, the lowest period rate 
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of R13.26 resulted in a 10% decrease in costs across all regimens. Fluctuations are 
particularly important when drugs are internationally sourced, with higher rates resulting 
in greater costs and vice versa with lower rates. The higher rate (weaker ZAR) is likely 
to reflect the more appropriate rate.  
 
Patient annual incomes were recorded as per hospital records. In cases where annual 
incomes were unknown or patients were classified as being unemployed, a proxy income 
equivalent to a minimum wage general worker was assigned. With this assumption, it is 
possible to both under- as well as overestimate patient incomes. Patients who were 
informally employed or earning more than estimated would be under-estimated, whereas 
those who were perhaps employed casually (working fewer days or not receiving any 
income or subsidy) would be over-estimated. To account for this, annual incomes were 
doubled and halved to assess their impact on societal cost. Within the rechallenge 
practice where patients spent more days in hospital with resultant higher loss of income 
doubling and halving their annual income increased and decreased societal costs by 5%. 
This was marginally higher than the 2% increase and decrease seen with the alternate 
regimens. This relatively small influence of patient costs on overall societal costs is 
likely to be due to the provider costs being substantial higher and thus a greater 
contributor. 
5.4 Study significance 
TB remains a major health concern with the sheer number of patients on treatment 
resulting in a higher incidence of adverse events as compared to other conditions. 
Extensive health economic evaluations on the cost of TB treatment exist, yet costing 
studies of adverse events are less frequent. To our knowledge this is the first piece of 
work that not only assesses the cost of the current practice of rechallenge in individuals 
developing CADR to first-line TB drugs, but also assesses potential alternatives. These 
hypothetical alternatives were evaluated not only in terms of what the best drug 
composition for treatment would be, but also where they would best fit into the treatment 
regimen and the estimated costs of these alternatives. Furthermore, patient and society 
costs were estimated for both current practice and alternate regimens, demonstrating the 
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significant impact CADR have on patients’ annual income and society as a whole. 
Through this analysis we have not only highlighted areas which contribute significantly 
to overall cost, particularly hospitalisation and drug costs, but proposed potential cost 
saving alternatives. This saving in the alternate regimens translates to both healthcare 
services and the patient. In the current economic climate with an overburdened 
healthcare system, analysis of the costs of current practice and potential cost saving 
alternatives are critical. More appropriate use of resources allows for optimal budget 
expenditure. This study provides more affordable hypothetical treatment regimens that 
need to be further studied in terms of their clinical efficacy. However, should alternative 
regimen use be delayed, study findings support the development of standardised 
rechallenge guidelines to assist with the management of CADR in terms of current 
rechallenge procedure to allow for decentralised cost saving options at secondary level 
hospitals or community based clinics.  Results of this study are potentially generalizable 




Although our study provides a novel option for the management of CADR to first-line 
TB therapy occurring in a predominantly HIV-infected population there are several 
limitations. These include those inherently associated with a retrospective review as well 
as those arising as a result of the proposed novel management. As there is no current 
protocol governing drug rechallenge, in cases of CADR or alternate treatment options, 
evidence was derived and based on expert opinion.  
 
The tertiary setting of the study results in a population selection bias, in that we were 
only able to evaluate patients referred to the dermatology unit. One could assume that 
the population is representative of the severe cases of CADR seen at the local clinics, 
where they manage the milder cases. The data on the proportion of patients with CADR 
that are referred was not available. Management of adverse reactions is largely based on 
literature guidance and personal experience of treating physicians. It is assumed that 
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specialist inpatient management is safer, but once alternate facilities have adequately 
trained staff it is feasible that these patients could be managed at lower levels of care. 
Following on this study we would hope to develop guidelines to assist in the 
development of management protocols to be implemented at a clinic level. This will not 
only improve patient outcomes, but also standardise management allowing for a 
comparison of outcomes at varying levels of care.  
 
Due to the retrospective nature of the study, clinical outcomes were not included, yet this 
has significant implications on the proposed regimens. Efficacy of the regimens in terms 
of cure are not known, as well as additional acquired resistance and ongoing 
transmission which are likely to increase the cost of rechallenge were not accounted for. 
As the proposed regimens in combination are novel, implications of cure, relapse and 
further complications with each regimen can only be based on literature and outcomes 
known for individual drugs. Combinations are proposed based on evidence that cure and 
relapse levels should be comparable to current practice, but this needs to be evaluated. 
Work conducted and under investigation by the TB Alliance with the REMoxTB and 
STAND trial are specific examples that provide evidence to the benefit of the proposed 
regimens and why we should continue to question the use of standard drug-regimens 
[116, 117].  
 
Furthermore, the authors acknowledge that in exposing DS-TB patients to traditionally 
DR-TB therapies, there may be increased development of drug-resistance with a 
resultant reduced efficacy of these drugs should patients subsequently acquire or develop 
DR-TB. Mechanisms and rates of development of resistance for the proposed drugs were 
discussed in the preceding sections. 
 
Possible drug-drug interactions of TB drugs and TB drugs and ART of the proposed 
alternative regimens, as discussed in the literature review, were not accounted for which 
could result in adverse events potentially increasing costs of the alternate regimens. With 
the lack of clinical outcomes for the proposed regimens it was not possible to carry out a 
cost-effectiveness analysis. Our aim was to report on the cost of current practice as well 
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as cost potential alternatives to provide a basis for future research, which could evaluate 
potential outcomes of the alternate treatment strategies.  
The use of cost data from GSH and local clinics and the NHLS is representative of 
healthcare services in the Western Cape. These costs may not be reflective of the rest of 
South Africa as hospitalisation and treatment facility costs, treatment regimens and 
rechallenge policies for CADR are likely to vary between provinces and countries.  
However, in the case of costing the CADR with current rechallenge practice, data to 
which costs were applied was collated from a substantial population at a single centre 
where the practice was standardised. The small population number of those with DR-TB 
do not allow for any significant analysis to be applied to this specific subset of the 
population.  
 
The costs of chronic medications, based on patient co-morbidities, including HIV and 
ART, was not included in the overall costing as they were not directly related to the 
management of the CADR and were continued in all patients where appropriate. In 
addition, the cost of any additional monitoring investigations required for HIV and ART 
were not included. Upon presentation where HIV status was unknown, testing and CD4 
counts were carried out. If HIV-infection was confirmed then CD4 counts were 
performed. This was common practice in the population and these investigations were 
carried out in the stabilisation phase, which is therefore accounted for in the alternate 
regimens.  
 
Patients were assumed to have completed treatment courses as outlined on discharge 
prescriptions, which results in an over-estimation of optimised treatment phase costs in 
cases of patients missing doses and not completing the treatment course. Monitoring 
costs included in the NTP were also included, further over-estimating these costs in 
patients who discontinue treatment or are lost to follow up. Statistical methods such as 
imputations were not used to evaluate missing data, with these costs rather being 




There is a paucity of data on the use of second-line drugs for DS-TB. Alternate regimens 
are based on available literature and expert opinion. Alternative drug therapies 
postulated are based on drugs that although have strong supporting clinical trial data 
have limited and restricted availability. Bedaquiline although currently available, is 
restricted to use in cases of XDR-TB and those not tolerant the other regimens of TB 
therapy. However, with time it is expected to become more readily available. Delamanid 
is unfortunately not available in South Africa other than through MSF and the DR-TB 
regulatory board approval. Costs were estimated based on literature, which may have 
resulted in costs of regimens based on delamanid being under- or overestimated.  
 
Within our population all alternative regimens comprised rifabutin with the assumption 
that the majority of individuals (80%) who react to rifampicin would be able to tolerate 
rifabutin. These options did however not account for the 20% who may react to rifabutin 
and those with multiple drug hypersensitivity syndromes. We do however feel that based 
on Lehloenya et al.’s experience on the successful use of rifabutin after rifampicin these 
options are validated [99].  
 
Individual costs for both current practice and the alternate regimens, were not estimated 
beyond loss of income due to days of work missed and expected patient expense liability 
as per the governmental hospital payment subsidy schedule. Patient specific information 
with regard to travel and other medical and nutritional expenses were not known. Loss in 
the optimised treatment phase did not include lost income as a result of not returning to 
work, but rather patient expenses incurred during this period.  As patients may or may 
not have returned to work during this period, this loss could be under-estimated in those 
who did not return to work. Furthermore, potential complications resulting in a longer 
treatment period would further compound this unaccounted loss. Societal costs did not 
include the cost to the state of potential disability grants that may be accessed by this 
population. 
 
Despite the above limitations costing estimates are robust and fairly present the costs of 
the current practice and alternative strategies.  Although carried out in a tertiary institute, 
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this study is generalizable to other developing settings with a high HIV prevalence 
where CADR are commonplace and management places a significant burden on 
healthcare as well as patient resources.  
 
Future research should focus on measuring health related outcomes of the alternate 
regimens in order to establish their efficacy and ultimately cost-effectiveness as well as 
influence on patient loss and wellbeing. Newer drugs should be incorporated into 






Despite worldwide decreasing incidence of TB in line with millennium development 
goals, the incidence in developing countries such as South Africa still accounts for a 
significant disease burden. HIV continues to fuel the epidemic. Despite TB treatment 
being highly effective, there are significant adverse events affecting treatment outcomes 
and attrition rates. These adverse events place significant burden on the suffering 
individual and the healthcare system. In resource-poor countries, expenditure needs to 
focus on optimal care. Money spent on treating adverse events could better be spent on 
treating more individuals in order to optimise health care expenditure. 
 
Newer drugs need to be considered and alternative options must be explored to allow the 
healthcare system to adapt to the continuing epidemic of TB. Research allows these 
options to be critically evaluated to determine their feasibility and potential benefits. 
Although research and innovation can be initially costly, the increasing demands and 
indications for drugs can result in subsequent long-term decrease in costs.  
 
Individual cost in terms of income loss and expenses needs to be prioritized. Patients are 
typically affected at the height of their earning potential, likely to be heads of households 
and often the sole source of income. This increases need for social support, placing 
further burdens on government departments and budgets.  
 
The study results demonstrated that second-line alternative regimens for managing a 
CADR to first-line TB therapy in patients with DS-TB are not only plausible, but also 
potentially more affordable for patients and providers. These alternative treatment 
options result in shorter periods of hospitalisation with subsequent reduction in cost and 
personal patient loss. A large proportion of the cost of alternative regimens is related to 
costs of newer drug therapies. With time and increasing use, these drugs too should 
become more affordable. However, it remains important to determine the outcomes of 
using these alternatives in the context of CADR to first-line TB therapy. One needs to 
balance the risk of resistance and future treatment failure should patients develop DR-
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TB, with the efficacy and cost-saving in instituting these drugs in the management of 
CADR to first-line TB therapy. 
 
6.1 Policy recommendations 
Based on the findings of this study the following policy recommendations can be made: 
- Government should take steps to increase availability of second-line TB drugs 
Efforts should be made to negotiate with suppliers and patent holders to gain 
access to these newer drugs at costs that are sustainable within our resource-
limited setting. This study has clearly shown that in the alternate treatment 
options, drug costs are the major driver of total cost, as has been shown in the 
literature. Furthermore, these drugs should be made available in cases of severe 
CADRs to first-line TB therapy where rechallenge may be life-threatening.  
 
- Hospitalisation should be limited or transferred to the lowest suitable level of 
care 
The cost of hospitalisation has been shown to have the biggest influence on the 
cost of the rechallenge procedure. Outpatient based therapy at tertiary hospitals, 
or even transfer of management to secondary level hospitals (half daily bed cost 
as compared to tertiary hospitals) once patients have been stabilised would result 
in significant cost saving.  
 
- Community based partnerships should be forged 
Service provision in terms of the optimised treatment phase at the community 
level is an essential component in ensuring adequate management of patients 
having experienced CADR. Patients need to be appropriately referred to 
community TB clinics for follow up and ongoing management. TB clinics in turn 
should have easy access to tertiary hospitals for ongoing support and advice in 
managing the patients, as well as referral should problems occur. Relationships 
are integral to maintaining the feasibility of the decentralised model. 
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6.2 Suggestions for further research 
Through this study the following areas for further research have been highlighted; 
- Study to assess the cost-effectiveness of alternative treatment options 
Although the alternate treatment regimens have been shown in this study to be 
more affordable and literature provides good evidence of efficacy of individual 
drugs, a study should be undertaken to follow up true outcomes of the regimens 
in the context of CADR development in DS-TB. Outcomes of interest would 
include; cure rate, time to sputum conversion, risk of drug-resistance as well as 
patient adherence to treatment and time to return to work for individual patients. 
 
- Standardised protocol for rechallenge 
A set method for rechallenge should be established detailing the order in which 
drugs should be re-introduced and guides to appropriate investigations. This 
would not only decrease costs due to inter-provider variability in ordering tests, 
but allow for more specific tests to be used as well as enable rechallenge to be 
adequately undertaken outside of specialist centres.  
 
6.3 Main conclusion 
This study has shown that the current cost of managing a CADR to first-line TB therapy 
is expensive. Alternatives strategies are not only feasible, but also more affordable, with 
the cost saving being due to the shortened period of hospitalisation. Based on these 
findings, it is economically feasible for alternatives to rechallenge to be employed in 
individuals who experience CADR to first-line TB therapy. Importantly clinical outcome 
data is required to determine the effectiveness of alternate regimens. Risk of 
development of drug-resistance to second-line drugs with increased use needs to be 
considered and accounted for. While second-line drug availability as per the alternative 
regimens can’t be ensured, the current practice should be decentralised to a lower level 
of care or outpatient management to reduce the healthcare and patient costs associated 
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8.1 Naranjo ADR probability scale 
 
Naranjo adverse drug reaction probability scale is the tool used to establish causality of 

















8.3 Table of costs related to the study population 
 
PARAMETER UNIT COST US$ 






Consultation (per 15min) 
 Specialist 
 Registrar 
 Allied Health professional 


















 Differential Count 
 Haemoglobin 
 White cell count 
 Urea and creatinine 
 Full liver function tests 
 Sodium 
 Potassium 
 Urea  
 Creatinine 
 Total bilirubin 
 Conjugated bilirubin 
 Alanine transaminase 
 Aspartate transaminase 




 HIV serology 
 CD4 count 
 Sputum geneXpert® 









































Bridging therapy TB drugs 
 Streptomycin  
 Ethionamide  
 Ofloxacin  
 Terizidone  



















 Acqeous cream 




 Natural tears 
 Lacrilube 
 Paraffin gauze (Jelonet™) 
 20%steroid/glycerine/H20 
 Betadine baths 
 Glycothymol mouthwash 
 Non-adherent dressings (Mepitel ™) 
 Fluocinolone gel 
 Flamazine 
 Benzac Gel 
 Betamethasone 10% 



























































$5 up to 30 
days 
$3 up to 30 
days 




$5/day $3/day $7 $4 50% of the full cost  








$56/day $30/day $13 $6 Unsubsidised 
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